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 Introduction and scope of this thesis
Chapter 1
10
Staphylococcus aureus – harmless commensal or dangerous pathogen?
The ancestors of today’s bacteria were single-cell microorganism that were the first forms 
of life to appear on earth about four billion years ago. Since then, these microorganisms 
have continuously adapted to very different ecological niches. As a result, bacteria are 
found in every environment on earth, from cold arctic soils to the warm waters of hot 
springs and sub-ocean hydrothermal vents. In addition, some bacteria adapted their 
lifestyles to colonize different hosts, including human beings. Thus, many different bacteria 
can be found within and on the human body. In most cases, both humans and microbes 
benefit from this co-evolution as exemplified by a plethora of bacteria in the human gut. 
However, some apparently commensal bacteria occasionally invade the host, which can 
lead to life- threatening diseases. One of these opportunistic bacteria is Staphylococcus 
aureus (Figure 1). 
Figure 1. Scanning electron microscopy image of S. aureus RN6390
S. aureus is a Gram-positive bacterium frequently found in the nasal cavity of humans and 
several animal species (120). In humans, the anterior nares are the most frequent carriage 
site for S. aureus. Other known carriage sites include the skin, perineum, pharynx as well 
as the gastrointestinal tract, vagina and axillae (59, 78). The colonization rate in the healthy 
human population is established at about 30% (50, 120). However, if the primary barrier 
function of the skin is disrupted, or if the immune system is compromised, S. aureus can 
become a dangerous pathogen that has the potential to invade almost all tissues and organs 
causing a broad range of diseases (66). These can vary from mild skin infections, such as 
impetigo, to life-threatening systemic infections (e.g. pneumonia, meningitis, osteomyelitis, 
and sepsis) (1, 19, 32, 125). Not only the diseases that this pathogen can cause are alarming, 
but also its high propensity to acquire resistance to antibiotics (65). In the pre-antibiotic era, 
the mortality of patients with S. aureus bacteremia exceeded 80%, and over 70% developed 
metastatic infections (105). The prognosis of patients with S. aureus infections improved 
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drastically since the introduction of penicillin in the early 1940s. However, already a few 
years later the first S. aureus strains resistant against penicillin emerged in hospitals (90). 
In the 1960s, a new semi-synthetic antibiotic - methicillin - was introduced for treatment of 
staphylococcal infections. Also in this case, the first methicillin resistant S. aureus strains 
(MRSA) were already observed within a period of two years (65). The first infections caused 
by MRSA used to be associated with hospitalized patients. This phenomenon is generally 
referred to as hospital-acquired MRSA (HA-MRSA). However, in recent years, the spread 
of so-called community-acquired MRSA (CA-MRSA) strains has laid an additional burden 
on the healthcare system (77, 95). In contrast to HA-MRSA, the CA-MRSA lineages easily 
spread within the young and healthy community, and they have now entered into hospitals 
causing nosocomial infections with even higher mortality rates than the hospital-acquired 
strains (79, 88).
Till now, the therapy against  S. aureus infections relies mainly on antibiotics. However, 
due to the fast development of antibiotic resistance by S. aureus, alternative ways to prevent 
and cure staphylococcal diseases need to be discovered, including immunization strategies. 
Importantly, there is currently no vaccine or passive immunization therapy available that 
could stop this successful pathogen from infecting humans. Therefore, various attempts 
have been made towards the development of anti-staphylococcal vaccines. In this context, 
efforts have been directed towards the identification of effective targets for vaccination 
or antibody therapy. These included the polysaccharide capsules of certain strains, or cell 
surface-exposed proteinaceous factors. Some of these candidate targets were selected 
for human vaccination studies after positive pre-clinical trials. These include the capsule 
serotypes 5 and 8, the clumping factor A (ClfA), ClfA in combination with the serine 
aspartate repeat protein G (SdrG), or the iron-responsive surface determinant B (IsdB). 
However, none of these have so far passed the stage of clinical trials (7, 22, 39, 94, 119). 
The probable cause of this is that S. aureus  possesses a strong ability to escape and to suppress 
the host immune responses (48, 58, 91). In addition, this pathogen displays an amazing 
genomic flexibility and heterogeneity in the expression of cell surface-exposed and secreted 
antigens (4, 37, 73). Other vaccine candidates that gave promising results in animal models, 
such as the immunodominant staphylococcal antigen A (IsaA) and the iron-responsive 
surface determinant A (IsdA), still need to be evaluated for their application potential in 
vaccines (47, 62).
S. aureus– human host interactions
A thorough understanding of the mechanisms by which S. aureus can colonize and 
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survive inside its human host is the key to the development of new anti-staphylococcal 
therapies and vaccines. S. aureus has traditionally been classified as an extracellular 
pathogen that is combated through innate immune factors, such as antimicrobial 
peptides and proteins (e.g. lysozyme, defensins and complement), or adaptive immune 
responses (e.g. different types of immunoglobulins) (49, 57, 108). However, in the past 
few years different studies have challenged this concept, showing that S. aureus is able 
to invade and survive in epithelial cells, keratinocytes, endothelial cells, fibroblasts and 
osteoblasts (6, 41, 76, 108). In addition, S. aureus has evolved different mechanisms to 
invade cell types that are incapable of phagocytosis (103). Via a modified ‘zipper-type’ 
mechanism with F-actin rearrangement, S. aureus enters the host cells (104), thereby 
triggering the relapse of S. aureus disease (108). S. aureus tissue invasion provokes 
migration of neutrophils and macrophages to the side of infection in order to phagocytose 
and kill this bacterium (23). The phagocytosis can be promoted either by opsonins, such 
as complement proteins or specific antibodies, which coat the S. aureus cell surface, or 
by direct binding to surface receptors (93). Once S. aureus is phagocytosed it resides in 
a phagosome, where it is exposed to different antimicrobial agents, such as reactive oxygen 
species, nitrogen intermediates and degradative enzymes (23). S. aureus can avoid such 
host defenses by (i) interfering with antimicrobial substances (e.g. staphylokinase protects 
against the bactericidal effects of defensins), (ii) resistance to antimicrobial peptides and 
proteins (e.g. lysozyme resistance due to peptidoglycan  modification), and (iii) by evading 
or resisting oxidative and nitrosative stresses (3, 23, 33, 93). The protection against 
toxic hydrogen peroxide and free radicals relies on protective antioxidants, including 
catalase, staphyloxanthin and the yellow carotenoid pigment (21, 61, 86). Notably, once 
it has entered professional phagocytes (Figure 2), S. aureus can take advantage of these 
cells for transport via the bloodstream and dissemination throughout the human body (108). 
Lastly, S. aureus is able to mediate host cell lysis by secreting cytolytic toxins and proteins 
involved in the manipulation of apoptotic cell death pathways (23, 118). The death of some 
of the internalized S. aureus cells after they have disseminated can lead to the release of 
surviving bacteria and their toxins in certain tissues, which will then drive local inflammation 
and infection (108).
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Figure 2. Internalization of S. aureus by THP-1 human macrophages. GFP-expressing staphylococcal cells are 
colored green, and actin filaments are colored red (Image generated in collaboration with J. Domingues and 
Prof. H.C van der Mei).
The interactions between S. aureus and its human host are central in the development 
of staphylococcal disease. As outlined above, S. aureus infections are usually limited 
by the primary barriers of the skin and mucosa, as well as the innate and adaptive 
immune responses of healthy individuals. However, the situation is different in patients 
where these defenses are compromised. Consequently, such patients are often heavily 
colonized by S. aureus. This has been extensively studied in patients with cystic fibrosis 
or atopic dermatitis (5, 14, 38, 42). In other groups of patients with defective barriers, 
the interactions with S. aureus have been studied to lesser extents. One of these diseases is 
epidermolysis bulosa (EB). EB refers to a group of inherited disorders caused by mutations 
in various structural proteins in the skin. Patients with EB develop blisters as a consequence 
of trivial mechanical trauma (31, 68). Four major EB subtypes can be distinguished, namely 
EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), and Kindler syndrome (29). 
Depending on the type of EB, the symptoms vary in severity from minor blistering of the 
skin to a lethal form involving other organs (97). The ulceration of the skin in patients with 
EB leads to the development of wounds that become colonized by different bacteria (9, 75). 
It has been shown that the most commonly isolated microorganisms from wound cultures of 
EB patients are S. aureus, Streptococcus species, and Pseudomonas aeruginosa (9).
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The presence of bacteria in wounds can be categorized as four different conditions, namely 
contamination, colonization, critical colonization and infection (Figure 3) (28). All chronic 
wounds should be considered as contaminated. In this case, mostly non-replicating 
microorganisms are present within or on the surface of the wound (24). The host defenses 
are usually able to clear these contaminants and, consequently, they do not interfere with 
wound healing. Colonization can be defined as the presence of replicating microorganisms 
adhering to a wound in the absence of tissue damage (24). Critical colonization refers to 
the transition state between colonization and invasive wound infection. This is represented by 
conditions where the bacterial bio-burden in the wound reaches levels at which it interferes 
with healing, but does not produce the classic signs and symptoms of infection (98). 
Whether the colonizing organism invades the tissue depends on a number of microbe-host 
interactions, such as the amount of bacteria per gram tissue, virulence and pathogenicity of 
the respective bacteria and proper innate and adaptive immune responses of the host (121). 
Wound infection is characterized by the presence of replicating micro-organisms within 
a wound with subsequent host injury (24). The wound infection symptoms include 
erythema, warmth, swelling, pain, odor and purulent drainage (60, 89). Notably, wound 
infections that are not adequately treated can progress into systemic infections and even 
sepsis (89). The wounds of patients with EB are highly colonized by S. aureus, since 95% of 
the EB patients with chronic wounds and 59% of the patients without chronic wounds tested 
positive for the presence of S. aureus in their wounds (9, 113). This high wound colonization 
is likely to contribute to the development of chronic wounds (75). In addition, it may 
predispose EB patients to life-threading infections. This view is critically underscored by 
the observation that sepsis is one of the leading causes of death amongst infants with EB. 
Specifically, septicemia was associated with mortality in 14 to 24% of the patients with 
Herlitz type JEB (JEB-H) (30, 123). JEB-H is caused by null mutations in the genes encoding 
an adhesion protein in the epidermal basement membrane: laminin-332 (123). In the absence 
of laminin-332, the skin is prone to generalized painful blistering with persistent erosions 
and granulation tissue formation (46). Possibly, the high susceptibility of patients with 
JEB-H to staphylococcal wound infections relates to the high numbers of recurrent erosions 
found over the diaper area of the skin. These are absent from the wounds of patients with 
other types of EB. This may explain why patients with such other types of EB seem to be 
less susceptible for invasive infections by S. aureus, despite high colonization rates (124). 
In the latter case, effective innate and adaptive immune responses may compensate at least 
partially for the impaired barrier function of the skin (112).
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Figure 3. Schematic representation of the presence of bacteria in a wound. The bacterial presence in wounds 
can be categorized as four different conditions: contamination, colonization, critical colonization and infection. 
Ultimately, this can lead to invasive diseases, such as sepsis. Adapted from Edwards and Harding (28).
Staphylococcal virulence factors 
The pathogenicity of S. aureus is caused by a broad range of cell surface-exposed or secreted 
virulence factors. These include: surface-exposed proteins involved in adherence and 
colonization of host tissues, surface-exposed factors involved in the inhibition of phagocytic 
engulfment (capsule and protein A), invasins exported into the host environment to promote 
the bacterial spread in invaded tissues (e.g. leukocidin, kinases, and hyaluronidase), 
biochemical properties that enhance staphylococcal survival in phagocytes (carotenoid 
and catalase production), immunological disguises (protein A, Sbi, coagulase, and clotting 
factor), superantigens (egc and non-egc SAgs), toxins damaging the membrane of host 
cells (hemolysins and leukotoxin), and determinants for inherent and acquired resistance to 
antimicrobial agents (102). It is known that S. aureus populations carry a range of unique 
variants of these virulence factors. The variation in genes coding for surface proteins and 
immune evasion factors has been shown to be lineage specific (73, 126). In particular, 
variations were observed for genes encoding surface proteins. These may be completely 
absent, or they may be truncated, which then affects predicted functional domains (73). 
The same applies also to genes encoding secreted proteins predicted to interact with the host 
immune system (73). However, the level of variation in the latter genes is less drastic than 
observed for genes encoding surface proteins, and their complete absence or truncation is less 
common (73). Notably, variations in cell surface-exposed and secreted proteins can also relate 
to different expression levels in different S. aureus lineages. The variations in the expression 
levels of virulence genes may relate to differential activities of specific regulators. One of 
the key regulators of virulence factor genes is the RNAIII, which is responsible for their 
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cell density-dependent expression (85). In addition, at least 16 two-component regulatory 
systems are to different extents involved in staphylococcal virulence (36). Strain-specific 
differences in gene regulation may results in different exoproteome patterns as has been 
shown for S. aureus cells grown in vitro (126). Notably, changes in the expression of virulence 
factors seem to relate to different host environments (11, 12, 55, 64, 67). In nasally-carried 
S. aureus cells, the genes encoding the most important adhesion molecules (e.g. clfB, isdA, 
fnbA, atlA, eap), immune-modulating factors (sak, chp, spa) and cell surface remodeling 
factors (sceD, oatA, atlA) are highly expressed, while genes encoding major toxins (hla, psm) 
are not detectably transcribed (11, 12). In contrast, in cutaneous abscesses, genes encoding 
toxin components, such as lukS-PV, lukE, hlgB and hla are up-regulated, while RNAIII, 
bsaB and spa expression seem to be down-regulated (64). In addition, S. aureus incubated in 
human serum or blood up-regulates the genes involved in iron and iron transport-associated 
molecules (67). Taken together, it can be concluded that S. aureus shows major adaptive 
responses to different host environments by changing the expression of different groups 
of virulence factors. Consistent with this idea, specific adaptive immune-responses might 
be raised against different staphylococcal virulence factors, depending on the infection site 
as well as invading strain. 
The immune responses against S. aureus and different staphylococcal proteins have 
been studied extensively both in healthy human individuals as well as patients with 
different diseases. Thus, it was reported that the levels of antibodies directed against 
the toxic shock syndrome toxin 1 (TSST-1), staphylococcal enterotoxin A (SEA) and 
ClfA and ClfB are significantly higher in healthy persistent carriers than in healthy 
non-carriers (117). Anti-staphylococcal antibody levels were shown to increase strongly 
during the course of infection in patients with bacteremia (52, 63, 116). This applied 
in particular to antibodies against IsaA, IsaB, the major cold shock protein (CspA) and 
the phosphocarrier protein (Hpr) (63). In addition, Kolata et al. have shown that during 
bacteremia caused by exogenous S. aureus strains (i.e. strains not carried by the patient), 
there was an increase of immunoglobulins G (IgG) binding to antigens from the invasive 
strain, but not the colonizing strain (52). These findings indicate that adaptive immune 
responses are important to combat invasive staphylococcal infections, which would 
support the concept that active or passive immunization strategies could represent effective 
antistaphylococcal therapies.
Secretion of virulence factors 
To colonize or invade the human host S. aureus expresses different virulence factors, which 
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are first synthesized as precursors with an N-terminal signal peptide to direct their transport 
from the cytoplasm to an extra-cytoplasmic location, such as the cell wall or extracellular 
milieu via different transport system (102). The most commonly used pathway for protein 
transport across the membrane is the general secretory (Sec) pathway. In addition, several 
other special-purpose pathways for protein transport are known, such as the twin-arginine 
translocation (Tat) pathway and the pseudopilin-specific (Com) pathway (Figure 4). 
The Sec translocation machinery is composed of several subunits. The SecA translocation 
motor binds pre-proteins and pushes them through the membrane-embedded 
SecYEG translocation channel via repeated cycles of ATP binding and hydrolysis (27, 
87, 102, 122). The structure of the SecA/SecYEG complex from the Gram-negative bacterium 
Thermotoga maritime suggests that one SecA molecule is bound to one set of SecYEG 
channel proteins. The core of the Sec translocon consists of the SecA, SecY, and SecE 
proteins, which are essential for growth and viability of bacteria, such as Escherichia coli, 
Bacillus subtilis and S. aureus (10, 15, 51). In contrast, the channel component SecG is 
dispensable for growth and cell viability (84, 101, 115). However, unlike the situation in 
B. subtilis, deletion of secG from S. aureus has a profound impact on the composition of 
the exoproteome (101). It was shown that various extracellular proteins were present in 
decreased amounts in the growth medium of secG mutant strains, which is consistent with 
impaired Sec channel function (101). Furthermore, the absence of secG caused a serious 
decrease in the amounts of the cell wall-bound Sbi protein. In addition to the major 
SecYEG channel proteins, S. aureus produces a second set of SecA and SecY proteins, 
generally referred to as SecA2 and SecY2 (100). Comparison of the amino acid sequences 
of the SecY1 and SecY2 proteins shows that their similarity is relatively low (about 20% 
identity) and that the conserved regions are mainly restricted to the membrane spanning 
domains (101). Interestingly, the deletion of the secY2 gene had no detectable effect on 
the exoproteome of S. aureus, which suggests that the SecY2 protein has a very specific role 
in protein export (101). Nevertheless, a secGsecY2 double mutant strain displayed synthetic 




Figure 4. Schematic representation of different protein secretion pathways in S. aureus. Proteins synthesized with an 
appropriate signal peptide are specifically directed to a respective pathway. Furthermore, proteins with a membrane 
anchor domain (TM) are retained in the cytoplasmic membrane, while proteins with a C-terminal LPxTG motif are 
covalently bound to the cell wall. Abbreviations: Psm, phenol-soluble modulin; Fnbp, fibronectin- binding protein; 
Clf, clumping factor; Isd, iron-regulated surface determinant protein; Sas, staphylococcal surface protein; Sdr, 
serine-aspartate repeat protein. Adapted from Sibbald et al. (102).
After membrane translocation of a pre-protein through the Sec channel, the signal peptide is 
removed by signal peptidase. This is a prerequisite for the release of the translocated protein 
from the membrane (2, 114). Thus, in order to be retained at the membrane, translocated 
proteins require specific retention signals (102). Such retention signals may be present in 
the form of a transmembrane anchor domain or lipid-modification that will, respectively, 
attach membrane proteins and lipoproteins to the membrane. Other specific amino acid 
sequence motifs can facilitate non-covalent or covalent cell wall attachment. 
The signal for covalent cell wall attachment is the so-called LPxTG motif that is positioned 
in the C-terminus of the respective exported proteins. The covalent cell wall attachment of 
LPxTG proteins requires the enzymatic activity of so-called sortases (69). These sortases 
are membrane-bound transpeptidases, which cleave the LPxTG motif between the Thr and 
Gly residues and catalyze the formation of an amide bond between the carboxyl group of 
the Thr residue and the free amino end of a pentaglycine cross bridge in peptidoglycan 
precursors (35, 56, 99, 107). The sortases are grouped into four classes (A-D) based on 
phylogenetic criteria (25). S. aureus possesses one sortase A (SrtA) enzyme, which recognizes 
the general LPxTG motif (71, 83). It has been shown that S. aureus lacking the srtA gene is 
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impaired in the retention of LPxTG proteins in the cell wall. As a consequence, the absence 
of SrtA causes a defect in the establishment of acute infections (70). In addition, the srtA 
mutation causes a hyper-spreading phenotype probably because it interferes with cell-cell 
attachment through surface-exposed LPxTG proteins (111). It has been reported that 
19 different S. aureus proteins carry the canonical C-terminal LPxTG motif and that two 
additional proteins carry a C-terminal LPxAG motif  (34, 69, 82, 92, 102). These include 
protein A (Spa), two fibronectin-binding proteins (FnbpA and FnbpB)(40), ClfA, ClfB, three 
cell wall-anchored proteins with large serine-aspartate repeat domains (SdrC, SdrD and SdrE) 
(45), a collagen- binding protein (Cna), a plasmin-sensitive protein (Pls) (96), the methicillin 
resistance determinant B (FmtB) (53), and eleven staphylococcal surface (Sas) proteins. 
In addition to SrtA, S. aureus contains a second sortase known as SrtB. SrtB is required for 
the cell wall anchoring of surface proteins that contain an NPQTN motif. So far, the only 
protein known to be covalently coupled to the cell wall by SrtB is IsdC (72). Another 
S. aureus protein with a motif that resembles NPQTN is the DNA-binding protein II, but 
this protein is probably not cell wall-bound, because it lacks a signal peptide for export from 
the cytoplasm (102). It is presently not known how important SrtB is for staphylococcal 
virulence in general, but S. aureus lacking srtB was shown to have a small defect in 
the establishment of arthritis in a mouse model (44). 
In recent years, the functions of many secretion machinery components of S. aureus 
have been elucidated, as exemplified by studies on the Sec and Tat pathways (8, 13, 20, 
43, 101, 106). Intriguingly however, for several other predicted secretion machinery 
components, no biological functions were so far described. This applies for example 
to the pseudopilin export machinery of S. aureus. This machinery is very similar to the 
Com machinery for DNA binding and uptake in B. subtilis. Interestingly, the genes coding 
for most Com proteins are present in the sequenced S. aureus strains, suggesting that this 
bacterium is able to assemble pseudopili of the Com type (102). In B. subtilis, the ComGC, 
ComGD, ComGE, and ComGG proteins form pilin-like structures that are localized to 
the cytoplasmic membrane and cell wall (16- 18, 109). Assembly of the pseudopilus in 
B. subtilis requires the specific signal peptidase ComC, which processes the N-terminal 
signal peptides of ComG proteins upon membrane translocation (16, 109, 110). Furthermore, 
stability of the B. subtilis ComGC pseudopilin requires post-translocational disulfide bond 
formation, which is catalyzed by the thiol-disulfide oxidoreductases BdbC and BdbD (16, 
26, 54, 74). In S. aureus, the transcription of the respective com genes, which are organized 
in the comG and comE operons, is directed by the staphylococcal alternative sigma factor 
σH (80). Judged by the presence of these com genes and  a dedicated transcription factor, 
it seemed likely that S. aureus can employ its Com proteins for DNA uptake. Indeed, this 
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was recently confirmed by Morikawa et al. (81), who showed that S. aureus cells producing 
active σH become competent for natural transformation by plasmid or chromosomal DNA.
Taken together, the remarkable success of S. aureus as an opportunistic pathogen seems to 
be based on the acquisition of highly effective systems for colonization and subversion of 
its human host, and for the evasion of innate and adaptive host defenses. On top of that high 
levels of genomic plasticity and variability in gene expression allow the S. aureus ‘superbug’ 
to change its appearance, which adds significantly to its capacity to avoid elimination by the 
human host. Accordingly, novel strategies to combat this pathogen through immunotherapy 
must be based on an integrated approach that requires the identification of invariant and 
immune-dominant targets. The identification of such targets requires (i) in-depth analyses on 
the localization of proteins and other compounds to the staphylococcal cell surface and (ii) 
a thorough understanding of the human immune responses to these cell surface-exposed 
compounds.
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Scope of this thesis
S. aureus is a commensal bacterium, which colonizes about 30% of healthy human 
population. However, if the primary barrier function of the skin is disrupted or if the immune 
system is compromised, S. aureus is given the opportunity to invade its human hosts, which 
can then result in systemic infections. Currently, the treatment of staphylococcal infections 
relies mainly on the administration of antibiotics. However, due to the high adaptability of 
this bacterium, many S. aureus lineages have become resistant to antibiotics. Therefore, 
alternative ways to prevent and cure staphylococcal diseases need to be discovered. 
An attractive but challenging option is the development of active or passive immunization 
strategies. To be able to develop effective anti-staphylococcal vaccines or therapeutic 
antibodies, the staphylococcal cell surface as well as exported virulence factors need to be 
mapped in detail. At the same time the immune responses of the human host to S. aureus need 
to be defined. Ideally, this involves investigations with volunteers, whose immune system 
has been heavily challenged with different staphylococcal lineages expressing a broad range 
of virulence factors. The overarching objective of the research presented in this thesis was 
therefore (i) to identify individuals who are heavily challenged by S. aureus, (ii) to map 
the cell surface-exposed S. aureus components that are targeted by the immune responses of 
these individuals, and (iii) to obtain a better understanding of the mechanisms that govern 
the expression and export of potential targets for antistaphylococcal therapies. The essential 
components in the interactions between S. aureus and its human host have been introduced 
in Chapter 1 of this thesis. In addition, Chapter 1 gives an overview of the different 
virulence factors produced by S. aureus and the mechanisms by which they are exported 
from the cytoplasm to the cell surface and the extracellular milieu of the bacteria which, in 
case of an infection, is synonymous with the cells and tissues of the human host. 
The studies described in Chapter 2 reveal that patients with the blistering disease 
epidermolysis bullosa (EB) are heavily colonized with S. aureus. The results of extensive 
sampling revealed that all EB patients with chronic wounds, and the majority of patients 
without chronic wounds carry S. aureus. Molecular typing of the collected isolates showed 
that the S. aureus population structure in EB patients mirrors the geographical distribution 
of S. aureus types in the Netherlands. Furthermore, typing revealed that self-transmission of 
S. aureus between wounds and the upper respiratory tract of individual EB patients occurs 
frequently, whereas transmission of S. aureus between different EB patients appears to be 
rare.
Chapter 3 focuses on the colonization of EB patients with S. aureus in time and its impact 
Chapter 1
22
on adaptive antistaphylococcal immune responses. Analysis of all collected isolates 
revealed major fluctuations in the S. aureus types carried over a period of ~2 years. Overall, 
the sera of EB patients contained higher antistaphylococcal IgG levels than those of healthy 
individuals. Specifically, this applied to IgGs against nine important virulence factors, 
including the superantigens SEM, SEN and SEO. Notably, EB patients carrying different 
S. aureus types contained higher levels of antistaphylococcal antibodies than EB patients 
colonized by only one type. This suggests that the immune system of EB patients is heavily 
challenged with S. aureus antigens. Notably, some of the IgGs that are present at elevated 
levels may compensate for the impaired barrier function of the skin of the investigated 
EB patients.
In Chapter 4, the staphylococcal topography of chronic wounds of five EB patients was 
examined by replica-plating of used bandages. Molecular typing of these isolates revealed 
that individual chronic wounds contained up to six different S. aureus types at one time point 
of sampling. Some of these isolates were closely related suggesting that they share a recent 
common ancestry. Importantly, other isolates derived from adjacent wound locations belong 
to distinct molecular complexes of S. aureus. These observations imply that the classical 
assumption that one individual is predominantly colonized by one type of S. aureus does 
not apply to chronic wounds of patients with EB.
Chapter 5 reports on the use of antibodies from EB patients to identify immunodominant 
targets in S. aureus. Specifically, cell surface-exposed staphylococcal proteins were profiled 
by tryptic ‘surface shaving’ approaches and gel-free mass spectrometry (MS). A subset of 
the identified proteins were screened for interactions with antibodies from EB patients. 
This led to the identification of immunodominant domains in several surface-exposed 
proteins, including the covalently cell wall-bound proteins ClfB and IsdB, a ‘YkyA-like’ cell 
wall- binding lipoprotein, the membrane proteins EbpS and LtaS, the non-covalently cell 
wall-bound and secreted proteins Atl, Sbi, IsaA, Emp, and the cytoplasmic proteins Afl1, 
Eno, and GAPDH. These proteins are thus potentially powerful targets for antistaphylococcal 
immune therapies.
The studies described in Chapter 6 report on the application of the surface shaving protocol 
to profile the binding of human serum proteins to S. aureus. As shown by surface shaving 
with trypsin and subsequent MS analysis of liberated peptides, several components of 
the complement system, the platelet factor 4 and the isoform 1 of the inter-α-trypsin  inhibitor 
heavy chain H4 are detectable on the staphylococcal cell surface upon incubation in 
human serum. The surface shaving technique is thus a versatile tool to profile global 
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interactions between human serum proteins and the S. aureus cell surface.
Chapter 7 describes the roles of the non-essential Sec channel components SecG and 
SecY2 in the biogenesis of the extracellular proteome of S. aureus. The results show that 
SecG is of major importance for protein secretion by S. aureus. No secretion defects were 
detected for strains with a secY2 single mutation. However, deletion of secY2 exacerbated 
the secretion defects of secG mutant cells. Furthermore, a secGsecY2 double mutant strain 
displayed a synthetic growth defect. This might relate to a slightly elevated expression 
of sraP, encoding the only known substrate for the Sec2 pathway, in cells lacking SecG. 
Additionally, the results suggest that SecY2 can interact with the Sec1 channel, which would 
be consistent with the presence of a single set of secE and secG genes in S. aureus.
Studies on the staphylococcal pseudopilin export pathway are documented in Chapter 8. 
The results show that ComGC from S. aureus localizes to the cytoplasmic membrane and 
cell wall, consistent with the formation of pseudopili. Furthermore, the studies show that 
the thiol-disulphide oxidoreductase DsbA is required for ComGC stability, suggesting that 
this pseudopilin contains a disulfide bond as is the case for its homologue in B. subtilis. 
The pseudopilin-specific signal peptidase ComC is needed for ComGC processing and 
optimal cell surface exposure. Notably, chapter 8 represents the first report where biological 
functions are demonstrated for S. aureus DsbA and ComC.
The studies presented in Chapter 9 were aimed at determining the relevance of sortase 
activity for in vitro staphylococcal growth in human plasma. The results show that, 
depending on the investigated strain, SrtA can be important for efficient growth in human 
plasma, whereas SrtB is not required. Transcript profiling of srtA mutant cells grown in 
human plasma revealed a typical phosphate starvation response, even though this ‘medium’ 
is known to contain relatively high phosphate concentrations. This suggests that one or more 
covalently cell wall-bound proteins, such as FnbpA and FnbpB, are involved in phosphate 
binding or uptake.
Although the sortase-mediated cell wall attachment of proteins has been characterized in great 
detail, it was thus far not known how sortases shape the actual surface of a staphylococcal 
cell with respect to proteins that are directly exposed to the extracellular milieu. Therefore, 
the studies described in Chapter 10 were aimed at determining the ‘surfacomes’ of srtA or 
srtB mutant cells of S. aureus. As shown by ‘cell surface shaving’ with immobilized trypsin, 
SrtA has a major impact on the staphylococcal surfacome, whereas SrtB is only of minor 
importance. Specifically, the results show that the sortase-dependent surfacome consists of 
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covalently cell wall-bound ‘LPxTG proteins’, non-covalently wall-bound proteins, known 
secreted proteins and cytoplasmic proteins. Intriguingly, the data suggest that certain LPxTG 
proteins serve as nodes in the cell wall interactome of S. aureus.
Finally, the results presented in this thesis are discussed in Chapter 11, where also an 
outlook for future research is presented.
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Patients with the blistering disease epidermolysis bullosa (EB) frequently suffer from chronic 
wounds that become colonized by pathogenic bacteria, such as Staphylococcus aureus. 
To  determine S. aureus colonization rates in EB patients, swabs were collected from 
the anterior nares, throats and wounds of 52 Dutch EB patients. Swabs were also collected 
from nares and throats of 13 healthcare workers who occasionally meet the sampled 
EB patients. All EB patients with chronic wounds and 75% of the patients without chronic 
wounds were colonized with S. aureus. In contrast, 39% of the sampled healthcare workers 
were colonized with S. aureus. Typing revealed a high degree of genetic diversity of 
184 collected S. aureus isolates. Autoinoculation of S. aureus in individual EB patients 
was shown to occur frequently, whereas transmission of S. aureus between EB patients is 
apparently rare. There was no evidence for S. aureus transmission between EB patients and 
healthcare workers. 




Epidermolysis bullosa (EB) is a genetic blistering disease (3, 11). Because the natural 
barrier function of their skin is breached (2, 13), EB patients are more likely colonized 
with opportunistic microorganisms. To date, only two studies addressed the microbial 
colonization of wounds of EB patients, indicating that they are mostly colonized by 
staphylococci, streptococci and Pseudomonas aeruginosa (1). Up to 86% of the EB patients 
tested positive for Staphylococcus aureus (1, 4). S. aureus is a commensal bacterium, which 
colonizes epithelial surfaces, such as the skin and the anterior nares in 25-37% of healthy 
adults (7, 9, 16). However, under certain circumstances, including a breach of the skin, 
S. aureus can become invasive which may lead to severe infections (8). Importantly, S. aureus 
nasal carriage is an important risk factor for infections (8, 15-17), and the presence of this 
bacterium in wounds can contribute to the development of chronic wounds (5, 7, 10, 12). 
Accordingly, one of the leading causes of death amongst infants with EB is sepsis (2).
Question addressed
Despite its clinical relevance, the colonization of EB patients with S. aureus has thus far not 
been investigated in great detail, and it was not known whether colonization of EB patients 
is biased towards certain S. aureus lineages. Therefore, the present studies aimed at defining 
the S. aureus population colonizing patients with EB. 
Methods
Patients and bacterial isolates
52 patients with EB were recruited from the Dutch epidermolysis bullosa Registry (DEBR) 
at the University Medical Center Groningen (UMCG). This patient cohort included 31 male 
and 21 female individuals, who ranged in age between 7 months and 76 years (mean 
25.5 years). Additionally, 13 healthcare workers from the UMCG were included in this study 
(6 males and 7 females, who ranged in age between 25 and 60 years), who have contacts 
with individual EB patients about one to four times four year. Samples were taken from 
3 distinct wounds, the left and right anterior nares, and the throat of each patient using 
transswabs (MWE, Corsham, England). As the included healthcare workers lacked wounds, 
they only donated samples from the left and right anterior nares and throat. The obtained 
samples were cultivated on blood agar (BA) plates with 5% sheep blood (Mediaproducts BV, 
Groningen, the Netherlands) and S. aureus was identified on the basis of colony morphology, 
Gram staining, a positive catalase reaction and the Pastorex Staph Plus test from Bio-Rad. 
All S. aureus strains were stored in 8% glycerol at - 80°C. For further analyses, the S. aureus 
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isolates were streaked on BA plates and cultivated overnight at 37°C. Cell lysates were 
prepared as previously described (14).
Ethical approval
The local medical ethics committee of the University Medical Center Groningen approved 
of the collection of bacterial samples from patients with EB on the basis of informed consent. 
The informed consent was obtained from all patients included in the present studies.
Multiple-locus Variable Number of Tandem Repeats Analysis
VNTR PCR reactions were performed as described by Schouls et al. (14). Briefly, repetitive 
DNA sequences from the genes encoding the V8 serine protease (sspa), protein A (spa), 
staphylocoagulase (coa) and from 5 non-coding regions were amplified in two multiplex 
PCR reactions. Diluted PCR products were mixed with the GeneScan 1200 LIZ marker 
(Applied Biosystems) and after heat denaturation separated on an ABI 3730 DNA sequencer. 
The number of the repeats of each VNTR was calculated with GeneMArker software 
(Softgenetics, State Collage,USA). Minimum spanning trees were created according to 
the procedure described before (14) using Bionumerics software (Applied Maths).
Spa typing
Spa sequence typing was performed according to the RIDOM protocol (http://www. ridom. de) 
with previously described modifications (14). Shortly, 1µl of staphylococcal lysate was 
included in a 25 µl PCR HotStart master mix (Qiagen, Hilden, Germany) containing 2.5 pmol 
of forward (5’-TAAAGACGATCCTTCAGTGAGC-3’) and reverse (5’-CAG CAG TAG 
TGC CGT TTG CTT-3’) primers. The resulting PCR product was sequenced and analyzed 
with Bionumerics software (Applied Maths). The nine novel spa-types that were identified 
have been submitted to the Ridom SpaServer. 
Statistical analyses 
Statistical analyses were performed with SPSS statistics for Windows.  Data were compared 
using two-tailed independent student t-tests, and P-values <0.05 were considered significant.
Results
The EB patients were divided into two groups consisting of EB patients with chronic 
wounds (n=20) who had multiple non-healing wounds over periods of more than 3 months, 
and EB patients without chronic wounds (n=32) who had relatively few wounds that 
healed in shorter periods of time. We collected 178 S. aureus isolates from EB patients and 
6 from healthcare workers. All patients with chronic wounds were colonized by S. aureus 
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on at least one site, and 75% of the patients without chronic wounds were colonized by 
this bacterium (Figure 1A). The highest colonization rates were identified in wounds, and 
the lowest in the throat. There was no specific correlation between patient age and S. aureus 
colonization (not shown). In contrast to the EB patients, 39% of the included healthcare 
workers carried S. aureus, which closely matches the S. aureus colonization rates in healthy 
adults (7, 9, 16).
Typing of all 184 S. aureus isolates by Multiple-locus-Variable-Number-of-Tandem-Repeats-
Analysis (MLVA) distinguised 67 S. aureus types (Table 1). 79 strains were selected for 
further analysis by spa-typing, which identified 51 different types including 9  novel types 
(Table 1). These analyses revealed that EB patients with chronic wounds were colonized with 
up to four different S. aureus MLVA types, and EB patients without chronic wounds with up 
to three different MLVA types (Figure 1B-C). To visualize the genetic diversity of the isolated 
S. aureus strains, they were plotted in a minimum spanning tree of ~23,000 S. aureus isolates 
collected in the Netherlands (Figure 2). This showed that the isolated S. aureus strains are 
randomly distributed amongst the different MLVA complexes. In most cases where different 
MLVA types were detected in one EB patient, they belonged to different MLVA complexes 
as exemplified for patient 44 (Figure 2). 
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Figure 1. Frequency of S. aureus detected in the patients with EB. (A) S. aureus colonization rates at different body 
sites of EB patients and healthy healthcare workers. A distinction was made between EB patients with chronic wounds 
(black bars) and EB patients without chronic wounds (white bars). Grey bars represent the S. aureus colonization 
rates in the sampled healthcare workers. The statistical significance of observed differences was assessed, and 
differences with P-values of = 0.05 are marked with a star (*). URT, upper respiratory tract. (B) The frequency 
of the occurrence of multiple S. aureus isolates of different MLVA types within individual patients is represented 
for the entire sampled EB patient cohort, (C) and for the sampled wounds of these patients. Patients with less than 
3 wounds were not included in this particular analysis. The numbers of different S. aureus MLVA types within 
individual patients are indicated in the differently marked fields in each bar. (D) Absence of autoinoculation is 
represented by the frequencies of EB patients who were colonized with S. aureus only in the nose/throat, or only in 
their wounds. In certain cases, the nose and/or throat and wounds were colonized by different S. aureus MLVA- types. 
(E) S. aureus autoinoculation in EB patients with three wounds. In case of ‘full autoinoculation’, a particular 
S. aureus MLVA type was detectable in all three wounds and in the nose and/ or throat. In case of ‘partial 
autoinoculation’, isolates from the nose and/or throat and at least one wound belonged to the same MLVA type. 
White bars, EB patients without chronic wounds; black bars, EB patients with chronic wounds.
The transmission of S. aureus between different EB patients is rare as maximally three 
patients were colonized with the same MLVA type (Table 1). None of the S. aureus MLVA 
types isolated from healthcare workers was identified amongst the EB patients, indicating 
the absence of transmission. To determine the autoinoculation rates of S. aureus within 
EB patients, we compared isolates from the wounds of individual patients with isolates 
from their nose and/or throat. This revealed that extensive autoinoculation of S. aureus 
from the nose/throat to the wounds (or vice versa) had occurred (Figure 1D-E). Several 
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cases of ‘partial autoinoculation’ were observed (Figure 1E). In these cases, strains isolated 
from nose or throat and at least one wound isolate belonged to the same MLVA type, while 
other wound isolates belonged to different MLVA types. In 25% of the patients with chronic 
wounds all wound isolates belonged to different MLVA types as compared to strains isolated 
from nose or throat (Figure 1D), suggesting that autoinoculation had not occurred or that it 
remained undetected.
Conclusion
Here we report an unexpectedly high rate of S. aureus colonization among EB patients. 
Even if only the colonization rates of the upper respiratory tract are compared, the rates 
determined for EB patients (56-90%) were substantially higher than those measured for 
healthy individuals (25-37%) (7, 16) or healthcare workers who meet the sampled EB patients 
(39%). This implies that the wounds of EB patients represent an attractive niche for S. aureus. 
Molecular typing showed that (i) colonization of the EB patients is not limited to specific 
genetic lineages of S. aureus; (ii) individual patients with EB can carry up to four different 
staphylococcal MLVA types; and (iii) autoinoculation of staphylococci between the upper 
respiratory tract and wounds of EB patients occurs frequently. The view that colonization of 
EB patients by S. aureus is a random process is supported by spa-typing analyses, which show 
that most of the identified spa-types belong to the most predominant spa-types in the areas 
of residence of the respective EB patients (6). Thus, the S. aureus population structure in the 
sampled EB patients mirrors the general S. aureus population structure in the Netherlands. 
An important finding is that the rate of S. aureus transmission between different patients in 
the sampled population is relatively low. The few cases where different EB patients did carry 
the same S. aureus MLVA types concern family members, or individuals who live in an area 
where the respective spa-types are very common also amongst the general population (14). 
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Figure 2. Minimum spanning tree based on MLVA of ~23,000 S. aureus isolates of which ~90 % were MRSA. 
Green circles represent S. aureus isolates from the nose and/or throat of EB patients. Red circles represent 
S. aureus isolates from the wounds of EB patients. The size of each circle is indicative for the number of S. aureus 
isolates with this particular MLVA type. Arrows indicate the tree location of S. aureus isolates from the upper 
respiratory tract (URT) or wounds (W) of chronic EB patient 44. 
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Table 1. Results of MLVA and spa-typing of S. aureus strains isolated from 52 patients with EB and the five 
S. aureus carrying healthcare workers. 
Chronic 
wounds
Left nare Right nare Throat Wound 1 Wound 2 Wound 3
MLVA spa MLVA spa MLVA spa MLVA spa MLVA spa MLVA spa
Patient 1 Yes 656 t1081 565 nd 656 nd 238 t377 538 t065
Patient 2 Yes 550 t026 550 nd 550 nd 550 nd 550 nd 550 nd
Patient 3 No 2024 t216 2024 nd 2024 nd 2024 nd 2024 nd
Patient 4 Yes 7 t091 7 nd 665 nd 7 nd
Patient 5 Yes 1965 t179 184 t085 1965 nd 1965 nd 1965 nd 1965 nd
1965 nd
Patient 6 Yes 1101 t5515 1162 nd 1162 t008
Patient 7 Yes 565 t571 656 nd 565 nd 565 nd 565 nd
Patient 8 Yes 332 t723
Patient 9 Yes 1966 t127 1967 t127 1967 nd 1966 nd 1966 nd
Patient 10 No 330 t008 1968 t349 1968 nd 330 nd 330 nd 330 nd
Patient 11 No 482 t148 482 nd 482 nd 482 nd 482 nd
Patient 12 No 538 t065 314 t008 8 t008 8 nd - -
Patient 13 No 613 t159 - - - -
Patient 14 Yes 2025 t311 67 t311 67 nd
Patient 15 Yes 330 t008 330 nd 330 nd 330 nd 330 nd 330 nd
Patient 16 No 1969 t084 1969* nd 1969 nd
1970 t010
Patient 17 No 1970* t010
Patient 18 Yes 1837 t502 1837 nd 1837 nd 1837 nd 1837 nd 1837 nd
Patient 19 No - -
Patient 20 No - -
Patient 21 Yes 1971 t4169 1972 t401
Patient 22 No 321 t1476 321 nd 321 nd 321 nd
Patient 23 No 321 t1476 321 nd 321 nd
Patient 24 No 321 nd 321 t1476 321 nd
Patient 25 No 2026 t1827 2026 nd 2031 t704 - - - -
Patient 26 No 1973 t1252 1973 nd 1973 nd 1973 nd 1973 nd
Patient 27 No 1973 t1252 1973 t1252 1973 nd 1973 nd 1973 nd
Patient 28 No 321 t377 321 nd 321 nd
Patient 29 Yes 322 t5511 322 nd 322 nd
Patient 30 Yes 1057 t5508 1057 nd 654 t5513 632 t267 632 nd 632 nd
Patient 31 No 2027 t291 2027 nd 2027 nd 2027 nd 2027 nd
Patient 32 No 534 t026 534 nd 534 nd 534 nd 534 nd
Patient 33 No 45 t050 45 nd 45 nd
Patient 34 Yes 1974 t015 1974 nd 1974 nd 1974 nd 1974 nd 1974 nd
Patient 35 No 490 t5510 490 t5510 490 nd 1975 t5510 1976 t5510
Patient 36 No 1977 t450 1977 nd 1978 t450 1979 t450 1981 t450 - -
Patient 37 No - - - - - -
Patient 38 No - - - - - -
Patient 39 No - - - - - -
Patient 40 No 1982 t130 510 t065 - - - - - -
Patient 41 No 510 t065 510 nd - - - - - -
Patient 42 Yes 46 t1154 46 nd 46 nd
Patient 43 Yes 1552 t224 1552 nd 1552 nd 1552 nd 1552 nd 1552 nd





Left nare Right nare Throat Wound 1 Wound 2 Wound 3
MLVA spa MLVA spa MLVA spa MLVA spa MLVA spa MLVA spa
Patient 44 Yes 67 t311 67 n 1983 t098 1983 nd 1316 t012
Patient 45 No - - - - - -
Patient 46 Yes 67 t311 1107 t021 1316 t012 1316 nd
Patient 47 No 770 t018 - - - - - -
Patient 48 No 1140 t005 - -
Patient 49 No
Patient 50 No 1984 t160 1984 nd 489 t1869 - - - -
Patient 51 Yes 1987 t5512 1987 nd 733 t067 1987 nd 1988 t5514 1989 t5512
Patient 52 No - -
HCW 3 N/A 536 t1601 N/A N/A N/A N/A N/A N/A
HCW 4 N/A 371 t091 N/A N/A N/A N/A N/A N/A
HCW 5 N/A 204 t364 204 nd N/A N/A N/A N/A N/A N/A
HCW 6 N/A 1985 t209 N/A N/A N/A N/A N/A N/A
HCW 8 N/A 1986 t159 N/A N/A N/A N/A N/A N/A
Abbreviations: nd, not determined; empty cell, negative for S. aureus; -, no swab obtained; HCW, healthcare 
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Patients with the blistering disease epidermolysis bullosa (EB) develop wounds that are highly 
susceptible to bacterial colonization. Recently, we reported that over 75% of the EB patients 
sampled at one particular point of time were colonized with Staphylococcus aureus. 
To determine possible changes in S. aureus colonization over time, swabs were collected 
from the nares, throats and wounds of 61 EB patients at three time points during a period of 
~2 years. All S. aureus isolates were typed by Multiple-locus Variable Number of Tandem 
Repeats Analysis and spa-typing. This revealed major fluctuations in the S. aureus types 
sampled from individual EB patients. In addition, blood donations were obtained from 
13 EB patients to determine their IgG levels against 43 virulence factors or whole cells of 
S. aureus. Overall, the sera of EB patients contained higher anti-staphylococcal IgG levels 
than those of healthy individuals. Specifically, this applied to IgGs against nine important 
virulence factors, including the superantigens SEM, SEN and SEO. Notably, EB patients 
carrying different S. aureus types contained higher levels of anti-staphylococcal antibodies 
than EB patients colonized by only one type. Our findings suggest that the immune system 
of EB patients is heavily challenged with S. aureus antigens. 
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Introduction 
Epidermolysis bullosa (EB) is a genetic blistering disease that renders patients susceptible to 
colonization by the opportunistic pathogen Staphylococcus aureus (1, 3, 10). Recently, we 
observed that all EB patients with chronic wounds, and 75% of the patients without chronic 
wounds were colonized with S. aureus (15). In contrast, only ~30% of the healthy human 
population carries this pathogen (22). Persistent S. aureus carriers have an increased risk for 
staphylococcal infections but, compared to non-carriers, their risk of death due to bacteremia 
is lower (23). This may relate to increased levels of protective anti-staphylococcal antibodies 
upon long-term exposure to colonizing strains (8). Furthermore, anti-staphylococcal 
antibody levels were shown to increase strongly during bacteremia (8, 18). Since high 
exposure to S. aureus is a potential health risk for EB patients, our present studies were 
firstly aimed at defining their S. aureus population over time and, secondly, at determining 
their anti- staphylococcal IgG levels.
Results and Discussion
Based on informed consent, 61 EB patients from the Dutch epidermolysis bullosa Registry 
were included in our studies. S. aureus colonization was determined in three rounds of 
sampling at half-yearly intervals. In each round, swabs were collected from 3 wounds, 
the left and right anterior nares, and the throat. 43 EB patients participated in the second 
sampling round, 40 in the third, and 35 patients participated in all three sampling rounds. 
Overall, we identified 101 different S. aureus types by molecular typing with Multiple- locus 
Variable Number of Tandem Repeats Analysis (MLVA). Only 18 of these MLVA types 
were encountered in all rounds (Figure 1A). 118 strains were also spa-typed, revealing 
48 different spa-types (Table 1). Next, we compared the variations in S. aureus types 
isolated from individual EB patients over time. This revealed that the same MLVA type 
was identified on ~42.5% of all sampled patients with minor variations for different sites of 
sampling (Figure 1B). Furthermore, 58.3% of the patients with chronic wounds and 43.5% 
of the patients without chronic wounds carried alternating S. aureus MLVA types over time. 
In 8.7% of the patients without chronic wounds, a different MLVA type was encountered in 
each sampling round. These findings show that the included EB patients are continuously 
challenged by different S. aureus types and that the carried S. aureus population can change 
rapidly. This seems to challenge the classical dogma that persistent carriers are mainly 
colonized by one S. aureus type (22). However, our studies specifically address a patient 
group that is highly susceptible to S. aureus due to continuous skin defects, which is different 
from the situation in healthy individuals. 
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Figure 1. S. aureus MLVA types identified in EB patients over a period of ~2 years. (A) Summary of the numbers 
of different MLVA types identified in three rounds of sampling. (B) Changes in the S. aureus MLVA types isolated 
from 35 EB patients in three rounds of sampling. The MLVA typing results were analyzed for individual EB patients 
with chronic wounds (n=12) or without chronic wounds (n= 23). Black bars, percentage of patients not carrying 
S. aureus; white bars, percentage of patients colonized by the same MLVA type in all three sampling rounds; 
dark gray bars, percentage of patients colonized by different types in all three sampling rounds; light gray bars, 
percentage of patients with alternating MLVA types. URT, upper respiratory tract.
To assess the anti-staphylococcal IgG levels in EB patients, we first performed whole-cell 
Enzyme-Linked Immunosorbent Assays (ELISAs) using an S. aureus mutant lacking 
the IgG-binding proteins Spa and Sbi, and IgGs isolated from patients with chronic 
wounds. Sera from healthy donors were used as controls. This revealed that EB patient sera 
contained significantly higher anti-staphylococcal IgG levels than the controls (Figure 2). 
To determine specific responses, the levels of serum IgGs from 13 EB patients against 43 
purified S. aureus antigens were measured using Luminex technology (Figure 3). As controls, 
the sera from 14 age-matched healthy individuals were used. For most antigens, the median 
fluorescence intensities (MFI) were higher in EB patients than in the control group. 
Especially, the MFI levels for IgGs against the surface proteins IsdA and SasG, the secreted 
proteins IsaA, SCIN, Nuc and LytM, and the superantigens (SAgs) SEM, SEN and SEO 
were statistically significantly higher in EB patients. The increased IgG levels against IsaA, 
SCIN, Nuc, and LytM could be explained by the fact that these proteins are expressed by 
many S. aureus types (24). Also, the egc gene cluster-encoded SAgs SEM, SEN and SEO 
are amongst the most prevalent SAgs of S. aureus (52%-66%) (6). Intriguingly, persistent 
carriers, bacteremia patients and furunculosis patients were found to develop no, or only 
low levels of antibodies against these SAgs (2, 5, 7). This suggests that EB patients are more 
significantly challenged by egc SAgs than healthy carriers and bacteremia or furunculosis 
patients.
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Figure 2. Serum IgG responses of EB patients to S. aureus cells. Cells of the S. aureus Newman spa sbi double 
mutant were grown till exponential phase, diluted to an OD
600
 of 0.4 and used in whole cell ELISA assays. Human 
IgG’s were applied at 250 ng/ml and the reaction was measured at 450 nm. Squares represent IgGs from patients 
with EB (n=11), and triangles represent IgGs from healthy control donors (n=6). The difference in the IgG responses 
of EB patients and the healthy control group to S. aureus was statistically significant (p<0.0001).
To determine whether carriage of multiple S. aureus strains impacts on anti-staphylococcal 
IgG levels, we compared patients colonized by 1 MLVA type (n= 7) with patients colonized 
by multiple MLVA types (n=5). Interestingly, the highest MFI levels were observed for IgG’s 
from patients carrying multiple MLVA types. This was particularly evident for IgG’s against 
IsdA, LukD, HlgB, LytM, LukS, LukF and ETA (Figure 3B). Notably, the incidence of 
LukS/F is very low so, conceivably, the respective Luminex signals represent cross- reactive 
IgGs against the more common HlgA/B or LukE/D proteins (4). A significant correlation 
between anti-staphylococcal IgG levels in serum, wound fluid and sterile blister fluid 
was revealed in samples from one EB patient (Figure 3C). Here, the largest difference 
concerned 4-fold lowered anti-IsaA levels in wound fluid. This implies that future studies 




Figure 3. IgG responses of EB patients to staphylococcal antigens. IgG levels were determined by Luminex assays 
with (A) sera of EB patients, (B) sera of EB patients colonized by 1 or multiple MLVA types, or (C) serum, 
blister fluid and wound fluid of one EB patient. Median fluorescence intensity (MFI) values reflect the levels 
of antigen- specific IgGs. (A) red diamonds, EB patient samples (n=13); blue triangles, age-matched healthy 
controls (n=14). (B) red triangles, samples from EB patients colonized over time by multiple MLVA types (n=5); 
green diamonds, samples from EB patients colonized by one MLVA type (n=7). (C) Green diamonds, blister fluid; 
black triangles, wound fluid; red squares, serum. Median levels of IgGs are indicated by horizontal lines. 
Stars indicate statistically significant differences (p<0.05). 
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In conclusion, EB patients are highly challenged with very diverse S. aureus types and carriage 
of multiple S. aureus types seems to elicit the highest humoral responses in these patients. 
However, we cannot exclude the alternative possibility of increased humoral- and reduced 
cell-mediated immunity in EB patients, which might impact on S. aureus carriage. Notably, 
EB patients do not frequently suffer from S. aureus bacteremia, and none of the patients 
who donated blood was treated for staphylococcal bacteremia in the 5 years prior blood 
donation. This suggests that their high anti-staphylococcal antibody titers may be protective 
against invasive S. aureus infections, which would be consistent with the protective effects 
of IsaA-specific antibodies in mice (9). 
Materials and methods
Ethical approval
The authors declare that experiments using human materials were performed with 
institutional approval upon written informed patient consent, and with adherence to 
the Helsinki Guidelines. Specifically, the medical ethics committee (METc) of the University 
Medical Center Groningen (UMCG) approved of the collection of non-invasive samples 
from patients with EB on the basis of written informed patient consent. Furthermore, 
the METc of the UMCG approved of the blood donations from patients with EB on the basis 
of written informed patient consent (approval no. NL27471,042,09). The Independent 
Ethics Committee of the Foundation ‘Evaluation of Ethics in Biomedical Research’ (Assen, 
the Netherlands), approved the protocol for blood donations from healthy volunteers on 
the basis of written informed patient consent. This protocol is registered by QPS Groningen 
(code 04132-CS011). The required informed consent was obtained from all EB patients and 
healthy volunteers included in the present studies.
Patients and bacterial isolates 
In total 61 patients with EB from the Dutch epidermolysis bullosa Registry (DEBR) were 
recruited and sampled as described. Samples were taken from 3 distinct wounds, the left 
and right anterior nares, and the throat of each patient using transswabs (MWE, Corsham, 
England). This sampling was performed three times with about half yearly intervals. 
In the second round of sampling, 43 patients with EB were included and in the third round 
40. In total, 35 patients with EB participated in all three sampling rounds. S. aureus was 
isolated from the obtained samples as previously described (15). Cell lysates were prepared 
as previously described (11).
Bacterial strains and culture conditions for whole-cell ELISA
A S. aureus Newman spa sbi double mutant strain (12) was grown overnight in RPMI 
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1640 without phenol red (PAA Laboratories, Austria) under vigorous shaking (250 rpm) 
at 37°C. The cultures were then diluted in pre-warmed RPMI 1640 medium without 
phenol red to an OD
600
 of 0.05, and cultivation was continued under the same conditions. 
Cells in the mid-exponential growth phase were collected by centrifugation, washed in 
phosphate-buffered saline (PBS) and diluted to an OD
600
 of 0.4. Conditions were optimized 
using a mix of three mouse anti-peptidoglycan monoclonal antibodies (QED, San Diego, 
US). These antibodies specifically recognize peptidoglycan of S. aureus and S. epidermidis. 
Multiple-locus Variable Number of Tandem Repeats Analysis and spa-typing
Variable Number of Tandem Repeat PCR reactions on S. aureus isolates from EB patients 
were performed as previously described (15). The spa-typing was performed according to 
the RIDOM protocol (http://www.ridom.de) with previously described modifications (15).  
Blood plasma, wound fluid and sterile blister fluid
Whole blood samples (12 ml) were donated by 13 patients with EB. The samples were 
processed for further analyses immediately after collection. In addition, 500 ml samples 
of whole blood were donated by 6 healthy volunteers from the UMCG and these were also 
processed immediately after collection. The donated blood was diluted 1:1 in Hanks’ Balanced 
Salt Solution (HBSS, Gibco). Plasma was obtained after separation from blood cells using 
Ficoll-Paque PLUS (GE Healthcare) according to manufacturer’s instructions. The collected 
human plasma was stored at -30°C. The preparation of control group serum from non-carriers 
that was used in the Luminex assays was previously described (17, 20, 21). Sterile blister 
fluid and wound fluid samples were donated by patient EB.60. Wound fluid was collected 
from a bandage as previously described with some modifications (13). Briefly, a bandage 
that had covered a wound for 1 day was removed and immediately soaked in sterile HBSS 
for 1 h at 4°C. The bandage was then placed in a sterile gaze (Medicomp, Germany) that was 
fixed in the upper part of a 50 ml tube (Corning) using the tube’s screw cap. Wound fluid was 
then separated from the bandage by centrifugation at 3500g for 15 min at 4°C. Blister and 
wound fluid samples were stored at -30°C.
Purification of IgG from human plasma
IgG’s were purified from the plasma of 11 patients with EB and 6 healthy volunteers by fast 
protein liquid chromatography using Mabselect Protein A columns and the ÄKTA explorer 
system (GE Healthcare). IgG was eluted in citrate buffer (pH 3.0) and immediately dialyzed 
against PBS. IgG concentrations were determined using a Nanodrop 2000 (Thermo 
scientific).
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Whole cell ELISA
Microlon High-affinity ELISA microtiter plates (Greiner Bio-one, Frickenhausen, 
Germany) were coated with 100 µl of S. aureus spa sbi double mutant culture and incubated 
overnight at 4°C. Plates were washed three times with 0.05% Tween-20 (Sigma Aldrich) 
in PBS (PBS-T20), blocked in 1% (w/v) bovine serum albumin (Sigma Aldrich) in PBS 
for one hour at 37°C, and washed with PBS three times. Human IgGs of EB patients or 
healthy volunteers were then applied in the concentration of 250 ng/ml. Next, the plates 
were incubated for 1 h at 37°C and washed three times. Diluted (1:5000) goat anti-human 
IgG-Fc-PO (Brunschwig Chemie, Basel, Switzerland) was added to the wells. The plates 
were incubated for 1 h at 37°C, and washed three times. The reaction was developed by 
addition of tetramethyl benzidine and stopped by adding 0.2 M sulphuric acid. Readouts 
were recorded at 450 nm in a Sunrise ELISA reader (Tecan, Männedorf, Switzerland). 
Luminex bead-based flow cytometry 
The relative amounts of IgGs against 43 S. aureus antigens were determined by 
the bead- based Luminex flow cytometry technique (xMAP®, Luminex Corporation, Austin, 
Texas, USA) using plasma, sterile blister fluid or wound fluid from patients with EB, and 
plasma from a healthy non-carrier control group (17, 20, 21). Purification of antigens was 
described previously (14, 19, 20). The coupling procedure and measurements of antibody 
levels were performed as described (16, 20). Independent duplicate Luminex assays 
were performed on different days, and the median florescence intensity (MFI), reflecting 
the antibody concentrations, was averaged. To determine non-specific binding, control beads 
without coupled protein were analyzed and the resulting fluorescence was subtracted from 
the MFI values. Human pooled serum was used as a standard.
Statistical analyses
Statistical analyses were performed with GraphPrism 5. The results of ELISA studies 
were compared using two-tailed independent student t-tests. The differences in the median 
antibody levels between the patients with EB and healthy individuals, or between EB patients 
colonized by one or multiple S. aureus MLVA types as measured by Luminex assays were 
assessed using the Mann-Whitney U test. Differences were considered statistically significant 
when 2-sided P-values were <0.05.
Abbreviations
Clf, clumping factor; EfB, extracellular fibrinogen-binding protein; ET, exfoliative toxin; Fnb, 
fibronectin binding protein; HlgB, gamma-hemolysin B; IsaA, immunodominant antigen A; 
Isd, iron-responsive surface determinant; Luk, leukocidin; LytM, peptidoglycan hydrolase; 
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Nuc, endonuclease; SasG, S. aureus surface protein G; SCIN, staphylococcal complement 
inhibitor; CHIPS, chemotaxis inhibitory protein of S. aureus; Sdr, serine-aspartate dipeptide 
repeat protein; SE, staphylococcal enterotoxin; SSL, staphylococcal superantigen-like 
protein; TSST-1, toxic shock syndrome toxin.
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Table 1. S. aureus MLVA types and spa-types collected from individual EB patients. nd not determined; empty cell, 
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The opportunistic pathogen Staphylococcus aureus is known to interfere with wound 
healing and represents a significant risk factor for wound infections and invasive disease. 
It is generally assumed that one individual is predominantly colonized by one S. aureus type. 
Nevertheless, patients with the genetic blistering disease epidermolysis bullosa (EB) often 
carry multiple S. aureus types. We therefore investigated whether different S. aureus types 
are present in individual wounds of EB patients and, if so, how they are spatially distributed. 
The staphylococcal topography in chronic wounds was mapped by replica-plating of used 
bandages and subsequent typing of S. aureus isolates. Individual chronic wounds of five 
patients contained up to six different S. aureus types. Unexpectedly, distinct S. aureus types 
formed micro-colonies that were located in close proximity and sometimes even overlapped. 
While some adjacent S. aureus isolates were closely related, others belonged to distinct 
molecular complexes. We conclude that the general assumption that one individual is 
predominantly colonized by one type of S. aureus does not apply to chronic wounds of 
EB patients. We consider this observation important, not only for EB patients, but also for 
other patients with chronic wounds in view of the potential risk for severe staphylococcal 
infections.




Staphylococcus aureus is a Gram-positive bacterium that colonizes ~30% of the healthy 
human population (10). However, under certain circumstances, S. aureus transforms from 
harmless commensal into a dangerous pathogen that can cause life-threatening invasive 
diseases (3). Accordingly, S. aureus carriage has been associated with an increased risk 
of severe infections (21-23). In most carriers, only one type of S. aureus is encountered, 
suggesting an intimate relationship between the carrier and the carried strain (22). However, 
the presence of multiple S. aureus types has also been reported in healthy individuals and 
in patients with particular diseases, such as cystic fibrosis, atopic dermatitis and the genetic 
blistering disease epidermolysis bullosa (EB) (7, 11, 15, 19, 20). The presence of multiple 
S. aureus types was shown to be exceptionally high in EB patients with chronic wounds, 
who were shown to carry up to four S. aureus types at one time point of sampling (20). 
Over longer periods of time, up to six alternating S. aureus types were isolated from these 
patients, and this high exposure to S. aureus seems to elicit strong antistaphylococcal 
immune responses (19). 
Notably, in most previous studies, the observed co-existence of multiple S. aureus types 
related to the analysis of swab samples from different body sites where one S. aureus colony 
was analyzed per swab sample (19, 20). In only one study, multiple S. aureus colonies 
derived from individual nasal and perianal swap samples were analyzed, showing that 
children selected for elective surgery carried up to three S. aureus types at one particular 
body site (15). To date, the co-existence of multiple S. aureus types has not been studied 
quantitatively and, due to the swab sampling methodology, nothing is known about 
the relative distances at which these co-existing S. aureus types are located from each other. 
Furthermore, little information is available on the genetic relatedness of co-existing S. aureus 
types and hence it is not known whether these are derived from in-patient evolution or the 
simultaneous acquisition from different sources (8, 13). The present studies were therefore 
aimed at investigating the co-existence of different S. aureus types in relation to their 
genetic relatedness and spatial distribution in vivo. This is only possible by investigating 
individuals that carry these S. aureus types on body sites that are readily accessible for direct 
sampling without disturbing the microbial topography. As shown here, such requirements 
are met by the chronic wounds of patients with EB (6), which are extensively colonized 
with S. aureus (4, 16, 20). Briefly, we investigated the spatial distribution of S. aureus in 
the chronic wounds of five EB patients by replica plating of used bandages onto agar plates, 
and subsequent typing of multiple S. aureus colonies. As shown by fluorescence in situ 
hybridization (FISH), the typed colonies on the replica plates represent micro-colonies of 
S. aureus that already existed in the investigated wounds. Up to six co-existing S. aureus 
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types were encountered in individual wounds, often in close proximity. While some adjacent 
S. aureus isolates were closely related, others belonged to distinct molecular complexes. 
Results and discussion
S. aureus topography in chronic wounds
To determine the topography of S. aureus in chronic wounds of EB patients, used bandages 
of five patients were replica plated onto cysteine lactose electrolyte-deficient (CLED) 
agar. These bandages had covered the wounds for ~24 h and they were replica plated 
immediately upon redressing of the wounds. The plates were then incubated overnight 
at 37°C. Depending on the patient and the investigated wounds, we observed either confluent 
growth or separate colonies at different densities. Where possible, regions of the plates 
with separate colonies (Figure 1) were directly used for further analysis by picking of 
colonies and subsequent species determination using standard diagnostic methods. In case 
of patient 62, only overlapping colonies were detectable. Therefore, these colonies were 
streaked on fresh plates so that individual colonies could be isolated for further analyses. 
The vast majority of the investigated colonies from all patients included in this study were 
shown to represent S. aureus. Next, we investigated whether such colonies were derived 
from individual cells or pre-existing micro-colonies in the investigated wounds. To this end, 
the bandages of one EB patient were pressed onto glass slides and FISH analyses were 
performed with an S. aureus-specific oligonucleotide probe (Figure 2). As a control, FISH 
was performed with a probe specific for bacteria in general. This confirmed that the vast 
majority of bacteria present in the investigated wounds were S. aureus. Importantly, these 
S. aureus cells were mostly present in micro-colonies, although individual S. aureus cells 
were also detectable. We therefore conclude that the bacterial wound topography as observed 
through replica plating of used bandages closely reflects the actual bacterial topography in 
the wounds that were dressed with the respective bandages. In those cases where confluent 
growth on plates was observed by replica plating, the bacteria in the wounds are apparently 
present in the form of biofilms (24). 
Co-existence of distinct S. aureus types in chronic wounds 
The presence of different co-existing S. aureus types in the investigated wounds was first 
assessed by Multiple-locus Variable Number of Tandem Repeats Fingerprinting (MLVF), 
because this technique allows the rapid and high-resolution typing of many S. aureus isolates 
in a short period of time (17). Per replica-plated bandage, we typed 12 to 48 colonies, and for 
each patient at least one replica-plated bandage was included from which 24 colonies were 
typed. In total, 368 S. aureus colonies were typed (36 to 85 colonies per patient at any particular 
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time point of sampling), which yielded 27 distinct S. aureus MLVF types. Thus, we typed a 
substantially larger number of colonies per patient than the 20 colonies per patient that were 
previously recommended for studies with small numbers of carriers (5). As shown in Figure 
3A, we detected between two and six different S. aureus types in individual chronic wounds 
of four EB patients at one time point of sampling. By investigating the wound colonization in 
patient 14 over time, we detected even up to 10 different S. aureus types (Figure 3B). In the 
wounds of patients 1 and 14, dominant MLVF types were identified, which were accompanied 
by several less abundant MLVF types. On the other hand, less drastic differences were 
observed in the relative abundance of identified MLVF types in the wounds of patients 62, 
63 and 64 (Figure 3A). Intriguingly, when the MLVF results were assessed in relation to the 
topography of typed S. aureus colonies, it  became clear that different S. aureus types can 
exist in very close proximity (Figure 1). This conclusion was underscored by the observation 
that six different types of S. aureus were separated from overlapping colonies in the sampled 
wound of patient 62. To our knowledge this is the first time that the relative numbers of 
co-existing S. aureus types at one particular body site have been quantified, and that their 
topography has been mapped in detail. Also, the co-existence of different S. aureus types in 
close proximity has not been shown before. 
Figure 1. S. aureus chronic wound topography. Used bandages from four chronic wounds (A-D) of patient 64 were 
replica-plated onto CLED agar plates. The plates were incubated overnight at 37°C. Individual S. aureus colonies 
were isolated for typing by MLVF. S. aureus colonies with different MLVF types are indicated in dfferent 
color codes: red, type 1; blue, type 2, yellow, type 3; green, type 4.
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To approximate the relatedness of the mapped S. aureus types, the results of our 
MLVF analyses were evaluated with GelCompar II (Applied Maths). As shown in 
the resulting dendrogram, the different S. aureus isolates from patient 14 all clustered 
together due to their similar MLVF patterns (Figure 4). This suggests that these isolates 
share a common ancestry, and that the dominant MLVF type 1 has been most successful 
in colonizing the investigated wounds of patient 14. Smaller clusters of two to four related 
S. aureus MLVF types were also identified in the wounds of patients 1, 62, 63 and 64, 
which suggests that some of the staphylococci in wounds of these patients have recently 
evolved from a common ancestor. However, individual wounds of the latter patients also 
contained apparently unrelated MLVF types. Since this suggested that the latter isolates 
represent very different S. aureus types, they were further analyzed in detail by spa-typing 
and Multiple-locus Variable Number of Tandem Repeats Analysis (MLVA). These analyses 
indeed demonstrated that the wounds of patients 62, 63 and 64 contained S. aureus types 
that belong to distinct molecular complexes (Table 1). Some of these types can actually also 
be recovered from the nares or throats of the respective patients (data not shown), but these 
body sites also contain other S. aureus types as shown in Figure 4 for patients 1 and 63. 
In conclusion, our present study shows that chronic wounds of individual EB patients can be 
colonized by several distinct S. aureus types. As shown here for the first time, these distinct 
S. aureus types can form micro-colonies that are located in close proximity (Figure 1). 
This implies that these different types are not mutually exclusive. It thus seems that the dogma 
that one individual is usually colonized by one S. aureus type does not apply to the wounds 
of patients with EB. We consider this finding important, not only for patients with EB, but 
also for other patients with chronic wounds, because S. aureus is known to interfere with 
wound healing and poses a significant risk factor for infections and invasive disease (12, 14).
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Figure 2. Chronic wounds contain microcolonies of S. aureus. To study the micro-topography of S. aureus in chronic 
wounds of patient 14 (A, B), a glass slide was pressed onto a freshly removed used bandage. The presence of S. aureus 
was visualized by FISH using an S. aureus-specific PNA probe. (C), FISH with a universal bacterial PNA probe; 
(D), FISH with an S. aureus-specific PNA probe; E, overlay of images (C-D; F), phase contrast image. The white 
bar in panel C indicates 10 µm.
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Figure 3. Relative numbers of MLVF types detected in the chronic wounds of five EB patients. (A) The percentages 
of different S. aureus MLVF types detected in individual chronic wounds from patients 1, 62, 63 and 64 at one 
particular time point are indicated by bar diagrams. Different MLVF types are marked in black, white or 
grey shading. (B), percentages of different S. aureus MLVF types detected in chronic foot and breast wounds 
from patient 14. Replica plating of used bandages was performed thrice at two-weekly intervals. Black bars mark 
the first, white bars the second and grey bars the third time point of sampling.
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Figure 4. MLVF dendrogram of different S. aureus types isolated from chronic wounds of patients with EB. 
The dendrogram was generated using the Dice coefficient with Tolerance 0.6 and optimization 0.5. Clusters of 
isolates were generated with a cut-off value set to 60%. The MLVF types of individual S. aureus isolates are 
indicated in the dendrogram together with the number of the patient from which they were collected.
Materials and methods
Ethical approval
The authors declare that experiments using human materials were performed with 
institutional approval upon written informed patient consent, and with adherence to the 
Helsinki Guidelines. Specifically, the medical ethics committee (METc) of the University 
Medical Center Groningen (UMCG) approved of the collection of non-invasive samples 
from patients with EB on the basis of written informed patient consent. The required 
informed consent was obtained from all EB patients included in the present studies.
Patients and bacterial isolates
In total, five patients with EB from the Dutch epidermolysis bullosa Registry (DEBR) 
were recruited in this study (note that patient numbers used in this paper correspond to van 
der Kooi-Pol et al. (2012a,b). Samples from three patients (62, 63, 64) were taken from 
three distinct wounds, the left and right anterior nares, and the throat of each patient using 
transswabs (MWE, Corsham, England). S. aureus was isolated from the obtained samples as 
previously described (20). In addition, the bandages from one to four different wounds were 
collected from all patients. In case of patient 14, the bandages from two distinct wounds 
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were collected three times at two-weekly intervals. All collected bandages were immediately 
replica-plated onto CLED agar (Oxoid) by gently pressing them for 5 to 10 s on the agar 
surface. To this end, bio assay plates were used (245x245x25 mm; Nunc). After 24 h of 
incubation at 37°C, 12 to 48 S. aureus colonies per wound/bandage were selected for further 
analysis. The isolation of S. aureus was confirmed by standard diagnostic methods.
Molecular characterization of S. aureus
The extraction of total DNA from S. aureus isolates for PCR amplification was performed as 
described by Schouls et al. (2009). All isolated S. aureus colonies were typed by MLVF as 
previously described (17). Only identical patterns were regarded as the same subtype. Isolate 
clusters were delineated with a 60% similarity cutoff value. In addition, unique S. aureus 
MLVF types isolated from bandages of EB patients 62, 63 and 64 were characterized by 
MLVA and spa-typing as previously described (20). 
Fluorescent in situ hybridization 
Bandages from EB patient 14 were used for FISH. Slides coated with gelatin-suspension 






O, Sigma) were pressed onto used bandages (15 s), 
air-dried, fixed with 96% ethanol (5 min), and stored at -20°C until further processing. FISH 
was performed as previously described with minor modifications (9, 9). Briefly, cells were 
fixed with 4% paraformaldehyde for 1 h at 4°C, and permeabilized with 2 U/ml  lysostaphin. 
After dehydration with 96% ethanol, the cells were hybridized for 2 h at 50°C with the 
STAUR (2) and EUB338 (1) probes (5 ng/µl each) in hybridization buffer, and then washed 
for 10 minutes in wash buffer (9). Fluorescence microscopy was performed with a Leica 
DM RXA microscope. The phase contrast and fluorescent images were merged using Adobe 
Photoshop CS4.
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Table 1. MLVA and spa-typing of S. aureus isolates from chronic wounds of EB patients. 
MLVF spa
MLVA VNTRa number (24)
type MCb 09_01 61_01 61_02 67_01 21_01 24_01 63_01 81_01
P a t i e n t 
62
Type 1 t254 1298 15 7 5 2 1 1 9 99 4
Type 2 t254 1298 15 7 5 2 1 1 9 99 4
Type 3 t6993 3393 none 7 5 2 1 1 8 99 4
Type 4 t254 1298 15 7 5 2 1 1 9 99 4
Type 5 t7473 532 45 11 3 3 4 1 12 1 5
Type 6 t9968 45 45 11 3 3 4 1 11 1 5
P a t i e n t 
63
Type 1 t002 23 5 14 2 1 3 2 11 7 5
Type 2 t078 2049 none 12 0 2 2 1 10 6 3
Type 3 t078 2049 none 12 0 2 2 1 10 6 3
P a t i e n t 
64
Type 1 t9969 3391 none 14 1 1 1 1 10 7 5
Type 2 t509 3392 none 14 1 1 1 1 9 6 5
Type 3 t015 45 45 11 3 3 4 1 11 1 5
Type 4 t509 3392 none 14 1 1 1 1 9 6 5
aVNTR, Variable Number of Tandem Repeats. 
bMC, molecular complex.
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The opportunistic pathogen Staphylococcus aureus has become a major threat for human 
health and well-being by developing resistance to antibiotics, and by its fast evolution into 
new lineages that rapidly spread within the healthy human population. This calls for the 
development of active or passive immunization strategies to prevent or treat acute phase 
infections. Since no such anti-staphylococcal immunization approaches are available as 
yet, the present studies were aimed at identifying new leads for their development. For 
this purpose, we thoroughly profiled the cell surface-exposed staphylococcal proteome by 
combining two surface shaving approaches. In parallel, non-covalently cell wall-bound 
proteins were extracted with KSCN and analyzed by gel-free proteomics, and also the 
exoproteome was analyzed through gel-free proteomics. Lastly, we screened a selection of 
the identified cell wall-attached proteins for binding of immunoglobulin G from patients that 
have been challenged with different types of S. aureus over extended periods of time due 
to chronic wound colonization. The combined results of these analyses highlight particular 
cell surface-exposed S. aureus proteins with highly immunogenic epitopes as potentially 
powerful targets for the development of protective anti-staphylococcal immunization 
strategies.




The Gram-positive bacterium Staphylococcus aureus is an opportunistic pathogen that 
asymptomatically colonizes approximately 30% of the healthy human population (2, 12, 27, 
43, 46, 55). Upon invasive growth, S. aureus can cause a wide variety of diseases ranging 
from relatively mild skin infections to severe sepsis. A major reason for concern is the 
high propensity of S. aureus to acquire resistance to antibiotics (6, 45). This is critically 
underscored by the rapid development of resistance to the antibiotic methicillin. When 
methicillin was first introduced into the clinic, only methicillin-sensitive S. aureus (MSSA) 
was encountered. However, within two years, the first methicillin-resistant S. aureus (MRSA) 
isolates were observed (30). While MRSA was initially only a threat for hospitalized, 
elderly and frail individuals, the last two decades have witnessed the emergence of so-called 
community-acquired MRSA lineages that rapidly spread within the young and healthy 
population (31, 36, 44). Importantly, community-acquired MRSA lineages have now also 
entered nosocomial settings, which gives rise to increased morbidity and mortality rates. 
It is therefore a major societal challenge to develop novel, effective and long-lasting 
anti-staphylococcal therapies (5, 36, 38, 41).
In principle, vaccination is a very effective approach for protecting individuals at risk 
against pathogenic microbes. Unfortunately however, no vaccines against S. aureus in 
general, or MRSA in particular, are currently available (37, 54). While there have indeed 
been various attempts to develop vaccines for preventing staphylococcal infections, none 
of the candidate vaccines has successfully passed (pre-) clinical trials. Most likely, this 
relates to multiple factors, including the ability of S. aureus to evade or suppress the human 
immune system (1, 23, 26, 42, 48) as well as the high genome plasticity and adaptability of 
this wide-spread pathogen (8, 14, 19, 31, 33, 56). Also, the published attempts to develop 
anti-staphylococcal vaccines were so far focused on a relatively narrow group of known 
S. aureus antigens, including capsular polysaccharides and a few cell wall-associated or 
secreted proteins (37, 54). In this context, it is noteworthy that recent proteomics analyses have 
indicated the presence of at least 449 different proteins in the S. aureus cell envelope (8, 9, 
13, 17, 47, 53). These proteins may include powerful targets for future anti-staphylococcal 
immunization strategies, especially if they are exposed to the extracellular environment 
where they are readily recognizable by the human immune system. However, relatively little 
is known about the S. aureus cell surface-exposed proteome - the ‘surfacome’ - in terms of 
the particular protein domains that are directly exposed to the extracellular milieu. Even less 
is known about the presence of possible immunodominant epitopes within such exposed 
protein domains that could be used for the development of novel immunization approaches.
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To pinpoint candidate targets for novel anti-staphylococcal immunization approaches, 
the present studies were focused on the identification of immunodominant cell surface-exposed 
protein domains of S. aureus. For this purpose, we first performed an in-depth proteomics 
analysis of the surfacome based on the incubation of S. aureus cells with immobilized trypsin 
that cannot penetrate into the cell wall (i.e. ‘cell surface shaving’ (8)) or with soluble trypsin 
that can penetrate into the deeper cell wall layers. In parallel, we analyzed proteins released 
from the cells by spontaneous shedding or by treatment with the chaotropic compound KSCN, 
and we analyzed the extracellular proteome (i.e. the ‘exoproteome’) of the investigated cells. 
Lastly, a screen for immunodominant epitopes in the identified cell surface-exposed proteins 
was performed using peptide arrays and serum immunoglobulin G (IgG) from patients with 
the genetic blistering disease epidermolysis bullosa (EB). As shown in previous research, 
these patients are exposed to multiple and alternating types of S. aureus over long periods of 
time due to chronic wound colonization (3, 51, 52). Altogether, the present ‘tryptic striptease’ 
of the S. aureus cell unveils a set of cell wall-localized and surface-exposed antigens that 
may serve as targets for novel active or passive immunization approaches to prevent or treat 
staphylococcal infections.
Methods
Bacterial strains and growth conditions
The S. aureus strains Newman, Newman ΔspaΔsbi and USA300 were grown overnight in 
tryptic soy broth (TSB, OXOID) under vigorous shaking at 37°C. The cultures were then 
diluted into pre-warmed RPMI 1640 medium (PAA) to an OD
600
 of 0.05 and cultivation 
was continued under the same conditions. Exponentially growing cells were again diluted 
into fresh and pre-warmed RPMI medium to a final OD
600
 of 0.05 and their cultivation was 
continued to an OD
600
 of 0.2.
Isolation and processing of sub-proteome fractions
Exoproteome- Cells were separated from the growth medium by centrifugation (15 min, 
6750 × g, 4°C). The growth medium fraction thus obtained was filtrated (pore size 
0.22 µm), and the exoproteome present in this fraction was precipitated overnight at 4°C 
with 10% trichloroacetic acid (TCA). Precipitated proteins were pelleted by centrifugation 
(20 min, 18620 × g, 4°C) and washed with acetone. Protein pellets were dried and resuspended 
in 50 mM ammonium bicarbonate and overnight digested with trypsin (Promega) at 37°C. 
Surfacome shaving with immobilized trypsin- Cells were harvested by centrifugation 
(10 min, 6080 × g, 4°C) and washed twice with PBS containing 40% sucrose (Acros) 
and 20 mM sodium azide (Sigma-Aldrich). Immobilized trypsin (Pierce) was activated 
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with 50 mM ammonium bicarbonate (Sigma-Aldrich), resuspended in 50 µl PBS with 
40% sucrose and 20 mM sodium azide, and added to the washed cells. The shaving reaction 
was conducted for 45 min at 37°C. Released peptides representing the surfacome were 
isolated, reduced with 10 mM DTT (30 min), alkylated with iodoacetamide (Sigma-Aldrich), 
and digested with trypsin overnight at 37°C.
Surfacome shaving with soluble trypsin- The protocol for cell shaving with soluble trypsin 
was essentially the same as the protocol for shaving with immobilized trypsin. In this case 
immobilized trypsin in 48 µl PBS with 40% sucrose and 20 mM sodium azide was added 
to the cells.
Spontaneously released proteins- The protocol for analysis of proteins spontaneously 
released from the cells was essentially the same as the protocol for shaving with immobilized 
trypsin. In this case, 50 µl PBS with 40% sucrose was added to the cells.
Non-covalently cell wall-bound proteins- Cells were harvested by centrifugation (10 min, 
6750 × g, 4°C), washed twice in PBS with 40% sucrose and 20 mM sodium azide, 
resuspended in 1 M potassium thiocyanate (KSCN), and incubated for 10 min on ice. 
After centrifugation (10 min, 6750 × g, 4°C), the resulting supernatant was filtrated (pore 
size 0.22 µm) and proteins in the filtrate were precipitated with TCA. The collected proteins 
were digested with trypsin overnight at 37°C.
Mass spectrometric analyses
Reduction and alkylation, desalting of the samples, mass spectrometric (MS) analysis and 
database searches were performed as previously described (8). The strain-specific uniprot 
databases were used for the S. aureus strains Newman and USA300, respectively including 
concatenated reversed databases with 5250 and 5298 entries. Validation of MS/MS-based 
peptide and protein identifications was performed with Scaffold (version Scaffold_2_04_00, 
Proteome Software Inc., Portland, OR). Peptide identifications were accepted if they 
exceeded the specific database search engine thresholds. Sequest identifications required at 
least deltaCn scores of greater than 0.10 and XCorr scores of greater than 1.9, 2.2, 3.8 and 
3.8 for singly, doubly, triply and quadruply charged peptides, respectively. All experiments 
were conducted in independent triplicates. Peptides were only accepted as identified if they 
were detected in at least two out of the three replicates per sample set. With these filter 
parameters no false positive hits were obtained. The identified peptides of strain Newman 
are listed in Supplemental Table 1 (available on request) and the identified peptides of strain 
USA300 are listed in Supplemental Table 2 (available on request).
Western Blotting
Protein samples were separated using NuPAGE gels (Invitrogen) and separated proteins 
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were subsequently transferred to a Protran nitrocellulose membrane (Whatman) by semi- dry 
blotting (75 min at 1 mA/cm²). Membranes were incubated with specific antibodies 
against TrxA and bound antibodies were detected as previously described (32).
Immunofluorescence
S. aureus cells were cultured in RPMI as indicated above, harvested by centrifugation (5 min, 
18620 × g, 4°C) and washed once in PBS with 20 mM sodium azide. Next, cells were 
resuspended in 100 µl PBS with 20 mM sodium azide and IsaA-specific (Sakata, Terakubo, 
& Mukai, 2005) or TrxA-specific antibodies. As a control, cells were incubated with 
IsaA-specific antibodies that had been pre-incubated with purified IsaA. After 30 min 
incubation on ice, the cells were collected by centrifugation (5 min, 18620 × g, 4°C) 
and resuspended in PBS with 20 mM sodium azide containing AlexaFluor® 594 labeled 
goat-anti-rabbit antibodies (Invitrogen). After 30 min incubation on ice, the cells were 
washing three times in PBS with 20 mM sodium azide, resuspended in MilliQ water and 
transferred to Polysine-slides (Thermo Scientific). After drying, Vectashield mounting 
medium (Vector Laboratories) was applied to the slides to prevent photobleaching. Images 
were recorded with a Leica DM5500 B fluorescence microscope (Leica Microsystems B.V), 
and image processing was conducted with the ImageJ 1.43m software. 
Pepscan analysis
To map regions of cell surface-exposed S. aureus proteins that are recognized by human 
IgGs, we synthesized libraries of linear 15-mer peptides with an overlap of 11 amino acids 
on solid support (Pepscan), as previously described (50). For some proteins, libraries of 
CLIPSTM constrained 15-mers were prepared as previously described (49). The peptide 
libraries were probed with heat-inactivated human sera, in a dilution of 1:1000, with 
goat-anti-human-HRP conjugate as a secondary antibody, and developed with 2,2’-azino-bis 
(3-ethylbenzothiazoline-6-sulphonic acid). A charge-coupled device camera was used to 
register absorbance at 405 nm. For every single Pepscan dataset, the data was normalized 
to the average signal intensity of the analysis. Furthermore, the signals for every single 
protein were normalized to the median of the corresponding protein. In addition the standard 
deviations of the normalized data sets were calculated for each protein. Peptides with a signal 
exceeding the median plus twice the standard deviation and a normalized signal intensity 
higher than three were regarded as being immunogenic domains.
Human plasma
Whole blood samples (12 ml) from EB patients were processed immediately after donation by 
1:1 dilution in Hanks’ Balanced Salt Solution (Gibco). Plasma was obtained after separation 
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from blood cells using Ficoll-Paque PLUS (GE Healthcare) according to manufacturer’s 
instructions. The collected human plasma was stored at -30°C prior to use. The authors 
declare that the experiments using human plasma were performed with institutional approval 
upon the receipt of written informed patient consent, and with adherence to the Helsinki 
Guidelines. 
Results
Complementary protein and peptide identifications in different sub-proteome fractions
To identify protein domains that are exposed on the cell surface of S. aureus, a comprehensive 
gel-free proteomics analysis was performed on the community-acquired MRSA strain 
USA300 and the MSSA laboratory strain Newman. Specifically, staphylococcal cells were 
shaved either with trypsin immobilized on agarose beads (Figure 1A, ‘shaving 1’) or with 
soluble trypsin (‘shaving 2’). Liberated peptides were collected and subsequently identified 
through MS. In parallel, gel-free proteomics was applied to define spontaneously released 
proteins (‘control’), non-covalently cell wall-bound proteins extracted with KSCN (‘wall’), 
and proteins in the exoproteome of the analysed cells. The rationale of this is approach 
was that the immobilized trypsin would only access protein domains that stick out from 
the cell surface, whereas the other approaches would help to distinguish the surface-exposed 
protein domains from proteins or protein domains that are present in the deeper cell envelope 
layers or in the exoproteome. Overall, this resulted in the identification of 255 unique proteins 
from the USA300 strain and 177 from the Newman strain (Figure 1, B and C). The pI and 
Mw values of the identified proteins are summarized in Supplemental Figure 1 (available 
on request). Furthermore, 1191 unique peptides were identified in all samples derived from 
strain USA300, and 762 in the samples derived from strain Newman (Figure 1, D and E). 
Importantly, only two proteins were identified in the control fractions (one protein for each 
strain), showing that the spontaneous release of proteins from the cells during collection 
and processing of the different sub-proteome fractions was negligible (Supplemental 
Tables 1 and 2 available on request). Therefore, the control fraction is not further specified 
in what follows. It is also noteworthy that shaving with immobilized trypsin identified fewer 
proteins/peptides than shaving with soluble trypsin, suggesting that the soluble trypsin does 
indeed reach targets in the deeper layers of the cell wall (Figure 1). The complementarity 
of the four sub-proteome fractionation approaches  is underscored by the relatively small 
numbers of proteins/peptides that were identified in all samples from each strain (Figure 1). 
In fact, this underscores the need to combine multiple approaches for a comprehensive 
description of the cell wall-, cell surface- and extracellular proteomes of S. aureus. 
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Figure 1. Schematic representation of the analysis of different sub-proteome fractions and proteomics results 
in numbers. A) Cells were harvested at identical optical densities and proteins in the growth medium fraction 
(‘culture supernatant’) were precipitated and digested with trypsin. Non-covalently cell wall-attached proteins were 
extracted with 1 M KSCN and also digested with trypsin (‘wall’). Cells were incubated in PBS with 40% sucrose 
and 20 mM azide alone (‘control’), or in the same buffer with either immobilized trypsin (‘shaving 1’) or 
soluble trypsin (‘shaving 2’). The Venn diagrams summarize the results obtained for strains USA300 (B, C) and 
Newman (D, E) at the protein- (B, D) and peptide levels (D, E). ‘Shaving 1’ and ‘shaving 2’ respectively mark 
the results from cell shaving with immobilized or soluble trypsin; ‘wall proteome’ marks the results from cell 
wall extraction with KSCN, and ‘exoproteome’ marks the results from the analysis of culture supernatants.
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Strain-specific protein identifications in sub-proteome fractions
A comparison of the total protein identifications revealed that the different analyzed 
sub-proteome fractions from strain USA300 were more complex than those from strain 
Newman (Figure 2, Supplemental Figure 2 available on request). Furthermore, a search for 
potential signal peptides, trans-membrane domains and cell wall-binding domains revealed 
that most proteins that were exclusively identified in samples from strains USA300 or Newman 
lack such signals, which suggests a predominant cytoplasmic localization (Figure 2, upper 
panels). Since about four times more proteins were identified in samples from strain USA300 
than in samples from strain Newman, it seems that strain USA300 is more susceptible 
to lysis. This view is supported by the observation that the bifunctional staphylococcal 
autolysin Atl- a typical cell wall-bound protein - was identified in the exoproteome of strain 
USA300, but not in the exproteome of strain Newman. To investigate the presumed lysis of 
strain USA300, Western blotting experiments were performed in which the localization of 
the cytoplasmic marker protein TrxA was assessed. As shown in Figure 3A, no TrxA was 
extracted from the cells with KSCN under conditions that were similar to those applied for 
cell surface shaving with trypsin. This implies that little if any lysis occurred during the 
isolation of the different cell-associated sub-proteome fractions. On the other hand, about 
two-fold more TrxA was detectable in growth medium fractions of strain USA300 than in the 
equivalent fractions of strain Newman (Figure 3B). This suggests that strain USA300 is more 
susceptible to cell lysis than strain Newman, and that cell lysis had occurred already during 
culturing. This is an important observation, because it implies that the cytoplasmic proteins 
identified on the surface of staphylcoccal cells used for our present sub-proteome analyses 
had reached the cell surface during culturing. It should be noticed here that, while we think 
that autolysis during culturing plays an important role in the apparent export of cytoplasmic 
proteins to the cell surface and growth medium, we cannot exclude the possibility that some 
of these proteins are actively exported from the cytoplasm via as yet undefined mechanisms. 
Proteins common to S. aureus strains USA300 and Newman
Despite clear differences, there are also many overlaps in the proteins identified in 
the respective sub-proteome fractions from S. aureus strains Newman and USA300 (Figure 2, 
Supplemental Table 3 available on request). This is in line with the fact that most of the proteins 
identified in the present studies are encoded by the genomes of both investigated S. aureus 
strains. Interestingly, seven proteins were identified in all four sub-proteome samples from 
the USA300 and Newman strains (Supplemental Tables 4 and 5 available on request). These 
are the IgG-binding protein Spa, the secretory antigen SsaA, the transglycosylase IsaA, the 
fructose-bisphosphate aldolase class 1, the DNA binding protein HU and the ribosomal 
proteins L29 and L30. To verify cell surface exposure, an immunofluorescence control 
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experiment was performed for IsaA, against which a highly specific antibody was available. 
As shown in Figure 3C, the IsaA antibody bound effectively to the cells of a ΔspaΔsbi 
mutant of strain Newman, which lacks the immunoglobulin-binding proteins Spa and Sbi. 
Titration of the antibodies with increasing amounts of purified recombinant IsaA confirmed 
the specificity of the IsaA antibody binding to the cells (Figure 3, D-J). Furthermore, 
antibodies against the secreted thermonuclease, which was not detected on the cell surface 
of strains Newman or USA300 did not bind to the cells (Figure 3K), and the same was true 
for antibodies against the cytoplasmic marker protein TrxA (Figure 3l), which was also 
not identified as being bound to the cell surface (Figure 3A). Based on these findings, we 
conclude that the surface shaving approach does indeed yield specific information on the 
surface exposure of particular S. aureus proteins.
Figure 2. Predicted subcellular localization of the proteins identified for strains USA300 and Newman. 
The overlapping as well as unique proteins identified in the four sub-proteome fractions from strains USA300 and 
Newman were analyzed with respect to their predicted subcellular localization as previously described (9). CW, 
covalently wall-bound proteins; M, transmembrane- and lipoproteins; Sec, secreted proteins; No, proteins with no 
predicted motif for subcellular localization.
Epitope mapping in surface proteins of S. aureus
Altogether, our proteomics analyses led to the identification of 281 unique 
proteins (Supplemental Table 6, sheet A available on request). Thereof, we selected 
54 proteins for further analysis by Pepscan epitope-mapping. The selected proteins include 
predicted cytosolic, membrane, lipid-modified, cell wall-associated as well as extracellular 
proteins (Supplemental Table 6, sheet B available on request). For all of these proteins 
linear 15-mer peptide arrays with 11-mer overlaps were prepared. Additionally, arrays with 
CLIPSTM constrained 15-mers were prepared for the IsaA, LytM and Nuc proteins. Plasma 
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donated by seven different EB patients, who have high IgG responses against staphylococcal 
proteins (51), was then used for the detection of immunogenic domains. In total, we 
analyzed the interaction of 6821 peptides with IgG’s in the plasma of EB patients. This 
revealed 358 human IgG-binding peptides from 48 different S. aureus proteins. Merging 
of overlapping sequences finally resulted in the delineation of 201 immunodominant 
domains (Supplemental Table 6, sheet C available on request). The most conserved peptides 
recognized by IgGs from human serum belong to a Zinc-binding lipoprotein (A6QJP6), the 
extracellular matrix-binding protein (Emp), and the iron-regulated surface determinant (IsdB) 
(Supplemental Table 6, sheet D; Supplemental Figure 3; available on request). The relative 
localization of immunodominant protein regions and peptides identified in the different 
investigated sub-proteomes is schematically presented in Supplemental Figure 4 (available 
on request). Notably, the peptides from certain other cell surface-exposed proteins did not 
bind IgGs from EB patient plasma (i.e. FtsL, RS7, the DNA binding protein HU, a putative 
thioredoxin, two CsbD-like proteins and an uncharacterized), and these proteins can thus be 
regarded as negative controls for our epitope mapping analysis.
The highest number of IgG-binding peptides was identified for IsdB, and a close analysis 
of their location within this protein revealed a highly immunodominant domain between 
amino acids 47 and 129. This domain was also identified by shaving with immobilized 
trypsin as being cell surface-exposed (Figure 4A, ‘shaving 1’). A second immunogenic 
region was detected in the C-terminal part of IsdB between amino acids 395 and 565, 
which is also identified by surface shaving. Notably, surface shaving with immobilized 
trypsin (‘shaving 1’) identified only peptides from the N- and C-terminal regions in IsdB, 
whereas shaving with soluble trypsin (‘shaving 2’) also identified peptides from the central 
region of IsdB. Peptides from the central region were also identified in extracellular IsdB. 
Thus, the central region of IsdB is not a substrate for immobilized trypsin, suggesting that it 
is protected by the cell wall.
A remarkable finding was that especially the surface-exposed N-terminal pro-region of the 
autolysin Atl was very well recognized by the IgGs from EB patients (Figure 4B). It should 
be noted that this region is removed from Atl during the processing of the exported pro-Atl 
into the active amidase and glucosaminidase domains (23). Furthermore, we detected 
strong immunogenic signals in apparently surface-exposed domains of other proteins, such 
as the extracellular matrix-binding protein (Emp), coagulase (Coa), fibronectin-binding 
protein A (FnbpA) and clumping factor B (ClfB) (Supplemental Figure 4 available 
on request). However, we also observed that for some proteins, such as the chemotaxis 
inhibitory protein (CHIPS), different protein regions were identified by cell surface shaving 
and epitope mapping. In the case of CHIPS, we observed an IgG-binding domain in the 
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N-terminus, next to the signal peptide, whereas proteomics identified most peptides in the 
C-terminal half of this protein (Supplemental Figure 4 available on request). Interestingly, 
immunogenic domains positioned next to the signal peptides were observed also for other 
proteins, such as Atl, Emp, the FPRL1 inhibitory protein (FLIPr), the lipoprotein YkyA, a 
peptide binding protein (Q2FKI7) and the MHC class II analog protein (Omp7; Supplemental 
Figure 4 available on request). Lastly, the epitope mapping revealed also numerous IgG-
binding domains in typical cytoplasmic proteins that were found to be exposed on the S. 
aureus cell surface. These include the fructose-bisphosphate aldolase Alf1, the enolase Eno, 
the triosephosphate isomerase Tim, the elongation factors G and Ts, the ribosomal proteins 
S5, S13 and L25, the phosphoglycerate kinase Pgk and the glyceraldehyde-3-phosphate 
dehydrogenase GAPDH (Supplemental Figure 4 available on request). 
Figure 3. Lysis controls and verification of cell surface localization of IsaA. A) Cells were harvested from cultures 
with an OD
600
 of 0.2, washed, and non-covalently cell wall-bound proteins were extracted with KSCN. The 
extracted wall proteins (cw) as well as crude cell extracts (ce) were analyzed by Western blotting with specific 
antibodies against the cytosolic marker protein TrxA. B) Cultures were harvested at an OD
600
 of 0.2. Cells were 
separated from the growth medium by centrifugation, and the presence of TrxA in crude cell extracts (ce) or growth 
medium fractions (sec) was assessed by Western blotting with specific antibodies. (C) Cells of S. aureus Newman 
ΔspaΔsbi were harvested at OD
600
 0.2, incubated with an IsaA-specific antibody plus a secondary antibody labeled 
with AlexaFluor® 594, and inspected by fluorescence microscopy. As a control for specific antibody binding, 
the IsaA- specific antibody was pre-incubated with increasing amounts of purified IsaA prior to fluorescence 
microscopy: (D) 10 pg IsaA, (E) 100 pg IsaA, (F) 1 ng IsaA, (G) 10 ng IsaA, (H) 100 ng IsaA, (I) 1 µg IsaA, 
(J) 10µg IsaA. Antibodies directed against (K) the secreted thermonuclease Nuc, or (L) the cytosolic marker 
protein TrxA were applied as negative controls for immuno-fluorescence.
Tryptic striptease of Staphylococcus aureus unveils the cell surface localization of 
immunodominant epitopes
95
Figure 4. Comparison of proteome and epitope mapping results. Peptides of the IsdB (A) and Atl (B) proteins as 
identified by proteomics analyses of four different sub-proteomes of S. aureus strains USA300 and Newman are 
highlighted in the linearly depicted protein sequence. In addition known protein domains are indicated. The graphs 
display the signals from the epitope mapping normalized to the median signal of the respective protein and serum 
for the seven different EB patients.
Discussion
The world-wide spread of highly antibiotic-resistant lineages of S. aureus calls for 
the development of novel anti-staphylococcal therapies. Such therapies could very well include 
active or passive immunization. Unfortunately, attempts to develop anti-staphylococcal 
immunotherapy have so far remained unsuccessful, which may relate to the selected 
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antigens. We therefore set out to define cell surface-exposed immunodominant epitopes in 
two important model strains for S. aureus, namely the laboratory MSSA strain Newman and 
the community-acquired MRSA strain USA300. 
Various elegant studies on the staphylococcal exoproteome, wall proteome and surfacome 
were published in recent years (8, 17, 47, 53, 56). However, the usefulness of these studies 
for the rational design of novel antistaphylococcal immunotherapy was limited by the fact 
that they were based on different S. aureus isolates grown in different media under different 
conditions, and that very different technical approaches were applied (9). Therefore, 
we designed an integrated work flow in which the cell wall proteomes, surfacomes and 
exoproteomes of two different strains (Newman and USA300) grown under identical 
conditions were analyzed in parallel following exactly the same protocol. An important 
outcome was that, despite substantial differences, there was indeed a significant overlap in 
the identified proteins of both investigated strains. A major pool of differentially identified 
proteins was formed by typical cytoplasmic proteins that were detected in and on the wall of 
both strains. While it is currently debated how such proteins leave the cytoplasm to become 
localized to the cell wall or the extracellular milieu, it is becoming increasingly clear that 
some of them have so-called ‘moonlighting functions’ in virulence (18). In line with this 
notion, our present studies show that the plasma of EB patients suffering from chronic 
staphylococcal wound colonization does indeed contain IgGs that specifically bind to 
a range of cytoplasmic proteins and that there is significant overlap between the IgG-binding 
domains and domains identified in our proteomic analysis (e.g. Tim, RS5, Eno, GAPDH). 
Notably, antibodies directed against Eno have been demonstrated to cause opsonophagocytic 
killing of S. aureus and this protein is a known protective antigen on the cell surface of 
Streptococcus suis (11, 13). Furthermore vaccination of rats with recombinant Eno caused 
protection against dental caries (7). First results also indicate GAPDH as a candidate for 
a broad spectrum vaccine to reduce infection in aquacultures (28). 
Notably, several surface-exposed proteins that were subjected to epitope mapping revealed 
clusters of epitopes that were specifically localized to certain domains within these proteins. 
This is best exemplified by the wall-anchored IsdB protein, the autolysin Atl, the adhesin 
Emp and the transglycosylase IsaA. The significance of these results is underlined by 
recent efforts to develop an IsdB-based vaccine, which showed that this protein is highly 
immunogenic (15, 16), and a study in which the binding site of a human monoclonal antibody 
was located to the IsdB domain between residues 50 to 285 (10). In the present studies, we 
identified the IsdB domain between residues 47 and 129 as a hot spot for recognition by 
IgGs from EB patients. This overlap is striking, especially because of the very different 
approaches that have been applied. Less effort has as yet been put into the development of 
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vaccines containing Emp or Atl, but passive immunization with antibodies against Emp did 
show a reduction of staphylococcal loads in an animal model (4), and passive immunization 
with a monoclonal antibody against IsaA gave protection against S. aureus in a central venous 
catheter-related infection model and a sepsis survival model (29). Furthermore, Atl was 
previously identified as a strong antigen through gel-based immunoproteomic approaches 
on growth medium fractions of S. aureus (20, 24). On this basis, it would be interesting to 
test the application potential of the N-terminal segment of Atl as a target for active or passive 
immunization. 
Interestingly, the IgGs from different EB patients did not always bind to the same S. aureus 
proteins or protein domains. This may have different reasons. Firstly, the Pepscan approach 
was based mainly on linear peptides and, therefore, certain conformational epitopes of 
particular proteins recognized by IgGs of the EB patients might be overlooked. A second 
reason for the observed variability in IgG responses could be that the different patients did 
not carry the same S. aureus types (51). Thus, it is conceivable that different surface-exposed 
antigens were either produced at low levels or not at all. This is a realistic possibility 
since an analysis of 58 different S. aureus genome sequences showed large variations in 
the composition and presence of genes for 25 surface-bound and/or immune-evasive 
proteins (33). Eighteen of these proteins were identified by our proteomic analyses of 
strains USA300 and Newman (i.e. ClfA, ClfB, Coa, Eap, Efb, EbpS, Emp, EsxA, FLIPr, 
FnbpA, IsdA, IsdB, SasG, Sbi, SCIN, SdrD, Spa, VWbp), and 12 were analyzed by our 
Pepscan approach showing that they were recognized by antibodies from at least one EB 
patient (i.e. ClfB, Coa, EbpS, Efb, Emp, EsxA, FLIPr, FnbpA, IsdB, SasG, Sbi, SdrD). It is 
relevant to note that some of the latter proteins, such as Coa, IsdA, IsdB and Spa, have been 
implicated as potentially effective targets for immunotherapy.
Altogether, our present analyses highlight several immunodominant  cell surface-exposed 
proteins of S. aureus and specific sub-domains of these proteins as potential targets for novel 
active or passive immunization approaches. These include the covalently cell wall-bound 
proteins ClfB and IsdB, a YkyA-like cell wall-binding lipoprotein, the membrane proteins 
EbpS and LtaS, the non-covalently cell wall-bound and secreted proteins Atl, Sbi, IsaA, Emp, 
and the cytoplasmic proteins Afl1, Eno, and GAPDH. Future studies will show whether any 
of these proteins can indeed serve as effective targets for antistaphylococcal immunotherapy.
Acknowledgements





1. Bestebroer, J., C. J. De Haas, and J. A. Van Strijp. 2010. How microorganisms avoid 
phagocyte attraction. FEMS Microbiol. Rev. 34:395-414. 
2. Bode, L. G., H. F. Wertheim, J. A. Kluytmans, D. et al. 2011. Sustained low 
prevalence of meticillin-resistant Staphylococcus aureus upon admission to hospital in 
The Netherlands. J. Hosp. Infect. 79:198-201. 
3. Brandling-Bennett, H. A., and K. D. Morel. 2010. Common wound colonizers in 
patients with epidermolysis bullosa. Pediatr. Dermatol. 27:25-28. 
4. Cheng, A. G., H. K. Kim, M. L. Burts, T. Krausz, O. Schneewind, and 
D. M. Missiakas. 2009. Genetic requirements for Staphylococcus aureus abscess 
formation and persistence in host tissues. FASEB J. 23:3393-3404. 
5. DeLeo, F. R., M. Otto, B. N. Kreiswirth, and H. F. Chambers. 2010. 
Community- associated meticillin-resistant Staphylococcus aureus. Lancet. 375:1557-
1568. 
6. Deurenberg, R. H., and E. E. Stobberingh. 2008. The evolution of Staphylococcus 
aureus. Infect. Genet. Evol. 8:747-763. 
7. Dinis, M., D. Tavares, I. Veiga-Malta, A. J. Fonseca, E. B. Andrade, G. Trigo, 
A. Ribeiro, A. Videira, A. M. Cabrita, and P. Ferreira. 2009. Oral therapeutic 
vaccination with Streptococcus sobrinus recombinant enolase confers protection against 
dental caries in rats. J. Infect. Dis. 199:116-123. 
8. Dreisbach, A., K. Hempel, G. Buist, M. Hecker, D. Becher, and J. M. van Dijl. 2010. 
Profiling the surfacome of Staphylococcus aureus. Proteomics. 10:3082-3096. 
9. Dreisbach, A., J. M. van Dijl, and G. Buist. 2011. The cell surface proteome of 
Staphylococcus aureus. Proteomics. 11:3154-3168. 
10. Ebert, T., S. Smith, G. Pancari, et al. 2010. A fully human monoclonal antibody to 
Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional 
activity in vitro and in vivo. Hum. Antibodies. 19:113-128. 
11. Feng, Y., H. Zhang, Y. Ma, and G. F. Gao. 2010. Uncovering newly emerging variants 
of Streptococcus suis, an important zoonotic agent. Trends Microbiol. 18:124-131. 
12. Foster, T. J. 2004. The Staphylococcus aureus “superbug”. J. Clin. Invest. 114:1693-
1696. 
13. Glowalla, E., B. Tosetti, M. Kronke, and O. Krut. 2009. Proteomics-based identification 
of anchorless cell wall proteins as vaccine candidates against Staphylococcus aureus. 
Infect. Immun. 77:2719-2729. 
14. Goerke, C., C. Wirtz, U. Fluckiger, and C. Wolz. 2006. Extensive phage dynamics 
in Staphylococcus aureus contributes to adaptation to the human host during infection. 
Mol. Microbiol. 61:1673-1685. 
15. Harro, C., R. Betts, W. Orenstein, E. J. Kwak, H. E. Greenberg, M. T. Onorato, 
J. Hartzel, J. Lipka, M. J. DiNubile, and N. Kartsonis. 2010. Safety and 
immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study 
of the vaccine dose range in humans. Clin. Vaccine Immunol. 17:1868-1874. 
Tryptic striptease of Staphylococcus aureus unveils the cell surface localization of 
immunodominant epitopes
99
16. Harro, C. D., R. F. Betts, J. S. Hartzel, M. T. Onorato, J. Lipka, S. S. Smugar, and 
N. A. Kartsonis. 2012. The immunogenicity and safety of different formulations of a 
novel Staphylococcus aureus vaccine (V710): results of two Phase I studies. Vaccine. 
30:1729-1736. 
17. Hempel, K., J. Pane-Farre, A. Otto, S. Sievers, M. Hecker, and D. Becher. 2010. 
Quantitative cell surface proteome profiling for SigB-dependent protein expression in 
the human pathogen Staphylococcus aureus via biotinylation approach. J. Proteome 
Res. 9:1579-1590. 
18. Henderson, B., and A. Martin. 2011. Bacterial virulence in the moonlight: multitasking 
bacterial moonlighting proteins are virulence determinants in infectious disease. Infect. 
Immun. 79:3476-3491. 
19. Holden, M. T., L. Y. Hsu, K. Kurt, et al. 2013. A genomic portrait of the emergence, 
evolution and global spread of a methicillin resistant Staphylococcus aureus pandemic. 
Genome Res. doi: 10.1101/gr.147710.112. 
20. Holtfreter, S., T. T. Nguyen, H. Wertheim, L. Steil, H. Kusch, Q. P. Truong, 
S. Engelmann, M. Hecker, U. Volker, A. van Belkum, and B. M. Broker. 2009. 
Human immune proteome in experimental colonization with Staphylococcus aureus. 
Clin. Vaccine Immunol. 16:1607-1614. 
21. Kim, H. K., A. DeDent, A. G. Cheng, M. McAdow, F. Bagnoli, D. M. Missiakas, and 
O. Schneewind. 2010. IsdA and IsdB antibodies protect mice against Staphylococcus 
aureus abscess formation and lethal challenge. Vaccine. 28:6382-6392.
22. Kim, H. K., C. Emolo, A. C. DeDent, F. Falugi, D. M. Missiakas, and O. Schneewind. 
2012. Protein A-specific monoclonal antibodies and prevention of Staphylococcus 
aureus disease in mice. Infect. Immun. 80:3460-3470.
23. Kim, H. K., H. Y. Kim, O. Schneewind, and D. Missiakas. 2011. Identifying protective 
antigens of Staphylococcus aureus, a pathogen that suppresses host immune responses. 
FASEB J. 25:3605-3612
24. Kolata, J., L. G. Bode, S. Holtfreter, et al. 2011. Distinctive patterns in the human 
antibody response to Staphylococcus aureus bacteremia in carriers and non-carriers. 
Proteomics. 11:3914-3927.
25. Komatsuzawa, H., M. Sugai, S. Nakashima, S. Yamada, A. Matsumoto, T. Oshida, 
and H. Suginaka. 1997. Subcellular localization of the major autolysin, ATL and its 
processed proteins in Staphylococcus aureus. Microbiol. Immunol. 41:469-479. 
26. Laarman, A. J., M. Ruyken, C. L. Malone, J. A. van Strijp, A. R. Horswill, and 
S. H. Rooijakkers. 2011. Staphylococcus aureus metalloprotease aureolysin cleaves 
complement C3 to mediate immune evasion. J. Immunol. 186:6445-6453. 
27. Lebon, A., J. A. Labout, H. A. Verbrugh, V. W. Jaddoe, A. Hofman, W. J.  van Wamel, 
A. van Belkum, and H. A. Moll. 2009. Role of Staphylococcus aureus nasal colonization 
in atopic dermatitis in infants: the Generation R Study. Arch. Pediatr. Adolesc. Med. 
163:745-749. 
28. Li, X., H. Wu, M. Zhang, S. Liang, J. Xiao, Q. Wang, Q. Liu, and Y. Zhang. 2012. 
Secreted glyceraldehyde-3-phosphate dehydrogenase as a broad spectrum vaccine 
Chapter 5
100
candidate against microbial infection in aquaculture. Lett. Appl. Microbiol. 54:1-9. 
29. Lorenz, U., B. Lorenz, T. Schmitter, K. Streker, C. Erck, J. Wehland, J. Nickel, 
B. Zimmermann, and K. Ohlsen. 2011. Functional antibodies targeting IsaA of 
Staphylococcus aureus augment host immune response and open new perspectives for 
antibacterial therapy. Antimicrob. Agents Chemother. 55:165-173. 
30. Lowy, F. D. 2003. Antimicrobial resistance: the example of Staphylococcus aureus. 
J. Clin. Invest. 111:1265-1273. 
31. McAdam, P. R., K. E. Templeton, G. F. Edwards, et al. 2012. Molecular tracing of 
the emergence, adaptation, and transmission of hospital-associated methicillin-resistant 
Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 109:9107-9112. 
32. McAdow, M., A. C. DeDent, C. Emolo, A. G. Cheng, B. N. Kreiswirth, 
D. M. Missiakas, and O. Schneewind. 2012. Coagulases as determinants of protective 
immune responses against Staphylococcus aureus. Infect. Immun. 80:3389-3398.
33. McCarthy, A. J., and J. A. Lindsay. 2010. Genetic variation in Staphylococcus aureus 
surface and immune evasion genes is lineage associated: implications for vaccine design 
and host-pathogen interactions. BMC Microbiol. 10:173.
34. Mera, R. M., J. A. Suaya, H. Amrine-Madsen, C. S. Hogea, L. A. Miller, E. P. Lu, D. 
F. Sahm, P. O’Hara, and C. J. Acosta. 2011. Increasing role of Staphylococcus aureus 
and community-acquired methicillin-resistant Staphylococcus aureus infections in the 
United States: a 10-year trend of replacement and expansion. Microb. Drug Resist. 
17:321-328. 
35. Miller, M., S. Donat, S. Rakette, T., et al. 2010. Staphylococcal PknB as the first 
prokaryotic representative of the proline-directed kinases. PLoS One. 5:e9057. 
36. Moore, C. L., A. Hingwe, S. M. Donabedian, M. B. Perri, S. L. Davis, N. Z. Haque, 
K. Reyes, D. Vager, and M. J. Zervos. 2009. Comparative evaluation of epidemiology 
and outcomes of methicillin-resistant Staphylococcus aureus (MRSA) USA300 
infections causing community- and healthcare-associated infections. Int. J. Antimicrob. 
Agents. 34:148-155. 
37. Ohlsen, K., and U. Lorenz. 2010. Immunotherapeutic strategies to combat 
staphylococcal infections. Int. J. Med. Microbiol. 300:402-410. 
38. Otter, J. A., and G. L. French. 2011. Community-associated meticillin-resistant 
Staphylococcus aureus strains as a cause of healthcare-associated infection. J. Hosp. 
Infect. 79:189-193. 
39. Otto, M. 2012. MRSA virulence and spread. Cell. Microbiol. 14:1513-1521. 
40. Pasztor, L., A. K. Ziebandt, M. Nega, et al. 2010. Staphylococcal major autolysin 
(Atl) is involved in excretion of cytoplasmic proteins. J. Biol. Chem. 285:36794-36803.
41. Patel, M., R. A. Kumar, A. M. Stamm, C. J. Hoesley, S. A. Moser, and K. B. Waites. 
2007. USA300 genotype community-associated methicillin-resistant Staphylococcus 
aureus as a cause of surgical site infections. J. Clin. Microbiol. 45:3431-3433. 
42. Ricklin, D., A. Tzekou, B. L. Garcia, et al. 2009. A molecular insight into complement 
evasion by the staphylococcal complement inhibitor protein family. J. Immunol. 
183:2565-2574. 
Tryptic striptease of Staphylococcus aureus unveils the cell surface localization of 
immunodominant epitopes
101
43. Rohde, R. E., R. Denham, and A. Brannon. 2009. Methicillin resistant Staphylococcus 
aureus: carriage rates and characterization of students in a Texas university. Clin. Lab. 
Sci. 22:176-184. 
44. Saravolatz, L. D., N. Markowitz, L. Arking, D. Pohlod, and E. Fisher. 1982. 
Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during 
a community-acquired outbreak. Ann. Intern. Med. 96:11-16. 
45. Schito, G. C. 2006. The importance of the development of antibiotic resistance in 
Staphylococcus aureus. Clin. Microbiol. Infect. 12 Suppl 1:3-8. 
46. Skramm, I., A. E. Moen, and G. Bukholm. 2011. Nasal carriage of Staphylococcus 
aureus: frequency and molecular diversity in a randomly sampled Norwegian community 
population. APMIS. 119:522-528. 
47. Solis, N., M. R. Larsen, and S. J. Cordwell. 2010. Improved accuracy of cell surface 
shaving proteomics in Staphylococcus aureus using a false-positive control. Proteomics. 
10:2037-2049. 
48. Stranger-Jones, Y. K., T. Bae, and O. Schneewind. 2006. Vaccine assembly from 
surface proteins of Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 103:16942-
16947. 
49. Timmerman, P., W. C. Puijk, and R. H. Meloen. 2007. Functional reconstruction 
and synthetic mimicry of a conformational epitope using CLIPS technology. J. Mol. 
Recognit. 20:283-299. 
50. Timmerman, P., E. Van Dijk, W. Puijk, et al. 2004. Mapping of a discontinuous 
and highly conformational binding site on follicle stimulating hormone subunit-beta 
(FSH-beta) using domain Scan and Matrix Scan technology. Mol. Divers. 8:61-77. 
51. van der Kooi-Pol, M. M., C. P. de Vogel, G. N. Westerhout-Pluister, et al. 2013. High 
Anti-Staphylococcal Antibody Titers in Patients with Epidermolysis Bullosa Relate to 
Long-Term Colonization with Alternating Types of Staphylococcus aureus. J. Invest. 
Dermatol. 133:847-50 
52. van der Kooi-Pol, M. M., Y. K. Veenstra-Kyuchukova, J. C. Duipmans, 
G. N. Pluister, L. M. Schouls, A. J. de Neeling, H. Grundmann, M. F. Jonkman, 
and J. M. van Dijl. 2012. High genetic diversity of Staphylococcus aureus strains 
colonizing patients with epidermolysis bullosa. Exp. Dermatol. 21:463-466. 
53. Ventura, C. L., N. Malachowa, C. H. Hammer, G. A. Nardone, M. A. Robinson, 
S. D. Kobayashi, and F. R. DeLeo. 2010. Identification of a novel Staphylococcus 
aureus two-component leukotoxin using cell surface proteomics. PLoS One. 5:e11634. 
54. Verkaik, N. J., W. J. van Wamel, and A. van Belkum. 2011. Immunotherapeutic 
approaches against Staphylococcus aureus. Immunotherapy. 3:1063-1073. 
55. Wertheim, H. F., D. C. Melles, M. C. Vos, W. van Leeuwen, A. van Belkum, 
H. A. Verbrugh, and J. L. Nouwen. 2005. The role of nasal carriage in Staphylococcus 
aureus infections. Lancet Infect. Dis. 5:751-762. 
56. Ziebandt, A. K., H. Kusch, M. Degner, et al. 2010. Proteomics uncovers extreme 
heterogeneity in the Staphylococcus aureus exoproteome due to genomic plasticity and 
variant gene regulation. Proteomics. 10:1634-1644.  
6
Surface shaving as a versatile tool to profile 
global interactions between human serum 
proteins and the Staphylococcus aureus 
cell surface 
Annette Dreisbach, Magdalena M. van der Kooi-Pol, Andreas Otto, Katrin Gronau, 
Hendrik P. J. Bonarius, Hans Westra, Herman Groen, Dörte Becher, Michael Hecker, and 
Jan Maarten van Dijl




The human commensal bacterium Staphylococcus aureus is renowned as a causative agent 
of severe invasive diseases. Upon entering the bloodstream, S. aureus can infect almost 
every tissue and organ system in the human body. To withstand insults from the immune 
system upon invasion, several immune-evasive mechanisms have evolved in S. aureus, 
such as complement inhibition by secreted proteins and IgG-binding by surface-exposed 
protein A. While it is generally accepted that S. aureus cells bind a range of host factors 
for various purposes, no global analyses to profile staphylococcal host factor binding have 
so far been performed. Therefore, we explored the possibility to profile the binding of 
human serum proteins to S. aureus cells by ‘surface shaving’ with trypsin and subsequent 
mass spectrometric analysis of liberated peptides. This resulted in the identification of 
several components of the complement system, the platelet factor 4 and the isoform 1 of 
the inter-α-trypsin inhibitor heavy chain H4 on the staphylococcal cell surface. We conclude 
that surface shaving is a versatile tool to profile global interactions between human serum 
proteins and the S. aureus cell surface.
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Introduction
Staphylococcus aureus is an important pathogen that can cause a wide range of 
infections ranging from superficial skin infections to severe invasive diseases (9, 18). 
The risk of intravascular and systemic infection by S. aureus rises significantly when 
the epithelial barrier is disrupted by surgery, intravascular catheters, implants, mucosal 
damage or trauma. Especially the surface-exposed and secreted proteins of S. aureus 
have major roles in the host-pathogen interactions that underlie staphylococcal diseases. 
Interestingly, recent genomic and proteomic analyses have revealed that the extracellular 
and surface-exposed proteomes of different S. aureus strains are highly variable, which 
seems to relate to a combination of genome plasticity and differential gene expression in 
different strains (11, 46). This heterogeneity impacts on the potential success of vaccination 
approaches, especially since the most promising candidate targets for vaccine development 
are the surface-exposed proteins. 
S. aureus produces a variety of microbial surface components recognizing adhesive 
matrix molecules (MSCRAMMs), which play critical roles in cell adhesion and invasion. 
In the past, the interaction between bacterial cell surface-exposed proteins and host proteins 
has mostly been addressed by targeted analyses in which genes for candidate bacterial 
interaction partners were either deleted or overexpressed. Subsequently, the particular 
binding regions in the identified bacterial proteins were mapped. The best characterized 
MSCRAMMs are the clumping factors A and B (ClfAB) as well as the fibrinogen-binding 
proteins A and B (FnbpAB) (5, 8, 13, 26,29, 42, 43). However, there are most likely 
additional MSCRAMMs exposed on the surface of S. aureus that can interact with host 
proteins. Besides the MSCRAMMs S. aureus also expresses proteins that interact with 
the host immune system thereby supporting immune evasion, like the staphylococcal 
complement inhibitor (SCIN) (34), the chemotaxis inhibitory protein (CHIPS) (33) and 
the staphylococcal superantigen-like protein 7 (SSL7) (3). While these proteins are secreted 
into the host environment, the immunoglobulin G (IgG)-binding protein A resides on 
the cell surface and binds host IgG in order to prevent immune recognition and subsequent 
destruction of the staphylococcal cell (15). 
Recently, we have developed a cell surface shaving approach that allows the identification of 
exposed domains of cell envelope proteins that can engage in interactions with extracellular 
biomacromolecules from the human host. In the present studies, we have investigated whether 
this surface shaving approach can be applied also to identify human serum proteins that bind 
to the S. aureus cell surface. Furthermore, we used two distinct S. aureus strains (i.e. USA300 
and Newman) with highly different surfacome composition (11) to investigate to what extent 
differences in surfacome composition impact on the binding of serum proteins. Importantly, 
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the USA300 strain represents the most successful community-associated methicillin-resistant 
S. aureus (MRSA) lineage (21, 27, 30, 31, 39), while the methicillin-sensitive strain Newman 
was recently shown to be highly virulent in animal experiments (6, 17, 23). The obtained 
results represent the proof-of-principle that surface shaving can be successfully applied to 
identify human serum proteins that bind to the S. aureus cell surface. 
Materials and methods
Bacterial strains and culture
Staphylococcus aureus strains Newman (2) and USA300 FPR3757 (10) were grown overnight 
in tryptic soy broth (TSB, OXOID) under vigorous shaking (250 rpm) at 37°C. The  cultures 
were then diluted into pre-warmed RPMI 1640 medium (PAA) to an OD
600
 of 0.1 and 
cultivation was continued under the same conditions. Exponentially growing cells were again 
diluted into fresh and pre-warmed RPMI medium to a final OD
600
 of 0.05 and the cultivation 
was continued until an OD
600
 of 0.2 was reached. 
Human serum
80 ml of fresh human blood from a healthy volunteer was collected in tubes (BD Vacutainer® 
SST™ II Advance) and incubated for 30 min at 37°C in a water bath. Subsequently 
the coagulated blood fraction was pelleted at 3000 rpm at room temperature for 5 min. 
The serum was transferred to fresh tubes and centrifuged for 10 min at 8000 rpm, 4°C. 
The resulting supernatant fraction was used for further experiments. 
Sample preparation
Three ml of each of the S. aureus cultures grown in triplicates were harvested at OD
600  
0.2 
by centrifugation (8000 rpm, 4°C, 10 min) and washed twice with PBS 40% sucrose 
(Acros), 20 mM sodium azide (Sigma-Aldrich). Thereafter, cells were resuspended in 3 ml 
of fresh human serum and incubated at room temperature for 15 min. Human serum 
without bacteria was treated in the same way and used as a control for unspecific binding 
of serum components to the reaction vessels. Thereafter, the samples were centrifuged to 
pellet the bacterial cells (8000 rpm, 4°C, 10 min), and the cells were washed twice with 
shaving buffer (PBS 40% sucrose, 20 mM sodium azide). The cells were then subjected to 
the shaving procedure (11). To verify the reproducibility of this approach the experiment 
was repeated three months later with fresh serum from the same donor.
Mass spectrometric analyses
Half of the peptides obtained from shaving were separated by liquid chromatography and 
measured online by ESI mass spectrometry. LC-MS/MS analyses were performed using 
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a nanoACQUITY UPLC™ system (Waters) coupled to an LTQ Orbitrap™ mass spectrometer 
(Thermo Fisher Scientific), creating an electro spray by the application of 1.5 kV between 
Picotip™ Emitter (SilicaTip™, FS360-20-10 Coating P200P, New Objective) and transfer 
capillary. Peptides were loaded onto a trap column (nanoAcquity UPLC TM column, 
Symmetry® C18, 5 µm, 180 µm inner diameter x 20 mm, Waters) and washed 3 min with 
99% buffer A (0.1% (v/v) acetic acid) with a flow rate of 10 µl/min. Elution was performed 
onto an analytical column (nanoAcquity UPLC TM column, BEH130 C18 1.7 µm, 100 µm 
inner diameter × 100 mm, Waters) by a binary gradient of buffer A and B (100% (v/v) ACN, 
0.1% (v/v) acetic acid) over a period of 80 min with a flow rate of 400 nl/min.
For MS/MS analysis a full survey scan was performed in the Orbitrap (m/z 300–2000) 
with a resolution of 30,000. The full scan was followed by MS/MS experiments of the five 
most abundant precursor ions acquired in the LTQ via CID. Precursors were dynamically 
excluded for 30 s, and unassigned charge states as well as singly charged ions were rejected.
For protein identification tandem mass spectra were extracted using Sorcerer™v3.5 
(Sage-N Research). Charge state deconvolution and deisotoping were not performed. 
All MS/MS samples were analyzed using Sequest (ThermoFinnigan, version v.27, rev. 11), 
applying the following search parameters: peptide tolerance, 10 ppm; tolerance for fragment 
ions, 1 amu; b- and y-ion series; an oxidation of methionine (15.99 Da) and alkylation of 
cysteine (57.02 Da) were considered as variable modification (max. three modifications 
per peptide). The raw data was searched against strain-specific bacterial databases (both 
containing a concatenated reversed database, 5250 and 5298 entries) and the human IPI 
database (v3.75, containing a concatenated reversed database, 179070 entries) assuming 
the digestion enzyme trypsin. Peptide identifications were accepted if they exceeded specific 
database search engine thresholds. Sequest identifications required at least deltaCn scores 
of greater than 0.10 and XCorr scores of greater than 1.9, 2.2, 3.8 and 3.8 for singly, doubly, 
triply and quadruply charged peptides. Protein identifications were accepted if present 
in at least two biological replicates per serum batch. With these filter parameter no false 
positive hits were obtained.
Data evaluation
Proteins were regarded as significantly identified when detected in at least two of the three 
replicates of serum samples from two independent blood donations. The normalized spectral 
abundance factor (NSAF) was calculated and averaged for the different sample sets (47). 
For statistical analyses the natural logarithm was calculated. To prevent problems during the 
logarithmic transformation, zero spectral counts were replaced by the value 0.1. The Student 
t-test was applied to the lnNSAF values and P-values below 0.05 were regarded as significant.
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Purification of human IgG
Plasma IgG was purified after separation of MNCs from human plasma using Ficoll-Paque 
PLUS (GE Healthcare). IgG was then purified by FPLC using Mabselect Protein A columns 
and the AKTA explorer system (GE Healthcare). IgG was eluted in citrate buffer (pH 3.0) 
and immediately dialyzed against PBS. IgG concentrations were subsequently determined 
with the Biorad DC protein assay.
Evaluation of trypsin digestion
Human IgGs or bovine serum albumin (BSA, Sigma) were diluted to a final concentration 
of 1 µg/µl by adding either PBS or PBS with 8 M urea (final concentration 7.6 M urea). 
All samples were then diluted with PBS resulting in a concentration of 3.4 M urea in 
the urea-treated samples and 30 mM DTT was added to a subset of the samples. After 
the addition of trypsin, the samples were incubated at 37°C for 45 min. As controls, human 
IgGs or BSA were incubated without trypsin on ice or at 37°C. Thereafter the proteins were 
separated by NuPAGE electrophoresis (Invitrogen) and stained with SimplyBlue SafeStain 
(Invitrogen) according to the manufacturers’ instructions.
Evaluation of bacterial cell stability after incubation in human serum
S. aureus cells were incubated in human serum or shaving buffer. Subsequently, the cells 
were washed twice with shaving buffer and, then, incubated in shaving buffer at 37°C for 
45 min. The samples were centrifuged (8000 rpm, 4°C, 10 min) and the resulting supernatant 
was precipitated overnight with a final concentration of 10% TCA. The precipitates were 
washed with ice cold acetone and resuspended in sample buffer (LDS, Invitrogen). Cells 
were resuspended in sample buffer and disrupted using the PreCellys24 bead beater 
(Bertin Technologies; three cycles of 30 s 6800 rpm and 30 s pauses). Cell debris and beads 
were pelleted and the supernatant was transferred to a fresh tube and designated crude 
extract. After separation by NuPAGE the proteins were transferred to a Protran nitrucellulose 
membrane (Whatman) by semi-dry blotting (75 min at 1 mA/cm²). Membranes were 
incubated with specific antibodies against TrxA (28). The signals were detected using the 
Odyssey system (LI-COR Biosciences) after incubation with IRDye 700 goat anti-rabbit 
antibodies.
Results and Discussion
Application of the surface shaving approach to S. aureus cells incubated with human serum 
resulted in the reproducible identification of 44 human proteins (Table 1, Supplemental 
Table 1 available on request). Notably, 32 of the identified proteins were also reproducibly 
detected in reaction vessels incubated with serum without added bacteria, indicating that these 
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serum proteins have a high affinity for the plastic surface of the reaction vessels. The most 
abundant of these 32 proteins were the serum albumin precursor and the apolipoproteins A-I, 
C-III, A-IV and A-II. While we initially anticipated that this approach might be hampered 
by high-level binding of IgGs to the staphylococcal Protein A, this turned out not to be the 
case. To test whether this could be due to resistance of Igs to tryptic digestion under the 
applied conditions, we incubated purified human IgG’s with trypsin for 45 min at 37°C. 
As shown in Figure 1, the purified native IgG’s were not degraded by trypsin, even after 
incubation with 7.6 M urea and 30 mM DTT. In contrast, the BSA was degraded by trypsin 
in the absence of DTT or urea, and the proteolysis of this control protein was significantly 
enhanced by the addition of urea and DTT (Figure 1). This finding is consistent with earlier 
publications showing that 6 M guanidinium-HCl and reduction with DTT are needed to 
completely unfold and digest IgGs (4, 16). In fact, the observed trypsin resistance of the 
IgGs is probably the main reason why it turned out possible to identify less abundant serum 
proteins that are enriched on the S. aureus cell surface.
Figure 1. Trypsin resistance of human IgG. 5µg of purified human IgGs were subjected to tryptic digestion 
at 37°C for 45 min. As a control the Bovine serum albumin (BSA) was used. Prior to the addition of trypsin, 
the samples were denatured with urea and/or reduced with DTT to disrupt the tertiary structure of the IgGs and 
BSA. As a negative control, both proteins were incubated on ice as well as at 37°C without the addition of trypsin. 
Subsequently, the proteins were separated using NuPAGE and visualized with SimplyBlue SafeStain (Invitrogen). 
Molecular mass markers are indicated on the left.
Chapter 6
110
All obtained MS data were quantified by spectral counting (Supplemental Table 2 available 
on request). The results showed that nine proteins were specifically enriched on the surfaces 
of the tested S. aureus strains. Five serum proteins were significantly identified in all 
bacterial samples, while these proteins were barely detectable in the negative controls. Four 
of these proteins are components of the complement system, namely factor H (fH), the 
fH-related proteins 1 and 5, and component 7 (C7; Figure 2, A-D). The enrichment of fH 
on the cell surface of S. aureus shown by our shaving experiments is consistent with recent 
binding studies from Sharp and Cunnion (36). Furthermore these authors demonstrated 
that binding of fH to the staphylococcal cell surface inhibits the alternative pathway. The 
complement component C7 is part of the so-called membrane attack complex (MAC). 
C7 was not very abundantly present in our samples, but it showed a strong enrichment on the 
staphylococcal cell surface. Interestingly, we identified exclusively the C-terminal domain 
of this complement component (Supplemental Table 1 available on request). This might 
indicate that components of the MAC cannot penetrate the cell wall, which could result in 
MAC resistance as has been described for Gram-positive bacteria in general (25). However, 
it is also conceivable that the C7 protein is proteolyzed in the serum or on the S. aureus cell 
surface, and that the resulting C-terminal peptide binds to the bacterial cell surface. Our 
shaving methodology does not distinguish between these two possibilities. 
Significant amounts of a fifth protein, the platelet factor 4 (PF4), were detectable in 
the samples derived from the surface of strain Newman (Figure 2E). In contrast, PF4 
was not identified on serum-treated USA300 cells. This indicates a differential binding 
specificity of the two S. aureus strains for this serum protein. Notably, PF4 is a kinocidin. 
The antimicrobial activity of this small protein was previously shown to be located in the 
C-terminal part (44). Interestingly, the C-terminal part of PF4 contains numerous positively 
charged amino acids, which are also involved in binding to polyanions like heparin (45). 
A recent study demonstrated the binding of PF4 to the cell surface of various bacteria, such 
as Escherichia coli, S. aureus and Streptococcus pneumoniae. Furthermore, it was shown 
that the PF4-coating of bacteria results in increased phagocytosis (24). The differential 
binding of PF4 to S. aureus cells as observed for strains Newman and USA300 may thus have 
implications for their survival upon invasive growth. Potentially, the lack of PF4 binding by 
S. aureus USA300 could represent yet another staphylococcal adaptation to avoid the human 
host defences. 
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Figure 2. Human serum proteins identified on the cell surface of S. aureus strains Newman and USA300. 
Bacterial cells were grown to early exponential growth phase (n=6), washed twice, incubated with human serum 
and washed again twice with shaving buffer. As a negative control, we incubated reaction vessels with human 
serum without adding bacteria. Immobilized trypsin was added to cleave surface-bound proteins. The resulting 
peptide samples were subjected to mass spectrometric analyses, and the results were evaluated qualitatively as 
well as quantitatively. Given are the normalized spectral abundance factors (NSAF) for proteins identified in 
the strains Newman (dark grey shading), USA300 (light grey shading) or control samples (no shading). Results 
with a P<0.05 are labeled with one star (*). Two stars (**) indicate results with P<0.001. (A-E), proteins were 
not reproducibly detectable in the control samples; (F-I), proteins were reproducibly detectable in all three samples; 
(J-L), examples of proteins that show now enrichment on the bacterial cell surface.
Four serum proteins were clearly enriched in the bacterial samples, while residual amounts 
of these proteins were also detectable in the negative controls (Figure 2, F-I). Properdin was 
10-and 8.3-fold enriched on the cell surfaces of the Newman and USA300 strains, respectively. 
With enrichment factors of 5.6 and 3.4 respectively, the complement component C3 was 
the second most enriched serum protein on the cell surfaces of these two bacterial strains. 
Notably, properdin is a positive regulator of complement activation and this protein was 
shown to bind to the processed complement component C3 (C3b) (19, 35). Both proteins are 
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well known to interact with the bacterial cell surface, which supports our present study (1, 14, 
38). The C3b protein also interacts with complement factor B (fB), which was not identified 
in the present study. However, a protein with high similarity to fB (i.e. the cDNA FLJ55673 
protein) was increased about 3-fold on the bacterial cell surfaces with a P-value of 0.06, just 
below our significance criteria. These findings suggest that not only fB, but also the cDNA 
FLJ55673 protein can bind to the S. aureus cell surface. The cDNA FLJ55673 protein might 
thus be an alternative interaction partner of the C3b protein. 
Fibrinogen alpha was identified with enrichment factors of 3.4 and 2.7, respectively, on strains 
Newman and USA300. This is another clear indication for the relevance of the present approach 
as this human protein is known to bind to various surface-exposed proteins like clumping 
factor A (ClfA) and fibronectin-binding protein A (FnbpA) (22, 26, 42). Furthermore, 2.4-fold 
enrichment of the isoform 1 of the inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) was 
exclusively shown for strain Newman. In contrast, other constituents of human serum, such 
as the isoform 1 of serum albumin, prothrombin (fragment) and apolipoprotein C-III variant 
1 were not enriched on the bacterial cell surface (Figure 2, J-L), which underscores the 
specificity of the presented assay. The identification of the ITIH4 on the surface of strain 
Newman was really unexpected. This protein has not yet been reported to interact with 
bacteria, but it is a well-known acute-phase serum protein. It was shown that an experimental 
infection of cattle with a mixture of Actinomyces pyogenes, Fusobacterium necrophorum and 
Peptostreptococcus indolicus induced a significant increase of the ITIH4 serum levels (32). 
Comparable results were obtained when inflammation was induced in mice by cutaneous 
burn injuries with a superimposed Pseudomonas aeruginosa infection (12). In addition, 
ITIH4 has been reported as a biomarker for several cancer types (41). It should be noted 
that the purified homologous protein from pigs does not inhibit trypsin, which rules out 
the possibility that ITIH4 interfered with our surface shaving assay. It will thus be relevant 
to study the physiological role of ITIH4 in relation to staphylococcal infections. Since we 
observed an enrichment of the ITIH4 exclusively on the cell surface of strain Newman, it 
seems likely that this protein interacts with a surface-exposed factor that is absent from 
the USA300 strain. Consistent with this view, we have previously demonstrated that the 
surface proteomes of these two strains vary considerably (11), which may be due to a 
combination of genomic plasticity and differences in gene expression as was also shown 
for secreted virulence factors (46). The observed surface proteome differences might thus 
lead to differential binding of host factors. However, it remains to be investigated whether 
the observed difference for ITIH4 binding relates to the presence or absence of certain cell 
surface-exposed proteins, or to differences in non-proteinaceous cell surface components. 
It will furthermore be of interest to investigate how binding of ITIH4 and other serum 
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proteins is affected by frequently occurring staphylococcal adaptations to the conditions 
in the host. Prominent examples of such adaptations are the dysfunction of the accessory 
virulence gene regulator agr, and the acquisition or loss of mobile genetic elements, like 
the staphylococcal cassette chromosome mec (7, 37, 49). 
Various S. aureus proteins were also identified in the present studies (Table 2, 
Supplemental Table 3; available on request). With one exception, these proteins were also 
identified in our previous S. aureus cell surface shaving analyses (Table 2) (11). Three 
secreted proteins, namely coagulase, fibronectin binding protein A and the secretory antigen 
SsaA were identified in the strain Newman samples. The surface-exposed coagulase and 
fibronectin-binding protein A are both known to interact with human fibrinogen (20, 42). 
The analyses of serum-treated S. aureus strain USA300 resulted in the identification of 
typical cytosolic proteins, including four ribosomal proteins, the elongation factor TU and 
the glyceraldehyde-3-phosphate dehydrogenase. This was also the case in our previously 
published studies in which the cells were not exposed to human serum (11). To check for 
cell lysis, the stability of the bacterial cells after incubation in human serum was assessed by 
Western blotting using the cytosolic protein TrxA as a lysis marker (Figure 3). The results 
show that the bacteria remained stable upon incubation in human serum, indicating that the 
identified cytoplasmic proteins on the surface of the USA300 strain were already present on 
this location before the incubation with serum. This is consistent with our previous surface 
shaving results (11). 
Figure 3. Cell stability after serum treatment. Bacterial cells were grown to the early exponential growth phase, 
washed twice, and incubated with human serum (s) or shaving buffer (c). After two additional washing steps, 
the cells were incubated for 45 min in shaving buffer. Cells were pelleted and the resulting supernatant was 
precipitated with 10% TCA. Crude extract (corresponding to 0.16 OD units) as well as the precipitated proteins 
from the incubation buffer (corresponding to 0.3 OD units) were separated by NuPAGE and subjected to Western 




To the best of our knowledge, a global analysis of serum protein binding to microbial cell 
surfaces has thus far never been performed, neither for S. aureus nor any other bacterium. 
Previous studies describing interactions between bacteria and serum proteins were focused 
on specific proteins from bacteria and their host, and the experimental set-ups involved 
pull-down assays and protein-protein interaction studies. Taken together, the present studies 
provide important proof-of-principle that our surface shaving approach can be applied 
for the profiling of human serum proteins that bind to the S. aureus cell surface. We are 
convinced that applications for this approach are not limited to studying the adherence of 
serum proteins to bacterial surfaces, but that it can also be used to investigate bacterial 
interactions with proteins in other body fluids or samples containing solubilized human cell 
envelope proteins. The surface shaving technique thus seems to be a versatile generally 
applicable tool for monitoring bacteria-host interactions. Depending on the specific aims, such 
applications may require further refinement of the developed protocol, such as the addition 
of reducing agents, detergents, and/or urea to make tightly folded cell surface-bound human 
proteins more susceptible to cleavage by trypsin or other proteases. Importantly, surface 
shaving can even be applied to profile the binding of human proteins to biomaterials as is 
underscored by our negative controls in which human serum proteins with a high propensity 
for the binding to naïve polypropylene were profiled. It thus seems that the shaving of 
surface-attached proteins opens up new avenues for studies on the interactions of bacterial 
and human proteins with each other, with plastics and other materials that are commonly 
used in medical implants. 
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Table 1. Human serum proteins binding to the cell surface of S. aureus strains Newman and USA300, or the 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Surface shaving as a versatile tool to profile global interactions between human serum 
proteins and the Staphylococcus aureus cell surface
117
Table 2. Bacterial proteins identified on the cell surface after incubation with human serum.
protein name function
previously identified on 




A6QJD9 secretory antigen SsaA, function unknown yes
A6QJY9 fibronectin binding protein yes
strain USA300
RS10 30S ribososmal protein S10 yes
RL13 50S ribososmal protein L13 yes
RL11 50S ribososmal protein L11 yes
RS6 30S ribososmal protein S6 yes
Q2FIM1 Glyceraldehyde-3-phosphate dehydrogenase, type I yes
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The Gram-positive pathogen Staphylococcus aureus secretes various proteins into its 
extracellular milieu. Bioinformatics analyses have indicated that most of these proteins are 
directed to the canonical Sec pathway, which consists of the translocation motor SecA and 
a membrane-embedded channel composed of the SecY, SecE and SecG proteins. In ddition, 
S. aureus contains an accessory Sec2 pathway involving the SecA2 and SecY2 proteins. 
Here we have addressed the roles of the non-essential channel components SecG and SecY2 
in the biogenesis of the extracellular proteome of S. aureus. The results show that SecG 
is of major importance for protein secretion by S. aureus. Specifically, the extracellular 
accumulation of nine abundant exoproteins and seven cell wall-bound proteins was 
significantly affected in the secG mutant. No secretion defects were detected for strains with 
a secY2 single mutation. However, deletion of secY2 exacerbated the secretion defects of 
secG mutants, affecting the extracellular accumulation of one additional exoprotein and one 
cell wall protein. Furthermore, the secG secY2 double mutant displayed a synthetic growth 
defect. This might relate to a slightly elevated expression of sraP, encoding the only known 
substrate for the Sec2 pathway, in cells lacking SecG. Additionally, the results suggest that 
SecY2 can interact with the Sec1 channel, which would be consistent with the presence of 
a single set of secE and secG genes in S. aureus.




Staphylococcus aureus is a well-represented component of the human microbiota as nasal 
carriage of this Gram-positive bacterium has been shown for 30-40% of the population (32). 
This organism can, however, turn into a dangerous pathogen that is able to infect almost 
every tissue in the human body. S. aureus has become particularly notorious for its high 
potential to develop resistance against commonly used antibiotics (20,49). Accordingly, the 
S. aureus genome encodes an arsenal of virulence factors that can be expressed when needed 
at different stages of growth. These include surface proteins and invasins that are necessary 
for colonization of host tissues, surface-exposed factors for evasion of the immune system, 
exotoxins for the subversion of protective host barriers, and resistance proteins for protection 
against antimicrobial agents (37,57). 
Most proteinaceous virulence factors of S. aureus are synthesized as precursors with 
an N-terminal signal peptide to direct their transport from the cytoplasm across the 
membrane to an extracytoplasmic location, such as the cell wall or the extracellular 
milieu (38,45). As shown for various Gram-positive bacteria, the signal peptides of 
S. aureus are generally longer and more hydrophobic than those of Gram-negative 
bacteria (38,54). Based on signal peptide predictions using a variety of algorithms, it is 
believed that most exoproteins of S. aureus are exported to extracytoplasmic locations 
via the general Secretory (Sec) Pathway (38). This seems to involve precursor targeting 
to the Sec machinery via the Signal Recognition Particle instead of the well-characterized 
proteobacterial chaperone SecB, which is absent from Gram-positive bacteria (16,19,53). 
The pre-proteins are then bound by the translocation motor protein SecA (38,45). Through 
repeated cycles of ATP binding and hydrolysis, SecA pushes the protein in an unfolded 
state through the membrane-embedded SecYEG translocation channel (12,30,33,52). 
Upon initiation of the translocation process, the proton-motive force is thought to 
accelerate pre-protein translocation through the Sec channel (26). Recently, the structure of 
the SecA/ SecYEG complex from the Gram-negative bacterium Thermotoga maritima was 
solved at 4.5 A resolution (58). In this structure, one SecA molecule is bound to one set of 
SecYEG channel proteins. The core of the Sec translocon consists of the SecA, SecY and 
Sec proteins, which are essential for growth and viability of bacteria, such as Escherichia coli 
and Bacillus subtilis (6,9,22). In contrast, the channel component SecG is dispensable for 
growth, cell viability and protein translocation (26,48). Nevertheless, SecG does enhance 
the efficiency of pre-protein translocation through the SecYE channel (26,48). This is of 
particular relevance at low temperatures and in the absence of a proton-motive force (17). 
Several studies suggest that E. coli SecG undergoes topology inversion during pre-protein 
translocation (25,27,43). Even so, van der Sluis et al. reported that SecG cross-linked to 
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SecY is fully functional despite its fixed topology (46). During or shortly after membrane 
translocation of a pre-protein through the Sec channel, the signal peptide is removed by 
signal peptidase. This is a prerequisite for the release of the translocated protein from 
the membrane (1,47).
Several pathogens, including Streptococcus gordonii, Streptococcus pneumoniae, 
Bacillus anthracis, Bacillus cereus, and S. aureus contain a second set of chromosomal secA 
and secY genes named secA2 and secY2, respectively (39). Comparison of the amino acid 
sequences of the SecY1 and SecY2 proteins shows that their similarity is low (about 
20% identity), and that the conserved regions are mainly restricted to the membrane spanning 
domains. It has been shown for S. gordonii that the transport of at least one protein is 
dependent on the presence of SecA2 and SecY2. This protein, GspB, is a large cell-surface 
glycoprotein that is involved in platelet binding (4). The protein contains an unusually long 
N-terminal signal peptide of 90 amino acids, large serine-rich repeats, and a C-terminal 
LPxTG motif for covalent cell wall binding. The gspB gene is located in a gene cluster with the 
secA2 and secY2 genes. Two other genes in this cluster encode for the glycosylation proteins 
GftA and GftB, which seem to be necessary for stabilization of pre-GspB. Furthermore, the 
asp4 and asp5 genes in the secA2 secY2 gene cluster show similarity to secE and secG, and 
they are important for GspB export by S. gordonii (44). Despite this similarity, SecE and SecG 
cannot complement for the absence of Asp4 and Asp5, respectively. The secA2/ secY2 gene 
cluster is also present in S. aureus, but homologues of the asp4 and asp5 genes are lacking. 
This seems to suggest that SecA2 and SecY2 of S. aureus share the SecE and SecG proteins 
with SecA1 and SecY1. The sraP gene in the secA2/secY2 gene cluster of S. aureus 
encodes a protein with similar features as described for GspB. Siboo and colleagues (41) 
have shown that SraP is glycosylated and capable of binding to platelets. Importantly, the 
disruption of sraP resulted in a decreased ability to initiate infective endocarditis in a rabbit 
model. Consistent with the findings in S. gordonii, SraP export was shown to depend on 
SecA2/ SecY2 (40). However, it has remained unclear whether other S. aureus proteins are 
also translocated across the membrane in a SecA2/ SecY2-dependent manner. 
The present studies were aimed at defining the roles of two Sec channel components, SecG 
and SecY2, in the biogenesis of the S. aureus exoproteome. The results show that secG 
and secY2 are not essential for growth and viability of S. aureus. While the absence of 
SecY2 by itself had no detectable effect, the absence of SecG had a profound impact on 
the composition of the exoproteome of S. aureus. Various extracellular proteins were present 
in decreased amounts in the growth medium of secG mutant strains, which is consistent 
with impaired Sec channel function. However, a few proteins were present in increased 
amounts. Furthermore, the absence of secG caused a serious decrease in the amounts of 
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the cell wall-bound Sbi protein. Most notable, a secG secY2 double mutant strain displayed 
synthetic growth and secretion defects.
Material & Methods
Bacterial strains and plasmids
All strains used in this study are listed in Table 1. Unless stated otherwise, E. coli strains 
were grown in Luria-Bertani broth (LB). S. aureus strains were grown at 37°C in tryptic 





0.1% glucose) under vigorous shaking, or on trypic soy agar (TSA) plates or B plates. 
If appropriate, media for E. coli were supplemented with 100 µg/ml ampicillin or 100 µg/ ml 
erythromycin, and media for S. aureus with 5 µg/ml erythromycin, 5 µg/ml tetracyclin or 
20 µg/ml kanamycin. To monitor β-galactosidase activity in cells of E. coli and S. aureus, 
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) was added to the plates at 
a final concentration of 80 µg/ml. 
Construction of S. aureus mutant strains
Mutants of S. aureus were constructed using the temperature-sensitive plasmid pMAD (2) 
and previously described procedures (23). Primers (Table 2) were designed using the genome 
sequence of S. aureus NCTC8325 (http://www.ncbi.nlm.nih.gov/nuccore/NC_007795). 
All mutant strains were checked by isolation of genomic DNA using the GenElute™ Bacterial 
Genomic DNA Kit (Sigma) and PCR with specific primers.
To delete the secG or secY2 genes, primer pairs with the designations F1/R1 and F2/R2 were 
used for PCR amplification of the respective upstream and downstream regions (each ~500 bp), 
and their fusion with a 21 bp linker. The fused flanking regions were cloned in pMAD, 
and the resulting plasmids were used to delete the chromosomal secG or secY2 genes of 
S. aureus RN4220. To delete the secG or secY2 genes from the S. aureus SH1000 genome, 
the respective pMAD constructs were transferred from the RN4220 strain to the SH1000 
strain by transduction with phage φ85 (29). 
To create the spa sbi double mutant of S. aureus Newman, the sbi gene was deleted from 
a spa mutant strain kindly provided by T. Foster (31). For this purpose, the kanamycin 
resistance marker encoded by pDG783 was introduced between the sbi flanking regions via 
PCR with the primer pairs sbi-F1/sbi-R1, sbi-F2/sbi-R2 and kan-F1/kan-R1. The obtained 
~1000 bp fragment was ligated into pMAD, and the resulting plasmid was used to transform 
competent S. aureus Newman spa cells. Blue colonies were selected on TSA plates with 
erythromycin and kanamycin, and the spa sbi double mutant was subsequently identified 
following the previously described protocol (23). 
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For complementation studies, the secG or secY2 genes were cloned into plasmid pCN51 (11). 
Expression of genes cloned in this plasmid is directed by a cadmium-inducible promoter. 
Primer pairs with the F3/R3 designation (Table 2) were used to amplify the secG or secY2 
genes. These primers contain an EcoRI restriction site at the 5’ end and a SalI restriction site 
at the 3’ end of the amplified gene. PCR products were purified using the PCR Purification 
Kit (Roche), and ligated into the TOPO-vector (Invitrogen). The resulting constructs were 
then cut with EcoRI and SalI, and the secG or secY2 genes (284 and 1233 bp, respectively) 
were isolated from an agarose gel and ligated into pCN51 cut with EcoRI and SalI. 
This resulted in the secG- and secY2-pCN51 plasmids. Competent S. aureus RN4220 ΔsecG, 
ΔsecY2 or ΔsecG ΔsecY2 cells were transformed with these plasmids by electroporation and 
colonies were selected on TSA plates containing erythromycin. The plasmids were then 
transferred to S. aureus SH1000 by transduction as described above. 
Analytical and preparative two-dimensional (2-D) PAGE
Extracellular proteins from 100 ml culture supernatant were precipitated, washed, dried, 
and resolved as described previously (56). The protein concentration was determined using 
Roti®-Nanoquant (Carl Roth GmbH & Co, Karlsruhe, Germany). Preparative 2-D PAGE 
was performed by using the immobilized pH gradient technique (5,13). The protein 
samples (350 µg) were separated on immobilized pH gradient strips (Amersham Pharmacia 
Biotech, Piscataway, NJ) with a linear pH gradient from 3 to 10. The resulting protein gels 
were stained with colloidal Coomassie Blue G-250G (10) and scanned with the light scanner. 
Each experiment was performed at least three times.
For identification of proteins by MALDI-TOF MS, Coomassie-stained protein spots were 
excised from gels using a spot cutter (Proteome Work™) with a picker head of 2 mm and 
transferred into 96-well microtiter plates. Digestion with trypsin and subsequent spotting of 
peptide solutions onto the MALDI targets were performed automatically in an Ettan Spot 
Handling Workstation (GE-Healthcare, Little Chalfont, United Kingdom) using a modified 
standard protocol. MALDI-TOF MS analyses of spotted peptide solutions were carried out 
on a Proteome-Analyzer 4700/4800 (Applied Biosystems, Foster City, CA) as described 
previously (13). MALDI-TOF-TOF analysis was performed for the three highest peaks of 
the TOF spectrum as described previously (13,51). Database searches were performed using 
the GPS explorer software version 3.6 (build 329) with the organism-specific databases.
By using the MASCOT search engine version 2.1.0.4. (Matrix Science, London, UK) 
the combined MS and MS/MS peak lists for each protein spot were searched against a database 
containing protein sequences derived from the genome sequences of S. aureus NCTC8325. 
Search parameters were as described previously (51). For comparison of protein spot 
volumes, the Delta 2D software package was used (Decodon GmbH Germany). The induction 
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ratio of mutant to parental strain was calculated for each spot (normalized intensity of 
a spot on the mutant image/normalized intensity of the corresponding spot on the parental 
image). The significance of spot volume differences of two-fold or higher was assessed by 
the Student´s t test (α<0.05; Delta 2D “statistics” table).
Transcriptional analysis
Total RNA from S. aureus RN4220 was isolated using the acid-phenol method (14). 
Digoxigenin-labeled RNA probes were prepared by in vitro transcription with T7 RNA 
polymerase, using the Dig-RNA labeling mixture (Roche, Indianapolis, IN) and 
appropriate PCR fragments as templates. The PCR fragments were generated by using 
the respective oligonucleotides (Table 2) and chromosomal DNA of S. aureus RN4220 
isolated with the chromosomal DNA isolation kit (Promega, Madison, WI) according to 
the manufacturer’s recommendations. Reverse primers contain the T7 RNA polymerase 
recognition sequence at the 5’ end. Northern blot and slot blot analyses were performed 
as described previously (50,57). Before hybridization, each RNA blot was stained with 
methylene blue in order to check the RNA amount blotted onto the membrane. Only blots 
showing equal amounts of 16S and 23S rRNA for each sample loaded onto the respective 
gels were used for hybridization experiments. The hybridization signals of the Northern blots 
were detected with a Lumi-Imager (Roche, Indianapolis, IN) and analyzed with the software 
package LumiAnalyst (Roche, Indianapolis, IN). Slot blot signal detection was performed 
with the Intas ChemoCam system and analysed with LabImage1D software (Intas Science 
Imaging Instruments GmbH, Göttingen, Germany). In slot blot experiments, the induction 
ratios were calculated by dividing the volumes obtained for the different RNA samples by 
the volume of the signals of the exponentially grown RN4220 parental strain. An internal 
RNA standard was spotted onto each membrane to correct for inter-membrane variations.
Cell fractionation, SDS-PAGE, and Western blotting
Overnight cultures were diluted to an OD
540
 of 0.05 and grown in 25 ml TSB under vigorous 
shaking. For complementation of mutant strains with pCN51-based plasmids, CdSO
4
 was 
added after three hours of growth to a final concentration of 0.25 µM. Samples were taken 
after six hours of growth and separated in growth medium, whole cell and non-covalently 
cell wall-bound protein fractions. Cells were separated from the growth medium by 
centrifugation of 1 ml of the culture. The proteins in the growth medium were precipitated 
with 250 µl 50% trichloroacetic acid (TCA), washed with acetone and dissolved in 100 µl 
Loading Buffer (Invitrogen). Cells were resuspended in 300 µl Loading Buffer (Invitrogen) 
and disrupted with glass beads using a Precellys®24 bead-beating homogenizer (Bertin 
Technologies). From the same culture 20 ml was used for the extraction of non- covalently 
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bound cell wall proteins using KSCN. Cells were collected by centrifugation, washed with 
PBS, and incubated for 10 min with 1M KSCN on ice. After centrifugation the non-covalently 
cell wall bound proteins were precipitated from the supernatant fraction with TCA, washed 
with acetone and dissolved in 100 µl Loading Buffer (Invitrogen). Upon addition of 
Reducing Agent (Invitrogen), the samples were incubated at 95ºC. Proteins were separated 
by SDS-PAGE using precast NuPage gels (Invitrogen) and subsequently blotted onto 
a nitrocellulose membrane (Protran®, Schleicher & Schuell). The presence of a cytoplasmic 
marker protein (TrxA), a lipoprotein (DsbA), and several cell wall-associated proteins 
(Sle1, Aly, ClfA, IsaA) or extracellular proteins (Sle1, Aly, IsaA, SspB) was monitored by 
immunodetection with specific polyclonal antibodies raised in mice or rabbits. Bound primary 
antibodies were visualized using fluorescent IgG secondary antibodies (IRDye 800 CW goat 
anti-mouse/anti-rabbit from LiCor Biosciences). Membranes were scanned for fluorescence 
at 800 nm using the Odyssey Infrared Imaging System (LiCor Biosciences). 
Mouse infection studies 
All animal studies were approved by the Animal Care and Experimentation Committee 
of the district government of Lower Franconia, Germany and conformed to University of 
Würzburg guidelines. Female Balb/C mice (16-18 g; Charles River, Sulzfeld, Germany) 
were housed in polypropylene cages and received food and water ad libitum. S. aureus 
isolates were cultured for 18 hours in B-medium, washed three times with sterile PBS 
and suspended in sterile PBS to 1.0x108 CFU/100 µl. As a control, selected dilutions were 
plated on B agar. Mice were inoculated with 100 µl of S. aureus via the tail vein. Control 
mice were treated with sterile PBS. For each strain, eight mice were used. Three days after 
challenge, kidneys and livers were aseptically harvested and homogenized in 3 ml of PBS 
using Dispomix (Bio-Budget Technologies Gmbh, Krefeld, Germany). Serial dilutions of 
the organ homogenates were cultured on mannitol salt-phenol red agar plates for at least 
48 h at 37°C. CFUs were calculated as CFU/organ. The statistical significance of bacterial 
load was determined using Mann Whitney tests.
Results
The exoproteomes of secG and secY2 mutant S. aureus strains
To investigate the roles of SecG and SecY2 in the biogenesis of the S. aureus 
exoproteome, the respective genes were completely deleted from the chromosome of 
S. aureus strain RN4220. This resulted in the single mutant strains ΔsecG and ΔsecY2, and 
the double mutant ΔsecG ΔsecY2. Next, cells of these mutants were grown in TSB medium 
until they reached the stationary phase (Figure 1; not shown for the ΔsecY2 strain). 
Synthetic effects of secG and secY2 mutations on exoproteome biogenesis in 
Staphylococcus aureus 
131
Figure 1 Growth of S. aureus secG and secG secY2 mutants. The S. aureus strains RN4220 ΔsecG (A), ΔsecG 
ΔsecY2 (B), and the parental strain RN4220 were grown in 100 ml TSB medium under vigorous shaking at 37°C. 
Sampling points for the preparation of extracellular proteins for 2-D PAGE analyses in Figure 2 are indicated in 
the growth curves by arrows.
All three mutants displayed similar exponential growth rates as the parental strain. However, 
the secG secY2 double mutant entered the stationary phase at a lower optical density 
(OD
540
=8) than the parental strain and the ΔsecG mutant (OD
540
=15). Since the amounts 
of most exoproteins of S. aureus increase mainly in the stationary growth phase at high 
cell densities (37,56), extracellular proteins for 2-D PAGE analyses were collected 
from the supernatant of cell cultures that had reached stationary phase (Figure 1 and 2). 
Comparison of the exoproteomes of the secG mutant and its parental strain revealed that 
eleven proteins with Sec-type signal peptides and type I signal peptidase cleavage sites 
(i.e. SAOUHSC-00094, SdrD, Sle1, Geh, Hlb, HlY, HlgB, HlgC, Plc, SAOUHC-02241 and 
SAOUHSC-02979) were present in significantly decreased amounts when SecG was absent 
from the cells. This was also true for the secreted moiety of the polytopic membrane protein 
YfnI, which is processed by signal peptidase I as was previously shown for the YfnI homologue 
of B. subtilis (1). In contrast, the amounts of three other exoproteins (i.e. IsaA, Spa and 
SsaA) were considerably increased due to the secG deletion (Figure 2A; Table 3). These 
effects of the secG mutation were fully compensated when secG was ectopically expressed 
from plasmid secG-pCN51 (Figure 2C). Northern blot analyses revealed similar transcript 
levels for geh, hlb and spa in the secG mutant and the parental strain RN4220. This shows 
that the changes in the amounts of the respective exoproteins in the secG mutant were 
not caused by a decreased transcription of the corresponding genes (Figure 3). Deletion of 
the secY2 gene encoding a channel component of the accessory Sec system in S. aureus, 
did not affect the extracellular protein pattern (data not shown). However, the deletion of 
both secG and secY2 caused additional changes in the extracellular proteome compared 
to the secG single mutant (Figure 2B). Specifically, one additional exoprotein was 
identified in decreased amounts (i.e. LipA) and one additional exoprotein (i.e. LytM) was 
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identified in increased amounts (Table 3). Furthermore, proteins such as IsaA, Spa, and 
SsaA were secreted in higher amounts not only by the secG mutant, but also by the secG 
secY2 double mutant. This effect was significantly exacerbated for IsaA and SsaA in the 
secG secY2 double mutant. It is interesting to note that IsaA, LytM, Spa, and SsaA represent 
cell surface-associated proteins (34,37,42). In contrast, most proteins that were secreted in 
reduced amounts in the secG or secG secY2 mutants are secretory proteins without retention 
signals, except for SAOUHSC-00094 (Table 3). Importantly, also the secretion and growth 
defects of the secG secY2 mutant strain could be fully reversed by ectopic expression of 
secG from plasmid secG-pCN51, and the synthetic effects of the secG and secY2 mutations 
could be reversed by plasmid secY2-pCN51 (data not shown).
Synthetic effects of secG and secY2 mutations on exoproteome biogenesis in 
Staphylococcus aureus 
133
Figure 2. The extracellular proteomes of S. aureus secG and secG secY2 mutants. (A) False-colored dual-channel image 
of 2-D gels of extracellular proteins of S. aureus RN4220 (green) and S. aureus RN4220 ΔsecG (red). Proteins (350 µg) 
isolated from the supernatant of S. aureus RN4220 and S. aureus RN4220 ΔsecG grown in TSB medium to an OD
540
 
of 15 were separated on 2-D gels by using immobilized pH gradient strips with a linear pH range of 3-10. Proteins 
were stained with colloidal Coomassie Brilliant Blue. Protein spots present in equal amounts in both strains appear in 
yellow, protein spots present in higher amounts in the secG mutant appear in red, and protein spots present in higher 
amounts in the parental strain appear in green. Only proteins with a Sec-type signal peptide of which the extracellular 
amounts were reproducibly affected by the secG mutation have been marked. (B) False-colored dual-channel 
image of 2-D gels of extracellular proteins of S. aureus RN4220 (green) and S. aureus RN4220  ΔsecG ΔsecY2 
(red). For experimental details see (A). Protein spots present in equal amounts in both strains appear in yellow, 
protein spots present in higher amounts in the secGsecY2 mutant appear in red, and protein spots present in higher 
amounts in the parental strain appear in green. (C) False-colored dual-channel image of 2-D gels of extracellular 
proteins of S. aureus RN4220 (green) and S. aureus RN4220 ΔsecG secG-pCN51 (red). For experimental details 
see (A). All protein spots are yellow, indicating that both strains secreted the respective proteins in equal amounts.
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Figure 3. Expression of SecG-dependent exoproteins. RNA and exoproteins were collected from S. aureus RN4220 
and S. aureus RN4220 ΔsecG grown in TSB medium at 37°C. Samples were collected at three different points 
during growth (OD
540
 of 1, 10 and 15). In the Northern blotting experiments, membranes were hybridized 
with digoxigenin-labeled RNA probes specific for geh, hlb or spa. Protein spots from 2-D PAGE analyses of 
the respective proteins collected at OD
540
 of 1, 10, and 15 are shown for the secG mutant and its parental strain both 
separately and as dual-channel images.
Elevated expression of sraP in secG mutant cells during the transition phase
To test whether the synthetic effects of the secG secY2 double mutation might relate to 
jamming of the SecYE translocation channel by SraP, the only known substrate for 
the Sec2 pathway, we tried to construct a secG secY2 sraP triple mutant. Unfortunately, 
despite several attempts we did not manage to obtain this triple mutant for reasons that 
have so far remained obscure. To obtain further insights into the expression of sraP under 
the conditions tested, we performed Northern blotting and slot blot experiments with RNA 
extracted from the secG single mutant, the secG secY2 double mutant and the parental strain 
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RN4220. These experiments revealed that sraP expression is highest in the transient phase 
between the exponential and stationary growth phases (Figure 4). Furthermore, the deletion 
of secG reproducibly triggered a two-fold elevated sraP transcript level during the transient 
phase. This moderate but reproducible effect was observed both in the secG single mutant 
and in the secG secY2 double mutant, which argues to some extent against the possible 
jamming of SecYE by SraP, at least when SecY2 is still present in the cells.  
Figure 4. Transcriptional analysis of sraP. RNA was prepared from S. aureus RN4220, S. aureus RN4220 ΔsecG 
and S. aureus RN4220 ΔsecG ΔsecY2 cells grown in TSB medium (37°C) at three different stages of growth: 
exponential phase (OD
540
 1), transient phase (RN4220 and ΔsecG at OD
540
 10; ΔsecG ΔsecY2 at OD
540
 6),  and 
stationary phase (RN4220 and ΔsecG at OD
540
 15; ΔsecG ΔsecY2 at OD
540
 8). (A) Serial dilutions of total RNA 
of the wild type and the mutant strains were blotted and cross-linked onto positively charged nylon membranes. 
The membrane-bound RNA was hybridized with a digoxigenin labelled RNA probe complementary to sraP. 
(B) Quantification of changes in the sraP mRNA levels during growth of S. aureus RN4220 and its ΔsecG or 
ΔsecG ΔsecY2 mutant derivatives. Induction ratios relate to sraP mRNA levels in exponentially growing cells of 
the RN4220 parental strain as described in the Materials and Methods.
Impaired export of cell wall-bound Sbi in secG mutant cells
Western blotting experiments were performed to investigate whether particular protein export 
defects of the secG and secY2 mutants had remained unnoticed in the proteomic analyses. 
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These analyses included secreted proteins in the growth medium (Sle1, Aly, IsaA, SspB), 
non-covalently attached cell wall proteins (Sle1, Aly, IsaA), a covalently attached cell 
wall protein (ClfA), a lipoprotein (DsbA) and a cytoplasmic marker protein (TrxA) in 
S. aureus strains RN4220 and S. aureus SH1000. For most tested proteins no differences 
were detectable between the secG and/or secY2 mutant strains and their parental strain. 
However, these analyses showed that a band of ~50 kDa, which was cross-reactive with all 
tested sera, had disappeared from the fraction of non-covalently bound cell wall proteins 
of the secG mutant. It is known that proteins, such as protein A (36) and Sbi (55) have 
IgG-binding properties. To investigate whether the missing band would relate to protein A 
or Sbi, protein fractions from a spa mutant, and a spa sbi double mutant, were included in 
the Western blotting analyses. As shown in Figure 5A, the band of ~50 kDa that was missing 
from the non-covalently bound cell wall proteins in the secG mutant was also missing 
from these proteins in the spa sbi double mutant, but not in the spa single mutant (only 
the results for S. aureus SH1000 are shown but essentially the same results were obtained 
for S. aureus RN4220). Taken together, these findings show that Sbi is non-covalently 
bound to the cell wall of S. aureus RN4220 and SH1000, and that SecG is required for 
export of Sbi from the cytoplasm to the cell wall. As was the case for the secreted S. aureus 
proteins detected by proteomics, Sbi export to the cell wall was not affected by the absence 
of SecY2 (Figure 5B). Finally, it is noteworthy that Sbi is only detectable amongst 
the non-covalently bound cell wall proteins of S. aureus RN4220 and SH1000, whereas it is 
detectable both in a cell wall-bound and a secreted state in S. aureus Newman. 
Deletion of secG and secY2 does not affect virulence in a mouse model
To test whether the deletion of secG and/or secY2 would affect the virulence of S. aureus 
SH1000, a mouse infection model was used. The results revealed no significant differences 
in virulence of the ΔsecG, ΔsecY2, or ΔsecG ΔsecY2 strains as compared to the parental 
strain SH1000 (Figure 6). This shows that SecG and SecY2 have no important roles in 
the virulence of strain SH1000 in the context of the used mouse infection model. 
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Figure 5. Sbi localization to the cell wall of S. aureus depends on SecG. (A) S. aureus SH1000 (WT), S. aureus 
SH1000 ΔsecG, and S. aureus SH1000 ΔsecG secG-pCN51 were grown in TSB medium at 37°C till the early 
stationary phase. Samples of extracellular proteins isolated from the growth medium (M), non-covalently cell 
wall-bound proteins (CW) and total cells (C) were used for Western blotting and immunodetection with serum of mice 
immunized with IsaA. As a contol for Sbi production, the strains S. aureus Newman Δspa and S. aureus Newman 
Δspa Δsbi were included in the analyses. (B) Proteins of S. aureus SH1000 (wt), S. aureus SH1000 ΔsecG, and 
S. aureus SH1000 ΔsecY2 were used for Western blotting and immunodetection as in (A). The position of Sbi is 
marked with an arrow.
Figure 6. Mouse infection studies with S. aureus secG and secG secY2 mutants. Eight mice were challenged 
with 1 x 108 CFU of S. aureus SH1000 ΔsecG, S. aureus SH1000 ΔsecY2, S. aureus SH1000 ΔsecG ΔsecY2 or 
the parental strain SH1000 (wt). After 3 days, the bacterial load of the kidneys (A) and livers (B) was determined 




The extracellular and surface-associated proteins of bacterial pathogens, such as S. aureus, 
epresent an important reservoir of virulence factors (38,39,57). Accordingly, protein export 
mechanisms will contribute to the virulence of these organisms. While protein export has 
been well characterized in model organisms, such as E. coli and B. subtilis, relatively 
few functional studies have addressed the protein export pathways of S. aureus. Notably, 
the Sec pathway is generally regarded as the main pathway for protein export but, to date, 
this has not been verified experimentally in S. aureus. Therefore, the present studies were 
aimed at assessing the role of the Sec pathway in establishing the extracellular proteome 
of S. aureus. We focused attention on the non-essential channel component SecG as this 
allowed a facile co-assessment of the non-essential accessory Sec channel component 
SecY2. Our results show that the extracellular accumulation of proteins is affected to 
different extents by the absence of SecG: some proteins are present in reduced amounts, 
some are not affected and some are present in elevated amounts. Furthermore, the effects of 
the absence of SecG are exacerbated by deletion of SecY2, suggesting that SecY2 directly 
or indirectly influences the functionality of the general Sec pathway. This is all the more 
remarkable since the absence of SecY2 by itself had no detectable effects on the composition 
of the extracellular proteome of S. aureus. 
The observation that the secretion of a wide range of proteins was affected by the absence 
of SecG is consistent with the fact that all of these proteins contain Sec-type signal peptides. 
On the other hand, this finding is remarkable since studies in other organisms, such as 
E. coli (26) and B. subtilis (48), have shown that deletion of secG had fairly moderate 
effects on protein secretion in vivo. In B. subtilis, a phenotype of the secG mutation was 
only observed under conditions of high overproduction of secretory proteins (48). Clearly, 
our present data show that SecG is more important for Sec-dependent protein secretion 
in S. aureus than in B. subtilis or E. coli. Importantly, the transcription of genes for three 
proteins (Geh, Hlb and Spa) that were affected in major ways by the absence of SecG was 
not changed, and all observed effects of the secG mutation could be reversed by ectopic 
expression of secG. This suggests that the observed changes in the exoproteome composition 
of the S. aureus secG mutant strain relate to changes in the translocation efficiency of 
proteins through the Sec channel rather than regulatory responses at the gene expression 
level. This could be due to altered recognition of the respective signal peptides or mature 
proteins by the SecG-less Sec channel, or combinations thereof. However, some indirect 
effects, for example at the level of translation of exported proteins, post-translocational 
folding, proteolysis or cell wall binding of proteins like IsaA, LytM, Spa and SsaA, can 
currently not be excluded especially since no proteins were found to accumulate inside 
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the secG mutant cells (data not shown). It remains to be shown why the extracellular 
accumulation of particular proteins is affected by the absence of SecG, while that of other 
proteins remains unaffected.
Unexpectedly, our studies revealed that export of the IgG-binding protein Sbi to the cell wall 
was almost completely blocked in secG mutant strains. The reason why this export defect 
was not detected by 2-D PAGE relates to the fact that Sbi is predominantly cell wall-bound 
in the tested S. aureus strains under the experimental conditions used. It has been proposed 
previously that Sbi would remain cell wall-attached through a proline-rich wall-binding 
domain and electrostatic interactions (55). Nevertheless, Burman and colleagues showed that 
Sbi is extracellular and they suggested that cell surface-bound Sbi might be disadvantageous 
for the bacterium due to its role in modulating the complement system (8). On the other 
hand, cell surface localization of Sbi would be appropriate for interference with the adaptive 
immune system through IgG binding (3). Irrespective of these previously reported findings, 
our Western blotting analyses show that Sbi is non-covalently bound to the cell wall, not only 
in S. aureus SH1000 and S. aureus RN4220, but also in S. aureus Newman. However, 
consistent with the findings of Burman et al., Sbi was also detected in the growth medium of 
S. aureus Newman, which indicates that the location of Sbi in the cell wall or extracellular 
milieu may differ for different S. aureus strains. In case of the Newman strain, the release 
of Sbi into the growth medium could be due to the fact that this strain produces Sbi and 
several other cell wall-bound proteins at increased levels compared to the RN4220 and 
SH1000 strains (35). Conceivably, this increased production of wall-bound proteins might 
lead to a saturation of available cell wall binding sites for Sbi. Remarkably, the absence of 
SecG was shown to impact on the relative amounts of various extracellular proteins, while 
effects of the absence of SecG were detected for only one cell wall-associated protein, namely 
Sbi. We do not believe that these differences in the numbers of identified proteins relate to 
the method that was used to monitor effects of the absence of SecG. Especially, the analysis 
of proteins secreted by secG mutant strains via regular 1-D SDS PAGE already revealed 
major differences in the composition of the exoproteome (not shown). It was for this reason 
that we initiated our 2-D PAGE analyses to identify the affected proteins. On the other 
hand, a 1-D SDS PAGE analysis of cell wall-associated proteins did not reveal any major 
differences, and this was in fact the reason why we investigated potentially wall-associated 
proteins by Western blotting. Furthermore, we have no evidence from the different studies 
that we performed that the time point at which the sampling was done during the stationary 
phase had any major influence on the outcomes of our analyses.
Many of the proteins of which the extracellular amounts are changed due to the absence 
of SecG are considered to be important virulence factors of S. aureus. These proteins are 
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involved in host colonization (e.g. the serine-aspartic acid repeat proteins SdrC and SdrD), 
invasion of host tissues (e.g. hemolysins and leukocidins), cell wall turnover (LytM), and 
evasion of the immune system (Spa, Sbi). The altered amounts of these proteins suggest that 
S. aureus strains depleted of SecG might perhaps be less virulent. However, in the applied 
mouse infection model no changes in virulence of the S. aureus SH1000 secG, secY2, or 
secG secY2 mutant strains could be detected. This implies that the presence or absence 
of SecG or SecY2 is not critical for the virulence of S. aureus SH1000, at least under 
the conditions tested in the applied mouse infection model. Clearly, this does not rule out 
the possibility that such mutants are attenuated in virulence in other infection models that 
were not tested so far. 
Since we were unable to detect secretion defects for secY2 single mutant strains, our 
studies confirm that only very few proteins are translocated across the membrane in 
a SecA2/ SecY2-dependent manner as has previously been suggested by Siboo et al. (40). 
Furthermore, we did not detect differences in the export of glycosylated proteins by 
the secY2 mutants (data not shown), which is in line with the suggestion that glycosylated 
proteins are not strictly dependent on the accessory Sec pathway for export (40). It was 
therefore quite surprising that the secY2 mutation exacerbated the secretion defect of 
the S. aureus secG mutant. In fact, the secretion of two additional proteins was found to 
be affected in the secG secY2 double mutant. Moreover, a synthetic growth defect was 
observed for this double mutant. At this stage, it is possible that both the growth defect and 
the secretion defects are consequences of an impaired Sec channel function. In addition, 
the exacerbated secretiondefects may relate to SecYE jamming by SraP, which is the only 
known SecA2/ SecY2 substrate. As shown by Northern blotting analyses, the deletion 
of secG somehow triggers a two-fold elevated sraP transcript level during the transition 
between exponential and post-exponential growth, not only in the secG single mutant but 
also in the secG secY2 double mutant. This argues to some extent against the jamming of 
SecYE by SraP, at least when SecY2 is still present in the cells. In the absence of SecG and 
SecY2, indeed jamming of SecYE by the overexpressed SraP may occur in the transient 
phase. On the other hand, sraP expression seems relatively low in the stationary phase during 
which we harvested the extracellular proteins for proteomics analyses, which would suggest 
that any jamming effects of SraP are relatively low in this growth phase. Unfortunately, 
we have so far not been able to assess the possibility of SecYE jamming by SraP directly, 
because we were unable to obtain a secG secY2 sraP triple mutant. Notably, it is also possible 
that the exacerbated secretion defects are, to some extent, a secondary consequence of 
the growth defect of the double mutant. Irrespective of their primary cause, these synthetic 
effects of the secG and secY2 mutations suggest that the regular Sec channel can somehow 
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interact with the Sec2 channel. Whether this means that mixed Sec channels with both SecY 
and SecY2 exist remains to be determined. However, this possibility would be consistent 
with the observation that S. aureus lacks a second set of secE and secG genes. It would thus 
be important to focus future research activities in this area on possible interactions between 
the regular Sec channel components and SecY2. 
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Table 1. Plasmids and bacterial strains used
Plasmids Properties Reference
TOPO pCR®-Blunt II-TOPO® vector; KmR Invitrogen Life 
technologies
pCN51 E. coli / S. aureus shuttle vector that contains a cadmium-
inducible promoter
(11)
pMAD E. coli / S. aureus shuttle vector that is 
temperature-sensitive in S. aureus and 
contains the bgaB gene, EryR, AmpR
(2)
pUC18 AmpR, ColE1, F80dLacZ, lac promoter (28)
pDG783 1.5-kb kanamycin resistance cassette in pSB118; AmpR (15)
secG-pCN51 pCN51 with S. aureus secG gene, AmpR; EryR This work
secY2-pCN51 pCN51 with S. aureus secY2 gene, AmpR; EryR This work
Strains Genotype Reference
E. coli
DH5α supE44; hsdR17; recA1; gyrA96; thi-1; relA1 (18)




ΔlacX74 recA1 araD139 Δ(ara-leu)7697 galU galK rpsL 
(StrR) endA1 nupG
S. aureus RN4220
Parental strain Restriction-deficient derivative of NCTC 8325, cured of all 
known prophages
(24)
ΔsecG secG This work
ΔsecY2 secY2 This work
ΔsecG ΔsecY2 secG secY2 This work
S. aureus SH1000
Parental strain Derivative of NCTC 8325-4 rsbU+, agr+ (21)
ΔsecG rsbU+, agr+, secG This work
ΔsecY2 rsbU+, agr+, secY2 This work
ΔsecG ΔsecY2 rsbU+, agr+, secG secY2 This work
S. aureus Newman
Δspa spa (31)
Δspa Δsbi spa sbi This work
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sraP_reva CTAATACGACTCACTATAGGGAGA CACTGATTGTCCAGCATTCG 
Overlap in primers are in bold; restriction sites are underlined
a Oligonucleotides containing the recognition sequence for T7 polymerase at the 5’ end (shown in italic) 
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Staphylococcus aureus is an important Gram-positive bacterial pathogen producing 
many secreted and cell surface-localized virulence factors. Here we report that 
the staphylococcal thiol-disulfide oxidoreductase DsbA is essential for stable biogenesis of 
the ComGC pseudopilin. The signal peptidase ComC is indispensable for ComGC maturation 
and optimal cell surface exposure.
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Introduction
Staphylococcus aureus is a major Gram-positive bacterial pathogen causing a broad range of 
infections. To subvert its mammalian hosts, S. aureus relies on different virulence factors that 
are localized at the cell surface or secreted into the host milieu (11,20). For export of newly 
synthesized virulence factors from the cytoplasm, their translocation across the membrane, 
and post-translocational modifications an intricate secretion machinery has evolved (20). 
In recent years, the functions of many secretion machinery components of S. aureus have 
been elucidated (3,4,9,13,19,21). Intriguingly however, for several other potential secretion 
machinery components no biological functions have been described so far. For example, this 
applies to the extracytoplasmic thiol-disulfide oxidoreductase (TDOR) DsbA, which is known 
as one of the strongest bacterial TDORs (12,15). Likewise, the role of the pseudopilin export 
machinery of S. aureus has not yet been documented. This machinery is very similar to the 
Com machinery for DNA binding and uptake in the related Gram-positive bacterium Bacillus 
subtilis. Interestingly, the genes coding for most Com proteins are present in the sequenced 
S. aureus strains (20). The transcription of these genes, which are organized in the comG and 
comE operons, is directed by the staphylococcal alternative sigma factor σH (17).
The biogenesis of the Com pseudopilin system has been well studied in B. subtilis. 
Among the B. subtilis Com proteins with orthologues in S. aureus are those encoded 
by the comG operon (1). Specifically, the B. subtilis ComGC, ComGD, ComGE, and 
ComGG proteins form pilin-like structures that are localized to the cytoplasmic membrane 
and cell wall (6-8,22). Assembly of the pseudopilus in B. subtilis requires the specific signal 
peptidase ComC, which processes the N-terminal signal peptides of ComG proteins upon 
membrane translocation (6,22,23). Furthermore, stability of the B. subtilis ComGC pseudopilin 
requires post-translocational TDOR-mediated disulfide bond formation (6,10,15,16).
Results and Discussion
ComGC of S. aureus is processed by ComC and stabilized by DsbA 
To study the processing and stability of S. aureus ComGC, the expression of the com genes 
was induced through constitutive expression of sigH from plasmid pRIT: sigH (17). 
As shown with specific polyclonal antibodies raised tagainst ComGC, exponentially 
growing cells of the S. aureus strains RN4220, SH1000, RN6911 and Newman produced 
only the precursor form of this pseudopilin (Figure 1). ComGC production depended strictly 
on ectopic expression of σH (Figure 1). Notably, relatively small amounts of mature ComGC 
were detectable when the investigated strains were grown to stationary phase (Figure 1A). 
This inefficient ComGC processing was due to limited ComC signal peptidase activity 
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as shown by ComC overexpression from plasmid pCN51:comC. This resulted in 
close-to-complete ComGC processing (Figure 1B). Conversely, ComGC processing in 
the post-exponential growth phase was completely abolished by a comC deletion. Consistent 
with these observations, no comC expression was detectable in exponentially growing 
S. aureus cells, and low-level comC transcription was detectable in the late stationary growth 
phase (data not shown). Together, these findings show that ComC is the signal peptidase 
needed for ComGC processing, and that the investigated strains produce limiting amounts 
of ComC under the tested conditions. 
To investigate whether the stability of S. aureus ComGC depends on TDOR activity, 
the production of this protein was analyzed in strain RN4220 lacking the dsbA gene. 
Western blotting analyses showed that ComGC was barely detectable in cells lacking DsbA. 
This effect did not relate to possible changes in the σH levels, which remained unaltered in 
the dsbA mutant (Figure 2 lower panel). These observations indicate that the intramolecular 
disulfide bond of B. subtilis ComGC is conserved in S. aureus ComGC, and that the formation 
of this disulfide bond between Cys46 and Cys87 of S. aureus ComGC is catalyzed by DsbA. 
Furthermore, this disulfide bond, which is positioned within the predicted extracytoplasmic 
domain of S. aureus ComGC, would be necessary to stabilize ComGC upon export from 
the cytoplasm. To test this idea, the reducing agent β-mercaptoethanol was added to 
the growth medium at concentrations up to 2.5 mM, which is the highest concentration of 
β-mercaptoethanol that can be added to the cells without affecting growth and cell viability 
(data not shown). Clearly, in the presence of 2.5 mM β-mercaptoethanol, ComGC was barely 
detectable (Figure 2, upper panels), whereas σH production remained unaffected (Figure 2, 
lower panels). The most simple explanation for these observations is that the TDOR activity 
of DsbA is required for disulfide bond formation in ComGC and that this disulfide bond is 
essential for ComGC stability. Nevertheless, it is possible that DsbA is indirectly involved in 
the stabilization of ComGC. To our knowledge, this is the first report describing a biological 
function for DsbA in S. aureus. 
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Figure 1. ComGC processing by ComC. S. aureus strains were grown overnight at 37°C in Luria-Bertani broth 
(LB) supplemented with 12.5 µg/ml chloramphenicol to select for pRIT:sigH or pRITH5, or 5 µg/ml erythromycin 
to select for pCN51:comC. Samples for Western blotting analyses with polyclonal rabbit antibodies against 
ComGC or chicken antibodies against SigH were collected after 4 h (t4) or 7 h of growth (A), or after 5h of growth 
(B). Cell extracts were prepared as previously described (19). Proteins were separated by SDS-PAGE (NuPage gels, 
Invitrogen) and blotted onto nitrocellulose membranes (Protran, Schleicher & Schuell). Immunodetection was 
performed with fluorescent secondary antibodies (IRDye 700 CW goat anti-rabbit, IRDye 800 goat anti-chicken, 
LiCor) in combination with the Odyssey Infrared Imaging System (LiCor Biosciences). The chromosomal 
comGC or comC genes were deleted from S. aureus strains RN4220 or Newman Δspa Δsbi (19) as previously 
described (2,14). Primers used for strain and plasmid constructions are listed in Table 1. Lanes relating to strains 
that carry pRIT:sigH for σH production are labeled with H; lanes relating to control strains with the empty 
vector pRIT5H that do not produce σH are labeled with v; lanes relating to strains that carry pCN51:comC (5) for 
ComC production are labeled with ComC+. 
Figure 2. ComGC stabilization by DsbA. S. aureus strains were grown for 7h in LB broth as described in Figure 1 
in the presence or absence of β-mercaptoethanol (final concentrations 1 mM or 2.5 mM). The preparation of 
cell extracts, SDS-PAGE and Western blotting with specific antibodies against ComGC or σH was performed as 
described in Figure 1. The chromosomal dsbA gene was deleted from S. aureus strain RN4220 as previously 
described (2,14). Primers used for strain construction are listed in Table 1. Lanes relating to strains that carry 
pRIT:sigH for σH production are labeled with H; lanes relating to control strains with the empty vector pRIT5H that 
do not produce σH are labeled with v. 
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ComGC localizes to the membrane, cell wall and cell surface of S. aureus 
To determine the localization of ComGC, cells of S. aureus strain RN4220 or strain RN4220 
overproducing ComC were subjected to subcellular fractionation. Cells were first protoplasted. 
Next, the protoplasts were separated from liberated cell wall proteins (i.e. the cellwall fraction) 
by centrifugation. The collected protoplasts were then disrupted by osmotic shock, and 
cytosolic proteins were separated from the membranes by ultracentrifugation as previously 
described (24). Proteins in all collected fractions were separated by SDS-PAGE and the 
presence of ComGC and thioredoxin A (TrxA) in each fraction was analyzed by Western 
blotting with specific antibodies (Figure 3A). TrxA was used as a cytoplasmic control 
protein. This analysis showed that both pre-ComGC and mature ComGC from S. aureus 
localize to the cytoplasmic membrane and cell wall. This dual localization is consistent with 
the localization of the homologous protein in B. subtilis. Furthermore, in S. aureus cells 
overproducing the ComC protein, we observed slightly increased amounts of ComGC in the 
cell wall fraction as compared to cells of the parental control strain that do not produce ComC 
under the tested conditions. Next, we investigated by immunofluorescence microscopy 
whether ComGC is detectable on the cell surface. For this purpose, we employed cells of 
strain Newman lacking the IgG-binding proteins Spa and Sbi, which displayed negligible 
background fluorescence (Figure 3B; compare panels for the spa sbi mutant and the parental 
strain Newman). Importantly, σH-producing cells showed elevated levels of immune 
fluorescence and strongly enhanced immune fluorescence was observed when the signal 
peptidase ComC was overexpressed together with σH. These observations are consistent 
with the view that the signal peptide of ComGC facilitates membrane translocation and 
exposure of ComGC to the cell wall, irrespective of signal peptide processing by ComC. 
Enhanced signal peptide processing upon ComC overproduction would then allow more 
of the translocated mature ComGC to penetrate the cell wall and to become exposed at 
the cell surface. These findings thus show that ComC-dependent processing of ComGC is of 
important for optimal cell surface exposure of ComGC. It should be noted that, for unknown 
reasons, cells overproducing ComC have a larger diameter which seems to relate mostly to 
a thickened cell wall (Figure 3B).
In summary, we show that biogenesis of the pseudopilin ComGC of S. aureus requires 
the TDOR DsbA for stability and the signal peptidase ComC for precursor maturation and cell 
surface exposure. This is thus the first report where biological functions are demonstrated for 
S. aureus DsbA and ComC. In B. subtilis, the Com system is needed for DNA uptake during 
genetic competence. Whether this is also true in S. aureus remains to be demonstrated, but 
natural competence has been reported for S. aureus (18). Our present findings suggest that 
expression of comC could be a limiting factor in competence development, even if S. aureus 
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cells overproduce σH for expression of other com genes.
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Figure 3. ComGC localizes to the membrane, cell wall and cell surface of S. aureus. (A), To determine the subcellular 
localization of ComGC in S. aureus RN4220 pRIT: sigH, or S. aureus RN4220 pRIT:sigH containing pCN51:comC, 
the cells were grown in LB broth for 5 h, collected by centrifugation and incubated for 1 h at 37°C in protoplast 
buffer (50mM Tris-HCl pH 7.6, 0.145 M NaCl, 30% sucrose, 0.01% DNase, and EDTA-free Complete protease 
inhibitors, Roche). The cell wall fraction (i.e. protoplast supernatant) was obtained by centrifugation (20 min, 
3000xg, 4°C). Protoplasts were disrupted by osmotic shock in 0.05 M Tris-HCl pH 7.6, 30 min incubation on 
ice, and vortexing at 5 min intervals. Cytosolic and solubilized membrane proteins were collected as previously 
described (24). SDS-PAGE and Western blotting with specific antibodies against ComGC or the cytoplasmic 
control protein TrxA was performed as described in Figure 1. (B), Cell surface exposure of ComGC was assessed 
in S. aureus Newman Δspa Δsbi or the parental strain (Newman) by immunofluorescence microcopy. For this 
purpose, cells were grown for 5 h in LB broth and 1 OD
600
 unit of cells was collected by centrifugation (8000 rpm, 
5’, 4°C). The cell pellet was resuspended in PBST+2% BSA, and incubated for 10 min on ice. Next, the cells 
were incubated for 60 min with ComGC-specific polyclonal rabbit antibodies (1:400 in PBST+1%BSA). Unbound 
antibodies were removed by three washes in PBST, and cell-bound ComGC antibodies were visualized using 
goat-anti-rabbit alexaFluor488 antibodies (Life technologies) and a Leica DM5500 B microscope. The overlay of 
phase contrast and fluorescence microscopy images was done with imageJ. The strains containing pRIT:sigH for 
σH production are labeled with H; the strain containing pCN51:comC for ComC production is labeled with ComC+. 
The magnification is indicated by scale bars.
The signal peptidase ComC and the thiol-disulfide oxidoreductase DsbA are required for 
optimal cell surface display of the pseudopilin ComGC in Staphylococcus aureus
161
Table 1. Primers used in this study. Overlapping parts are shown in bold. Restriction sites used for cloning are 
underlined and shown in parentheses.
Primer Sequence (5’→3’)
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Staphylococcal sortase A mutant cells 
display a phosphate starvation response in 
human plasma





Surface proteins of Staphylococcus aureus play important roles in the pathogenicity of 
this bacterium. Several of these proteins are covalently attached to the cell wall by the 
sortases SrtA and SrtB. The present studies were aimed at determining the relevance of 
sortase activity for in vitro staphylococcal growth in human plasma. The results show 
that, depending on the investigated strain, SrtA can be important for efficient growth in 
human plasma, whereas SrtB is not required. Transcript profiling of srtA mutant cells 
grown in human plasma revealed a typical phosphate starvation response, even though 
this ‘medium’ is known to contain relatively high phosphate concentrations. This suggests 
that one or more covalently cell wall‑bound proteins are involved in phosphate binding or 
uptake. Intriguingly, the fnbpA gene and, to lesser extent, the fnbpB gene were induced in 
SrtA‑deficient cells. Similar to genes encoding the phosphate transporter Pst and the alkaline 
phosphatase PhoB, the fnbpA and fnbpB genes are preceded by a typical Pho box, indicating 
that they are part of the phosphate starvation‑inducible pho regulon of S. aureus. Since the 
FnbpA and FnbpB proteins are known SrtA substrates, our observations implicate these two 
covalently cell wall‑bound proteins in the binding and uptake of phosphate by S. aureus.




Staphylococcus aureus is a Gram‑positive commensal bacterium carried by about 20‑30% 
of the human population. However, this commensal is far from harmless, because under 
certain circumstances it can become invasive causing potentially life‑threatening infections, 
such as sepsis (26). The ability of S. aureus to invade and colonize almost all human tissues 
depends on various cell surface‑associated and secreted virulence factors. These virulence 
factors are first synthesized with an N‑terminal signal peptide to direct them into one of 
the secretion pathways of the staphylococcal cell (44). After their translocation across 
the membrane, the signal peptide is proteolytically removed, which is necessary for release 
from the extracytoplasmic side of the membrane (1, 50). The translocated proteins will 
then pass the cell wall and are released into the extracellular environment, unless they 
are specifically retained in the cell wall. The retention of proteins in the cell wall requires 
specific signals that facilitate covalent or non‑covalent attachment to particular cell wall 
components (44). 
The signal for covalent attachment of translocated proteins to the cell wall is formed by 
a so‑called LPxTG motif, which is located in the C‑terminus of the exported proteins. 
This LPxTG motif is recognized by membrane‑associated transpeptidases known as 
sortases (27). Upon binding to the LPxTG motif, sortase hydrolyses the bond between the Thr 
and Gly residues and, then, it covalently attaches the liberated C‑terminus of the Thr residue 
to the free amino group of a pentaglycine cross‑bridge in the cell wall peptidoglycan (14, 24, 
42, 47). S. aureus possesses two sortase enzymes, namely sortase A (SrtA), which recognizes 
the canonical LPxTG motif, and sortase B (SrtB), which specifically recognizes an NPQTN 
motif (29, 34). It has been reported that 21 different S. aureus proteins carrying an LPxTG 
motif are attached to the cell wall by SrtA (13, 27, 33, 40, 44). These include protein A (Spa), 
two fibronectin‑binding proteins (FnbpA and FnbpB) (16), two clumping factors (ClfA, 
ClfB), three cell wall‑anchored proteins with large serine‑aspartate repeat domains (SdrC, 
SdrD and SdrE) (22), a collagen‑binding protein (Cna), a plasmin‑sensitive protein (Pls) (41), 
the methicillin resistance determinant B (FmtB) (23), and eleven staphylococcal surface 
(Sas) proteins. The iron‑regulated surface determinant protein C (IsdC) is the only protein 
known to be covalently coupled to the cell wall by SrtB (30).
It has been shown that S. aureus lacking the srtA gene is impaired in the retention and 
proper display of LPxTG proteins at the cell surface (43, 49). This explains why SrtA 
is of major importance for the establishment of systemic and localized staphylococcal 
infections (28, 52). Specifically, S. aureus srtA mutant cells are unable to bind fibrinogen 
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in solution (52). Furthermore, S. aureus cells lacking SrtA were shown to be affected in the 
binding to cardiac cells, which is probably due to a reduced ability for fibrin binding by 
otherwise covalently attached cell surface proteins (52). A srtA mutant was also found to 
be impaired in the establishment of arthritis in a mouse model, which seems to be related 
to defects in the adhesion to collagen and fibrinogen in the target tissue of the joints (21). 
Unlike the srtA mutation, a srtB mutation was shown to cause only a minor defect in the 
establishment of arthritis in a mouse model (20).
Altogether, the impact of srtA mutations on protein binding to the staphylococcal cell wall and 
binding of staphylococci to particular compounds and tissues of the host has been studied in 
substantial detail. In contrast, nothing was so far known about possible staphylococcal stress 
responses that are elicited by impaired sortase activity. Therefore, the aim of the present study 
was to examine how the global transcription of S. aureus genes is influenced in the absence 
of srtA or srtB. The rationale behind these experiments was that possible stress responses 
would shed further light on the specific roles of proteins that are covalently bound to the 
staphylococcal cell wall. To mimic the in vivo situation, all analyses were performed with 
cells grown in human plasma. Interestingly, the present results reveal a phosphate starvation 
response in srtA mutant cells. Our data imply that certain LPxTG proteins, especially FnbpA 
and FnbpB, are involved in phosphate acquisition.  
Materials and methods
Ethical approval
The Independent Ethics Committee of the Foundation ‘Evaluation of Ethics in Biomedical 
Research’ (Assen, the Netherlands) approved the protocol for blood donations from healthy 
volunteers. This protocol is registered by QPS Groningen (code 04132‑CS011). The required 
informed consent was obtained from all healthy volunteers included in the present studies.
Human plasma
Whole blood samples (500 ml) were donated by 3 healthy adult volunteers. The samples were 
processed for further analyses immediately after collection. The donated blood was diluted 















, 4.2 mM 
NaHCO
3




 and 5.6 mM D‑Glucose (Dextrose). Plasma 
was obtained after separation from blood cells. The collected human plasma was stored at 
‑30°C. Thawed plasma from the different volunteers was mixed and then heat‑inactivated 
for 30 min at 56°C in a water bath. Subsequently, heat‑inactivated plasma was centrifuged 
for 15 min at 12000 rpm, 4°C and filtered with a 65 µm millipore filter. The resulting fraction 
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was stored at 4°C and used within 12 h for further experiments.
Bacterial strains and culture
The S. aureus strains SH1000 and HG001 and their ΔsrtA or ΔsrtB derivatives (49) were grown 
overnight in tryptic soy broth (TSB, OXOID) under vigorous shaking (250 rpm) at 37°C. 
The bacterial cultures were diluted to an OD
600
 of 0.05 in pre‑warmed TSB and cultivation 
was continued under the same conditions. Exponentially growing cells (OD
600 
~0.5) were 
then diluted into pre‑warmed human plasma to a final OD
600
 of 0.05 and the cultivation 
was continued under the same conditions. Finally, exponentially growing cells were again 
diluted into fresh and pre‑warmed human plasma to a final OD
600
 of 0.05 and the cultivation 
was continued until four hours after the entry into stationary phase.
Extraction of total RNA 
Total RNA was isolated as previously described (35). Briefly, 15 OD units of the parental 
strain S. aureus HG001 and its ΔsrtA or ΔsrtB derivatives grown in human plasma 
were harvested at OD
600
 0.5, and at four hours after entering into the stationary growth 
phase (Figure 1B). Samples withdrawn from the different cultures were added to 0.5 
volumes of frozen killing buffer (20 mM Tris HCl pH 7.5, 5 mM MgCl
2
, 20 mM NaN
3
) 
and immediately centrifuged (10 min, 3279 × g, 4°C). The collected cells were then 
immediately frozen in liquid nitrogen and stored at ‑80°C. Cells were mechanically 
disrupted in a Mikro‑Dismembrator (Santorius) for 2 min at 2600 rpm and resuspended in 
pre‑warmed lysis solution (4 M guanidine thiocyanate, 25 mM sodium acetate [pH 5.2], 
0.5% N‑laurylsarcosinate 40 [wt/vol]). Total RNA was isolated by acid‑phenol extraction 
and precipitated with isopropanol, washed with 70% ethanol and dissolved in 100 μl of 
RNase‑free water. For transcriptome analyses, 35 μg RNA was DNase‑treated using the 
RNase‑Free DNase Set (Qiagen) and purified using the RNA Clean‑Up and Concentration 
Micro Kit (Norgen). The RNA concentration was measured using a NanoDrop 
spectrophotometer and the RNA quality was assessed with an Agilent 2100 Bioanalyzer as 
previously described (35). 
Microarray experiments
For the microarray experiments, the BaSysBio Sau T1 NimbleGen 385K array was used (12). 
20 µg of each RNA sample was labeled and hybridized to an array using the BaSysBio 
protocol for strand‑specific gene expression analysis (35, 38). All tiling array experiments 
were performed in triplicate using RNA isolated from independent cultures.
An aggregated expression value for each Genbank annotated CDS was computed as the median 
log2 intensity of probes lying entirely within the corresponding region. Possible cross‑
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hybridization artefacts were controlled by BLAST‑alignment as previously described (12, 
51). The aggregated intensity values of the individual samples were normalized by median 
centering. The statistical analysis of differential mRNA levels between the parental strain 
and the respective ΔsrtA or ΔsrtB mutant strains was performed using the moderated t‑test 
(GeneSpring 12, Agilent Technologies). Genes were considered  to be differentially expressed 
at fold changes (FC) of ≥1.8 with a p‑value <0.05. The microarray data set is available at the 
NIH Gene Expression Omnibus (GEO) database under record number GSE44761.
Results 
Growth of srtA or srtB mutant S. aureus cells in human plasma
Since human plasma is a poorly defined growth medium, we performed extensive growth 
experiments with different S. aureus strains and their srtA or srtB mutant derivatives. 
Unexpectedly, the results showed that a srtA mutant of strain SH1000 grew at a much lower rate 
in human plasma than the respective parental strain or a srtB mutant (Figure 1A). In contrast, 
the srtA mutant derivative of strain HG001 did not show this growth defect (Figure 1B). 
These findings indicated that SrtA can be of major importance for staphylococcal growth 
in human blood, depending on the strain. By contrast, SrtB appeared to be dispensable for 
growth in human plasma, at least in the case of strains SH1000 and HG001. For an optimal 
comparison of global transcript profiles of parental and mutant bacterial strains, it is 
important that these strains grow at comparable rates so that growth‑specific effects on 
gene expression can be excluded. Therefore, all further experiments were performed with 
strain HG001 and its srtA or srtB mutant derivatives, which displayed comparable growth in 
human plasma (Figure 1B). 
Figure 1. Growth of S. aureus srtA and srtB mutants in human plasma. S. aureus strains were grown in human 
plasma under vigorous shaking at 37°C strains A) Growth curves of  S. aureus SH1000 and its ΔsrtA or ΔsrtB 
mutant derivatives. B) Growth curves of  S. aureus HG001 and its ΔsrtA or ΔsrtB mutant derivatives. Time points 
at which aliquots were withdrawn from the cultures for RNA isolation are indicated by arrows.
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Transcriptome of srtA or srtB mutant strains
To examine whether the absence of sortase genes influences the genome‑wide gene 
expression profile of S. aureus, we performed tiling array experiments. For this purpose total 
RNA was isolated from exponentially growing as well as stationary phase cells of S. aureus 
HG001 and its srtA or srtB mutant derivatives. As show in Table 1, deletion of the srtA 
gene resulted in the differential expression of 39 genes, from which 31 were up‑regulated, 
and 8 were down‑regulated. Functional annotation clustering of up‑regulated genes revealed 
an enrichment of two clusters (17, 18). The first cluster contains eight genes known to 
be involved in the pathogenesis of S. aureus, namely fnbA, hlb, psmβ1, psmβ2, hlgA and 
hlgC. The second cluster contained five genes (yjbB, pstS, pstC, pstA, pstB), which encode 
the phosphate transport system. Notably, the pstSCAB operon was up‑regulated both in 
exponentially growing srtA mutant cells and srtA mutant cells in the stationary phase. This 
implies that the srtA mutant grown in human plasma displays a typical phosphate starvation 
response. In contrast, deletion of srtB did not influence the transcriptome of S. aureus 
cells grown in human plasma with exception of the gene coding for the cold shock protein 
SAOUHSC_03045 (data not shown).
The S. aureus Pho box 
To investigate whether the phosphate starvation response in S. aureus is similar to that of 
the closely related Gram‑positive bacterium Bacillus subtilis, we compared both systems. 
B. subtilis responds to phosphate starvation via the PhoP‑PhoR two‑component regulatory 
system (19, 46). In B. subtilis, the PhoP response regulator controls the expression of 
31 genes in 10 operons, acting as a transcriptional activator or repressor depending on 
the respective promoter (5). Importantly, the comparison of PhoP from S. aureus with 
PhoP of B. subtilis revealed an overall amino acid sequence identity of 68% (Figure 2). 
A more detailed inspection of both protein sequences showed that all residues required for 
DNA binding at the so‑called Pho box are identical in both proteins (Figure 2, circles) (7). 
Furthermore, all residues required for transcriptional activation through the interaction 
with RNA polymerase (Figure 2, diamonds) (7), and all residues involved in PhoP dimer 
formation (Figure 2, triangles and hexagons) (4, 8) are conserved in both proteins.
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Figure 2. Sequence alignment of PhoP from S. aureus and B. subtilis. The secondary structure elements of PhoP are 
indicated by coils for α helices and arrows for β strands. Identical residues are indicated with a black background. 
Residues positioned at the PhoP dimer interface are indicated by triangles, and two residues involved in PhoP 
protein‑protein interactions via salt a bridge are indicated with hexagons (8). PhoP residues that are essential for 
transcriptional activation (interaction with RNAP) are indicated by diamonds. PhoP residues involved in DNA 
binding are indicated by circles (7).
The B. sublilis Pho box to which both phosphorylated and non‑phosphorylated PhoP dimers 
bind is composed of two to four 6‑bp direct repeats with the consensus sequence TT(A/C/T)
A(C/T)A and a spacing of 3 to 7 bp (11). To determine whether this consensus sequence is 
present in S. aureus, the Pho box regions of the B. subtilis glpQ, phoA, phoB and pstS genes 
were used for a motif search in the S. aureus genome following the Virtual Footprint 
software package (32). These Pho box regions were chosen for the motif search, because 
the genomic organization of the respective genes is conserved in B. subtilis and S. aureus. 
This search yielded 87 matches in the S. aureus genome (Supplemental Table 1 available on 
request). Seven of the matching sequences were located upstream of genes that were found 
to be upregulated in the srtA mutant grown in human plasma, namely yjbB, pstS, phoB, 
mapW, hlb (phosholipase C), hlgC and SAOUHSC_02842 (Table 1). The promoter regions 
of yjbB, pstS, phoB, hlb and SAOUHSC_02842 were then used for a gapped alignment (15) 
and the resulting consensus sequence TT[AT]AC[AT] was defined as a putative Pho 
box of S. aureus (Figure 3). To approximate the potential Pho regulon of S. aureus, the 
upstream sequences of all genes were searched with the Virtual Footprint software for the 
presence of the putative Pho box consensus TT[AT]AC[AT]. These analyses resulted in 
35 hits (Supplemental Table 2 available on request). As expected, yjbB, pstS, phoB, hlb 
and SAOUHSC_02842 were included among these genes. Importantly, several other genes 
identified by Virtual Footprint encode proteins with an LPxTG motif. These proteins include 
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FnbpA, FnbpB, SasA, SasF and SasG. Notably, the mRNA levels of fnbpA and fnbpB were 
increased in the srtA mutant, whereas no changes were observed for the sasA, sasF and 
sasG mRNA levels (Table 1). In this respect, it is noteworthy that the TT[AT]AC[AT]‑like 
sequences in the promoter regions of sasF and sasG are located on the opposite strand.
Figure 3. The putative Pho box sequence of S. aureus. (A). The consensus sequence for a Pho box site was generated 
using the WebLogo tool (http://weblogo.berkeley.edu/) by alignment of the upstream sequences of the 5 potential 
regulon genes identified in silico. (B) Determination of a consensus sequence for putative S. aureus PhoP binding 
site repeats. The TTAACA‑like sequences in five Pho‑regulon promoters were aligned and the nucleotide positions 
in the TTAACA‑like sequence were labeled 1‑6. The numbers tabulated represent the number of times that 
the respective nucleotide appears at the indicated position.
Discussion
Cell wall‑associated proteins play important roles in the pathogenicity of S. aureus. Several 
of these proteins are covalently attached to the cell wall by the transpeptidases SrtA or 
SrtB. In particular, cell wall‑attached ‘microbial surface components recognizing adhesive 
matrix molecules’ (MSCRAMMs) promote the adherence of S. aureus to human host matrix 
molecules, such as fibronectin, fibrinogen and collagen, in a the SrtA‑dependent manner. 
The present study, was aimed at assessing the roles of SrtA and SrtB in the in vitro growth 
of S. aureus in human plasma, which mimics to some extent the in vivo growth condition 
encountered during bacteremia. As exemplified with the S. aureus strain SH1000, the results 
show that srtA can be an important determinant for efficient growth of certain staphylococcal 
strains in human plasma. Importantly, transcript profiling analyses showed that a srtA 
mutation affected the expression of 39 genes of which eight are potentially phosphate 
starvation‑ inducible as judged by the presence of a typical Pho box motif. In contrast, no 
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phosphate stress  response was detectable in srtB mutant cells grown in human plasma.
Among the genes affected by the srtA mutation, the genes putatively required for 
phosphate acquisition by S. aureus appeared to be enriched. These include the genes for 
the phosphate‑specific transport (Pst) system, which is similar to the Pst system from B. subtilis, 
and the gene for a secreted alkaline phosphatase (PhoB; Table 1). In B. subtilis the pst operon 
is a member of the Pho regulon (37), which is controlled by the PhoP‑PhoR two‑component 
regulatory system (25). The high similarity between the PhoP regulator components of 
S. aureus and B. subtilis suggested that the Pho box motif could be conserved in these two 
species. Indeed, a Pho box‑like motif was identified in the upstream region of the S. aureus 
pstSCAB and phoB genes. Together, these findings imply that the srtA mutant cells grown 
in human plasma displayed a phosphate starvation response. Since SrtA is responsible for 
the proper covalent cell wall attachment of LPxTG proteins, this would suggest that one 
or more of these proteins are involved in the binding and/or uptake of phosphate. In this 
respect, it is noteworthy that human serum contains about 1.12 to 1.45 mM phosphate of 
which ~15% is bound to proteins (3). Thus, after 2:1 dilution of serum with HBSS, the final 
phosphate concentration in the plasma used for our experiments was about 1 to 1.2 mM. 
At these concentrations, a phosphate starvation response seems rather unlikely, unless cells 
are impaired in their ability to bind or take up phosphate. By comparison, a phosphate 
starvation response in B. subtilis is triggered by phosphate levels in the growth medium of 
about 0.1 mM or lower (31). 
Interestingly, our tiling array data show that the gene encoding the LPxTG protein FnbpA, was 
2.3 times up‑regulated in the srtA mutant. In addition, the fnbpB gene was also up‑regulated, 
albeit only 1.7‑fold, which was just below the somewhat arbitrarily chosen cut‑off of 
1.8 fold (data not shown). This would suggest that FnbpA and possibly also FnbpB have 
a role in phosphate acquisition. Both proteins are important in infections caused by S aureus, 
because of their central role in the adhesion to and invasion of host cells. Especially, FnbpA 
was shown to be a multifunctional adhesin with capacity to bind to fibrinogen, fibronectin, 
elastin and several other proteins (10, 36, 39, 45). Intriguingly, it has been shown that soluble 
fibronectin contains covalently bound phosphate (48). Thus, it is conceivable that Fnbp’s are 
somehow involved in the scavenging of phosphate from fibronectin, thereby contributing 
to the phosphate homeostasis in S. aureus. This idea is further supported by the fact that 
putative Pho boxes are present in the promoter regions of both fnbA and fnbB. On the other 
hand, most phosphate in human serum is present in an unbound state, at least according to 
the literature data (3). This would imply that FnbpA and FnbpB could also be involved in 
the binding of free phosphate.
Lastly, two small genes, vraX and cwrA, were most strongly induced in the absence of srtA. 
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The vraX gene is known to be regulated by the VraTSR three‑component regulatory system, 
which responds to cell wall and antibiotic stress (6). Likewise, cwrA is induced upon cell wall 
damage (2). This might suggest that the srtA mutant cells experience some cell wall stress 
when grown in human plasma. On the other hand, the srtA mutant cells displayed no typical 
cell wall stress signatures as reported for vraTSR, graRS or walKR mutant strains (2, 9, 12). 
In fact, apart from the pstSCAB and phoB genes, none of the other differentially regulated 
genes in the srtA mutant could be directly connected to previously defined stress signatures. 
Thus, the biological meaning of these gene regulatory responses to the SrtA‑deficiency and 
their connection to particular LPxTG proteins remains to be determined.
In summary, the present studies revealed that srtA mutant cells grown in human plasma 
display a typical phosphate starvation response. Upregulation of fnbpA and, to lesser 
extent, fnbpB suggests that the encoded fibronectin‑binding proteins, which are known SrtA 
substrates, may have roles in phosphate acquisition by S. aureus. How exactly these proteins 
could be involved in this process is currently not known, but it is conceivable that the Fnbp’s 
are needed to acquire phosphate that is bound to particular serum proteins, like fibronectin, 
as well as free phosphate.
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Table 1. Differentially regulated genes of srtA mutant cells grown in human plasma.
NCTC 8325 
ORFa




00035 hypothetical protein 2.0
00036 hypothetical protein 1.9
00060# yjbB phosphate:Na+ symporter 2.1
00192 coa staphylocoagulase 1.8
00561 vraX hypothetical protein 6.7
00898 argH argininosuccinate lyase 3.5
00899 argG argininosuccinate synthase 3.7
01135 psmB1 phenol‑soluble modulin beta 2.1
01136 psmB2 phenol‑soluble modulin beta 1.8
01384 phoU PhoU  family  transcriptional regulator 1.8
01385 pstB phosphate ABC transporter ATP‑binding protein 2.5 1.8
01386 pstA phosphate ABC transporter permease protein 3.4 2.0
01387 pstC phosphate ABC transporter permease protein 4.2 2.4
01388 hypothetical protein 4.2 2.6
01389# pstS
phosphate ABC transporter periplasmic phosphate‑binding 
protein
7.7 2.8
01570 PVL orf 37‑like protein 1.8
01571 SLT orf 71‑like protein 2.3
01573 conserved hypothetical phage protein 1.8
01574 helix‑turn‑helix domain protein 2.0
01761 conserved hypothetical protein 2.1
01990 glnQ amino acid ABC transporter ATP‑binding protein 1.9
01991 putative ABC transporter permease protein 1.8
02160 truncated‑mapW 2.0
02161# mapW MHC class II analog protein 2.4
02163# hlb phospholipase C 3.7
02708 hlgA gamma‑hemolysin component A 2.1
02709# hlgC gamma‑hemolysin component C 2.3
02803 fnbA fibronectin‑binding protein A 2.3
02842# conserved hypothetical protein 5.1
02872 cwrA cell wall responsive for antibiotics 6.9
02958# phoB alkaline phosphatase III precursor 2.4
00169 peptide ABC transporter, permease component ‑2.0
00170 RGD‑containing lipoprotein ‑2.0
00171 gamma‑glutamyltranspeptidase ‑1.8









00555 hydrolase haloacid dehalogenase‑like ‑1.8
01079 isdB iron‑regulated surface determinant protein B ‑1.9
02555 hypothetical protein ‑1.8
02697 amino acid ABC transporter, ATP‑binding protein ‑1.8
02834 srtA sortase A ‑135.3 ‑131.0
aGene names according to the annotated S. aureus NCTC 8325 genome sequence SAOUHSC_ 
bFC, fold change; determined as the ratio of the signal values in the HG001 ΔsrtA strain and the parental strain.
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Cell surface-exposed proteins of Gram-positive bacterial pathogens have important roles in 
the binding of ligands and tissues of their human host. Such proteins can be covalently bound 
to the cell wall through the action of sortases. In Staphylococcus aureus, sortase A (SrtA) 
and sortase B (SrtB) recognize C-terminal ‘LPxTG’ motifs, which are cleaved by the 
respective sortase and covalently attached to peptidoglycan. Although this process has been 
characterized in great detail, it was thus far not known how sortases shape the actual surface 
of a staphylococcal cell with respect to proteins that are directly exposed to the extracellular 
milieu. Therefore, the present studies were aimed at determining the ‘surfacomes’ of srtA or 
srtB mutant cells of S. aureus. As shown by ‘cell surface shaving’ with immobilized trypsin 
and subsequent mass spectrometric analyses (ProteomeXchange identifier PXD000179), 
SrtA has a major impact on the staphylococcal surfacome, whereas SrtB is only of minor 
importance. Specifically, our results show that the sortase-dependent surfacome consists 
of covalently cell wall-bound ‘LPxTG proteins’, non-covalently wall-bound proteins, 
known secreted proteins and cytoplasmic proteins. The secreted and cytoplasmic proteins 
are most likely retained at the surface of SrtA-proficient cells by binding to one or more 
LPxTG proteins. These LPxTG proteins thus seem to represent crucial nodes in the cell 
wall interactome of S. aureus that bind not only factors of the human host, but also other 
staphylococcal proteins. This may have important implications for the actual, direct or 
indirect roles of LPxTG proteins in the virulence of S. aureus.
Contributions of the sortases A and B to surfacome biogenesis in Staphylococcus aureus
185
Introduction
Staphylococcus aureus is a Gram-positive bacterium frequently encountered in the nasal 
cavity of humans (34). However, if the primary barrier function of the skin is disrupted 
or if the immune system is compromised, S. aureus has the potential to invade almost 
all tissues and organs causing a broad range of diseases (18). These can vary from mild 
skin infections, such as impetigo, to life-threatening systemic infections (e.g. pneumonia, 
meningitis, osteomyelitis, and sepsis) (1, 3, 7, 36). The pathogenicity of S. aureus is caused 
by a broad range of cell surface-exposed or secreted virulence factors, such as toxins, 
exoenzymes, adhesins, and immune-modulating proteins (5, 6, 30). The majority of these 
virulence factors are first synthesized as precursors with an N-terminal signal peptide to 
direct their export from the cytoplasm via the general secretory (Sec) pathway (30). During 
or after membrane translocation, the signal peptide is removed by a signal peptidase in 
order to release the translocated protein from the trans side of the membrane (2, 33). 
Furthermore, if certain retention signals in the form of specific amino acid sequence motifs 
are present, the translocated proteins can be attached to the cell wall (30). The covalent 
cell wall attachment of proteins with a so-called LPxTG motif requires the activity of 
specific transpeptidases known as sortases (19). These enzymes cleave the LPxTG motif 
between the Thr and Gly residues and catalyze the formation of an amide bond between 
the carboxyl group of the Thr residue and the free amino end of a pentaglycine cross bridge 
in peptidoglycan precursors (9, 17, 28, 31). S. aureus possesses one sortase A (SrtA) enzyme, 
which recognizes the canonical LPxTG motif (21, 25). It has been shown that S. aureus 
lacking the srtA gene has defects in the retention of ‘LPxTG proteins’ in the cell wall (29). 
As a consequence, the absence of SrtA causes a defect in the establishment of acute infections 
(20). In addition, the mutation of srtA was shown to cause a hyper-spreading phenotype, 
allowing S. aureus to migrate over soft agar plates at an increased rate. This probably relates 
to the fact that surface-exposed LPxTG proteins promote cell-cell attachment, thereby 
antagonizing spreading (32). 
It has been reported that 19 different S. aureus proteins carry a canonical C-terminal LPxTG 
motif and that two additional proteins carry a C-terminal LPxAG motif  (8, 19, 24, 26, 30). 
These include protein A (Spa), two fibronectin-binding proteins (FnbpA and FnbpB)(13), 
ClfA, ClfB, three cell wall-anchored proteins with large serine-aspartate repeat domains 
(SdrC, SdrD and SdrE) (15), a collagen-binding protein (Cna), a plasmin-sensitive protein 
(Pls) (27), the methicillin resistance determinant B (FmtB) (16), and eleven staphylococcal 
surface (Sas) proteins. In addition to SrtA, S. aureus contains a second sortase known as 
SrtB. SrtB is required for the cell wall anchoring of surface proteins that contain an NPQTN 
motif. So far the only protein known to be covalently coupled to the cell wall by SrtB is 
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IsdC (22). It is presently not known how important SrtB is for staphylococcal virulence in 
general, but S. aureus lacking srtB was shown to have a small defect in the establishment of 
arthritis in a mouse model (14). 
While the cell wall attachment of proteins by sortases has been well documented, it was to 
date not known to what extent these enzymes shape the actual surface of a staphylococcal cell 
in terms of proteins that are exposed to the extracellular milieu. These proteins, collectively 
termed the surfacome, are of particular importance for staphylococcal pathogenesis as they 
can potentially bind to cells and tissues of the host. Also, they could be relevant targets for 
novel antistaphylococcal therapies. Therefore, the present studies were aimed at determining 
the surfacomes of srtA or srtB mutant cells of S. aureus. Briefly, the results obtained by 
surface shaving with immobilized trypsin show that the surfacomes of srtA or srtB mutant 
cells display significant differences that may either be directly or indirectly caused by 
the respective sortase-deficiencies.
Materials and Methods
Bacterial strains and culture
The S. aureus strain SH1000 (12) and its ΔsrtA or ΔsrtB derivatives (29) were grown overnight 
in tryptic soy broth (TSB, OXOID) under vigorous shaking (250 rpm) at 37°C. The different 
S. aureus cultures were then diluted into pre-warmed RPMI 1640 medium (PAA) to an OD
600
 
of ~0.05 (SH1000, ΔsrtB), or to an OD
600
 of ~0.03 (ΔsrtA). The cultivation was continued 
under the same conditions. Exponentially growing cells (OD
600
 of ~0.2) were again diluted 
into fresh and pre-warmed RPMI medium to a final OD
600
 of ~0.04 (SH1000, ΔsrtB), or to 
a final OD
600
 of ~0.02 (ΔsrtA), and the cultivation was continued until the stationary phase 
was reached.
Shaving sample preparation
S. aureus cultures were harvested at OD
600
 0.25 (SH1000, ΔsrtB) or OD
600
 0.17 (ΔsrtA), 
and at 1 h after transition into the stationary growth phase. Cells were collected by 
centrifugation (10 min, 6080 × g, 4°C) and washed twice with PBS containing 40% 
sucrose (Acros), and 20 mM azide (Sigma-Aldrich). Immobilized trypsin (Pierce) was 
activated with 50 mM ammonium bicarbonate (Sigma-Aldrich) and resuspended in 
50 µl PBS plus 40% sucrose and 20 mM azide. The activated immobilized trypsin was 
then added to the cells. The shaving reaction was conducted for 45 min at 37°C. Released 
peptides were isolated, reduced with 10 mM DTT (30 min, room temperature), alkylated 
with iodoacetamide (30 min in the dark at room temperature), and digested with trypsin 
overnight at 37°C (5). As a control for spontaneous release of proteins from the cells during 
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the shaving reaction,  the cells were incubated with 50 µl PBS containing 40% sucrose, but 
lacking the immobilized trypsin.
Mass Spectrometry
Reduction and alkylation, desalting of the samples, MS analysis and database searches were 
performed as previously described (5). The strain-specific uniprot database was used for the 
NCTC8325 strain (including a concatenated reversed database, 5862 entries). Validation 
of MS/MS based peptide and protein identifications was performed with Scaffold (version 
Scaffold_3.6.5, Proteome Software Inc., Portland, OR). Peptide identifications were accepted 
if they exceeded specific database search engine thresholds. Sequest identifications required 
at least deltaCn scores of greater than 0.10 and XCorr scores of greater than 1.9, 2.2, 3.8 and 3.8 
for singly, doubly, triply and quadruply charged peptides. All experiments were conducted in 
independent triplicates. Peptides were only accepted as being identified if they were detected 
in at least two out of the three replicates per sample set. With these filter parameters no false 
positive hits were obtained. The mass spectrometry proteomics data have been deposited 
to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the 
PRIDE partner repository with the dataset identifier PXD000179. All peptide identifications 
are listed in Supplemental Table 1 (available on request).
Results and discussion
Impaired growth of srtA mutant S. aureus cells in RPMI medium 
S. aureus SH1000 and its sortase mutant derivatives were grown in RPMI medium, which 
is also suited for culturing of human blood cells. Accordingly, this medium is believed to be 
more physiologically relevant than other commercially available growth media that are used 
to culture S. aureus (5). As shown in Figure 1, deletion of srtA drastically affected the growth 
rate of S. aureus in RPMI. Furthermore, the optical density reached in the stationary phase 
was about two-fold lower than that of the parental strain SH1000. Unlike the srtA mutation, 
the srtB mutation did not affect the growth S. aureus SH1000 in RPMI (Figure 1). This 
shows that SrtA is important for the growth of S. aureus in RPMI medium. Interestingly, our 
previous studies showed that the srtA mutation did not affect growth in TSB medium (29, 32). 
This indicates that S. aureus cells lacking the srtA gene have a defect in the cell wall 
localization of one or more  LPxTG proteins that are necessary for the proper growth of 
S. aureus SH1000 in RPMI medium. This prompted us to investigate the surfacome of 
sortase mutant cells using the previously developed shaving technique that makes use of 
immobilized trypsin (5). As previously shown (5), this method mainly identifies protein 
domains exposed on the cell surface, but not those that are buried within the cell wall.
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Figure 1. Growth of S. aureus srtA and srtB mutants. The S. aureus strains SH1000 ΔsrtA, ΔsrtB and the parental 
strain were grown in RPMI medium under vigorous shaking at 37°C.
The surfacome of srtA or srtB mutant cells
To investigate the influence of the srtA and srtB mutations on the S. aureus surfacome, 
shaving experiments were performed with exponentially growing cells as well as cells 
that had entered the stationary growth phase. Notably, our previous cell surface shaving 
studies were focused on early-exponential phase cells, because cell lysis was minimal 
under these conditions and because the low cell density would more closely reflect the low 
cell densities encountered during bacteremia. However, it is known that many secreted 
S. aureus proteins are up-regulated at late growth stages, some of which can also be detected 
in a cell wall-bound state (5, 30). Therefore, we also investigated cells in the stationary 
phase. 
The analysis of exponentially growing cells of the parental strain SH1000, the ΔsrtA mutant 
and the ΔsrtB mutant resulted in the identification of 27, 11 and 17 surface-exposed proteins, 
respectively (Figure 2A). It should be noted that a few of these proteins (e.g. Atl, GAPDH 
and the putative lipoprotein Q2G2D8) were also detected in control experiments where 
the spontaneous protein release in the absence of immobilized trypsin was investigated 
(Supplemental Table 1 available on request). When the cells had reached the stationary 
growth phase, the numbers of identified surface-exposed proteins of each of these strains 
were increased to 31, 23 and 19 proteins, respectively (Figure 2B). These findings indicate 
that not only the numbers of secreted S. aureus proteins increase in the stationary phase, but 
also the numbers of cell surface-exposed proteins. This is most clearly evident for the srtA 
mutant strain.
The comparison of all identified surface-exposed proteins in srtA or srtB deficient cells, or 
the parental strain showed that 12 proteins were detectable in all three strains. In contrast, 
12 proteins were exclusively detectable in cells of the parental strain, 5 exclusively in srtA 
mutant cells, and 2  exclusively in srtB mutant cells (Figure 2C). The highest degree of 
overlap in identified proteins was observed for the srtB mutant cells and cells of the parental 
strain (Figure 2). Only two proteins, DnaK and the cell wall-bound SsaA2 protein, were 
detected exclusively on the surface of srtB mutant cells. It is presently not clear why these 
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proteins were detected on the surface of srtB mutant cells, but not on the surfaces of the srtA 
mutant cells or cells of the parental strain. Notably, DnaK is a protein that is normally active 
in the bacterial cytoplasm. However, it belongs to the class of HSP70 heat shock proteins 
of which human homologues are known to bind to the autolysin Atl at the S. aureus cell 
surface (11, 23). Since Atl was detected in the srtB mutant (Table 1), it is conceivable that 
the detected DnaK was bound to this protein. 
Our analyses revealed that the identified surface-exposed proteins of the parental strain 
included eight LPxTG proteins (Figure 2D, Table 1). Of these eight, only the SasG protein 
was identified exclusively in the parental strain. Five LPxTG proteins, namely SdrD, 
ClfA, ClfB, IsdA and IsdB were identified in the parental strain, but not in the srtA mutant. 
This suggests that these proteins require SrtA for proper cell surface exposure, or retention 
at this location. This idea is consistent with the view that proteins with an LPxTG motif 
will not be covalently anchored to the cell wall if SrtA is absent, and that such proteins may 
be secreted into the growth medium or that they are degraded due to an aberrant cell wall 
localization. Consistent with this view, processed forms of the SdrD and ClfA proteins 
were previously detected in the cell culture medium of cells lacking SrtA (29). Despite 
the fact that the lack of detection of SdrD, ClfA, ClfB, IsdA and IsdB at the cell surface of 
srtA mutant cells is consistent with our expectations, a note of caution is in place, because 
for technical reasons certain proteins may not be identified by MS even though they are 
present. For example, such proteins may be present in small amounts or they may not have 
surface-exposed trypsin cleavage sites. 
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Figure 2. Proteins identified at the surface of srtA or srtB mutant cells. The numbers of proteins identified by 
cell surface shaving are indicated in venn diagrams. (A) Proteins detected in exponentially growing cells (OD
600 
of ~0.2); (B) proteins detected in cells in the postexponential growth phase (1 h after entering into stationary 
phase); and (C) all identified proteins. (D) Predicted subcellular localization of proteins identified at the surface of 
cells in the exponential (exp) or stationary (stat) growth phases. No, proteins lacking known motifs for subcellular 
localization; Cyt, cytoplasmic proteins; CW-nc, non-covalently cell wall-bound proteins; CW-LPxTG, covalently 
cell wall-bound proteins; Sec, known secreted proteins.
Intriguingly, the LPxTG proteins Spa and SasF were not only identified at the surface of 
cells of the parental strain, but also at the surface of srtA mutant cells (Table 1). Previous 
studies have shown that, indeed, some Spa remains bound to the cell wall of srtA mutant 
S. aureus cells, albeit in reduced amounts, while this protein is secreted into the growth medium 
at substantially increased levels (29). Our present findings now show that the wall-bound 
Spa of SrtA-deficient mutant cells is exposed at the cell surface, but potentially in a different 
manner than in SrtA-proficient cells. Specifically, our MS analyses identified only three 
peptides corresponding to the first and second IgG-binding domains as surface exposed in 
SrtA-proficient cells (Figure 3). In contrast, additional peptides from the second and third 
IgG-binding domains and the C-terminal LysM domain of Spa were identified as being 
surface-exposed in SrtA-deficient cells (Figure 3). Possibly, this reflects a mis-localization 
of Spa in the absence of its covalent binding to the peptidoglycan. The LysM domain, which 
is still present in the non-covalently cell wall-bound Spa, is most likely responsible for 
the observed cell wall retention of this protein. However, at least a part of the LysM domain 
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is cell surface exposed, which may explain why Spa is only loosely bound to SrtA-deficient 
cells. Like Spa, the LPxTG protein SasF was detected at the surface of srtA mutant cells and 
cells of the parental strain (Figure 3). However, in case of SasF there was no difference in 
the identified peptides, and this protein was only detectable in the stationary phase. 
Figure 3. Location of identified peptides in the Spa and SasF proteins. The peptides identified by MS upon surface 
shaving of S. aureus strain SH1000 (wt) and its ΔsrtA or ΔsrtB mutant derivatives are highlighted in the linear 
protein sequences of the IgG-binding protein Spa and the staphylococcal surface protein F (SasF). In addition, 
known protein domains are indicated as explained in the associated legend.
It is noteworthy that six of the eight LPxTG proteins identified in this study (i.e. ClfA, ClfB, 
IsdB, SasG, SdrD, Spa) contain the so-called YSIRK/GS motif in their signal peptides. It 
was previously shown that proteins with the YSIRK/GS motif are directed to the cross-wall, 
which is the peptidoglycan layer that forms during cell division to separate the daughter 
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cells (4, 35). Our observation that surface shaving with immobilized trypsin preferentially 
detects LPxTG proteins with the YSIRK/GS motif thus indicates that cross wall proteins are 
readily detectable with this technique. The fact that the IsdA and SasF proteins lacking the 
YSIRK/GS motif are also detected suggests that there is no major bias for the identification 
of cross wall-localized proteins. This further supports the view that our surface shaving 
approach with immobilized trypsin is broadly applicable for studies on the composition of 
the S. aureus surfacome. 
Lastly, several non-LPxTG proteins were identified at the cell surface of the parental 
SH1000 strain, which were not detected at the surface of the srtA mutant cells. These proteins 
include β-hemolysin, δ-hemolysin, the Efb homologous protein (Ehp) and several ribosomal 
subunits. During host invasion β-hemolysin and δ-hemolysin are secreted to attack the host 
cells, while Ehp serves to inactivate complement (10). Our present findings suggest that such 
non-LPxTG proteins could be retained in the cell wall of SrtA-proficient cells by binding 
to certain LPxTG proteins that are not effectively localized to the surface of SrtA-deficient 
cells.
In conclusion, the present cell surface shaving studies with immobilized trypsin provide 
a first proteomic view of the sortase-dependent surfacome of S. aureus. This sub-proteome is 
shown to consist of covalently cell wall-bound LPxTG proteins, non-covalently wall-bound 
proteins, known secreted proteins and cytoplasmic proteins. Our findings indicate that 
the latter secreted and cytoplasmic proteins are retained at the surface of SrtA-proficient cells 
by binding to one or more LPxTG proteins. If so, these LPxTG proteins represent crucial 
nodes in the cell wall interactome of S. aureus, which may have important implications for 
their roles in the virulence of this important pathogen. 
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The most diverse organisms on earth are bacteria. They adapted their lifestyles to colonize 
different ecological niches, including human beings. It is estimated that 500 to 1000 
species of bacteria live in the human gut and a roughly similar number of bacteria can be 
identified on the skin. In most cases, both humans and microbes seem to benefit from this 
co‑existence. However, in some cases the commensal bacteria invade the human host, which 
can then lead to life‑threatening diseases. One of these opportunistic commensal bacteria is 
Staphylococcus aureus. The S. aureus colonization rate in the healthy human population is 
established at about 30%. Especially, if the primary barrier function of the skin is disrupted, or 
if the immune system is compromised, S. aureus has an increased potential to invade almost 
all tissues and organs causing a broad range of diseases. As introduced in Chapter 1 of this 
thesis, the pathogenicity of S. aureus is dependent on a broad range of cell surface‑exposed, 
or secreted virulence factors. These include: surface‑exposed proteins involved in adherence 
and colonization of host tissues, invasins exported into the host environment to promote 
the bacterial spread in invaded tissues, biochemical properties that enhance staphylococcal 
survival in phagocytes, immunological disguises, superantigens, and toxins damaging the 
membrane of host cells. 
Not only the diseases that this pathogen can cause are alarming, but also its high propensity 
to acquire resistance to antibiotics. Till now, the therapy against S.  aureus infections 
relies mainly on antibiotics. However, due to the fast development of antibiotic resistance 
by S.  aureus, alternative ways to prevent and cure staphylococcal diseases need to be 
discovered, including immunization strategies. Importantly, there is currently no vaccine 
or passive immunization therapy available that could stop this successful pathogen 
from infecting humans. Accordingly, novel strategies to combat this pathogen through 
immunotherapy must be based on an integrated approach that requires the identification 
of invariant and immune‑dominant targets. The identification of such targets requires (i) 
in‑depth analyses on the localization of proteins and other compounds to the staphylococcal 
cell surface and (ii) a thorough understanding of the human immune responses to these cell 
surface‑exposed compounds. This thesis therefore describes investigation on the interactions 
between S. aureus and its human host in vivo and in vitro. In particular, studies of immune 
responses as a result of S. aureus colonization in patients with the genetic blistering disease 
epidermolysis bullosa (EB) revealed several highly immunogenic staphylococcal proteins 
and their epitopes. In addition, in vitro studies have pinpointed various mechanisms that are 
important for the cell surface exposure of different S. aureus proteins that are known to be 
involved in staphylococcal infections. Taken together, the findings reported in this thesis 
contribute to a better understanding of the interactions between humans and S. aureus during 
colonization and infection. 
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EB refers to a group of inherited disorders caused by mutations in various structural proteins 
in the skin. Patients with EB develop blisters as a consequence of trivial mechanical trauma. 
The resulting ulceration of the skin in patients with EB leads to the development of wounds 
that become readily colonized by different bacteria. In Chapter 2 an unexpectedly high rate 
of S. aureus colonization among EB patients is reported. All EB patients with chronic wounds 
and 75% of the patients without chronic wounds were shown to be colonized with S. aureus 
on at least one body site. Even when only the colonization rates of the upper respiratory tract 
were compared, the rates determined for EB patients (56‑90%) were substantially higher than 
those measured for healthy individuals (25‑37%) or healthcare workers who occasionally 
meet the sampled EB patients (39%). This implies that the wounds of EB patients represent 
an attractive niche for S. aureus. Molecular typing showed that (i) colonization of the EB 
patients is not limited to specific genetic lineages of S. aureus; (ii) individual patients with 
EB were carrying up to four different staphylococcal MLVA types; and (iii) autoinoculation 
of staphylococci between the upper respiratory tract and wounds of EB patients must occur 
frequently. The view that colonization of EB patients by S. aureus is a random process is 
supported by spa‑typing analyses, which showed that most of the identified spa‑types belong 
to the most predominant spa‑types in the areas of residence of the respective EB patients. 
Thus, the S.  aureus population structure in the sampled EB patients mirrors the general 
S. aureus population structure in the Netherlands. An important finding was that the rate 
of S. aureus transmission between different patients in the sampled population is relatively 
low. The few cases where different EB patients did carry the same S. aureus MLVA types 
concerned family members, or individuals who lived in an area where the respective 
spa‑types are very common also amongst the general population.
Research described in Chapter 3 revealed the variation in S. aureus types colonizing patients 
with EB over time, as well as the influence of high‑level colonization on anti‑staphylococcal 
antibody titers in these patients. The data show that the same S. aureus MLVA type was 
identified only in ~42.5% of all sampled patients with minor variations for different sites of 
sampling. Furthermore, 43.5%‑58.3% of the patients with EB carried alternating S. aureus 
MLVA types over time. These findings show that the included EB patients are continuously 
challenged by different S. aureus types and that the carried S. aureus population can change 
rapidly. This seems to challenge the classical dogma that persistent carriers are mainly 
colonized by one S. aureus type. Most importantly, it was found that the sera of EB patients 
contained higher anti‑staphylococcal IgG levels than those of healthy individuals. Specifically, 
this applied to IgGs against nine important virulence factors: the surface proteins IsdA and 
SasG, the secreted proteins IsaA, SCIN, Nuc and LytM, and the superantigens (SAgs) SEM, 
SEN and SEO. Notably, EB patients carrying different S.  aureus types contained higher 
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levels of anti‑staphylococcal antibodies than EB patients colonized by only one type. This 
was particularly evident for IgGs against IsdA, LukD, HlgB, LytM, LukS, LukF and ETA. 
Altogether, these observations show that EB patients are highly challenged with very diverse 
S. aureus types, and that carriage of multiple S. aureus types apparently elicits the highest 
humoral responses in these patients. 
In most previous studies, the colonization with S. aureus was investigated by taking swabs 
from different body sites, which was followed by the analysis of only one S. aureus colony 
per swab. This is likely to result in an underestimation of the number of colonizing S. aureus 
types, especially in hosts that are more susceptible to S. aureus colonization than healthy 
individuals. Therefore, the studies described in Chapter 4 were aimed at investigating the 
co‑existence of different S. aureus types in wounds of EB patients in relation to their genetic 
relatedness and spatial distribution in vivo. Upon replica‑plating of used bandages of five 
different EB patients, either confluent growth or separate colonies at different densities were 
observed. Species determination of 12 to 48 colonies per investigated wound revealed that 
most obtained isolates were S. aureus. As showed by  fluorescence in  situ hybridization, 
S. aureus was mostly present in micro‑colonies, although individual S. aureus cells were 
also detectable upon replica plating of bandages. It was therefore concluded that the bacterial 
wound topography as observed through replica plating of used bandages closely reflects 
the actual bacterial topography in the wounds. Typing of all collected S.  aureus isolates 
revealed that individual chronic wounds contained up to six different S.  aureus types at 
one time point of sampling and even up to 10 different S. aureus types when the wound 
was  investigating over time. Some of these isolates are closely related suggesting that they 
share a recent common ancestry. Importantly, other isolates derived from adjacent wound 
locations belong to distinct molecular complexes of S. aureus. It can therefore be concluded 
that the general assumption that one individual is predominantly colonized by one type of 
S. aureus does not apply to chronic wounds of patients with EB.
As shown in Chapters 2, 3 and 4, patients with EB are highly colonized by various 
S. aureus strains. This seems to result in increased IgG levels directed against S. aureus 
in general and, consistent with this view, high IgG titers against particular staphylococcal 
proteins were identified. To date, it is not known whether these antistaphylococcal IgGs 
are protective against invasive disease caused by S.  aureus, but this is an interesting 
possibility that focused attention on the, so far, unsuccessful attempts to develop 
antistaphylococcal immunotherapy. To design a rational approach for the development of 
novel antistaphylococcal immunotherapies, the studies described in Chapter 5 combined 
an in‑depth assessment of the staphylococcal cell wall‑ and cell surface proteomes with an 
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array‑based screen for epitopes in identified cell wall‑bound or surface‑exposed proteins of 
S. aureus. For the epitope screen, plasma donated by EB patients was used. The proteomics 
analyses identified a large set of proteins on the surface of two different S. aureus strains, 
the MSSA strain Newman and the community‑acquired MRSA strain USA300. In particular 
the USA300 strain was found to expose many typically cytoplasmic proteins on its surface. 
Previous studies by others have also reported on this remarkable phenomenon. Importantly, 
for several exported cytoplasmic proteins, so‑called moonlighting functions in pathogenesis 
have been documented and, in accordance with the idea that cytoplasmic proteins may be 
exposed on the staphylococcal cell surface also in vivo, it was observed that the plasma of 
EB patients indeed contained IgGs against cytosolic proteins, such as the fructose‑bisphosphate 
aldolase (Alf1), the enolase (Eno), the triosephosphate isomerase Tim, the elongation factors 
G and Ts, the ribosomal proteins S5, S13 and L25, the phosphoglycerate kinase Pgk and 
the glyceraldehyde‑3‑phosphate dehydrogenase GAPDH. Antibodies directed against Eno 
have previously been demonstrated to cause opsonophagocytic killing of S. aureus and this 
protein is a known protective antigen on the cell surface of Streptococcus suis.
Interestingly, the studies documented in Chapter 5 also showed that some of the proteins 
identified on the S.  aureus cell surface display clusters of epitopes that appear to be 
exposed into the extracellular host milieu. The best examples for this group of proteins are 
the cell wall‑anchored IsdB protein, the bifunctional autolysin Atl, the adhesin Emp and 
the transglycosylase IsaA. Notably, the IgGs from different EB patients did not always bind 
to the same epitopes of particular investigated proteins. This may have several possible 
reasons. In the first place, with a few exceptions, the epitope mapping was performed 
with arrays that contained mostly linear peptides. Accordingly, IgGs that recognize only 
conformational epitopes will be overlooked by this approach. Another possible reason for 
the high variability in the binding of IgGs from EB patients to the peptide libraries may 
relate to the fact that different EB patients were colonized by different S. aureus types. These 
different types of S. aureus might express different sets of cell surface‑exposed antigens and, 
thus, elicit different immune responses. In this respect, it is important to take into account 
the previously demonstrated variability of different S.  aureus lineages with respect to 
the presence of particular genes for surface‑exposed or exported proteins. Nevertheless, the 
analyses described in Chapter 5 have altogether highlighted several immunodominant cell 
surface‑exposed proteins of S. aureus and specific sub‑domains of these proteins as potential 
targets for novel active or passive immunization approaches. These include the covalently 
cell wall‑bound proteins ClfB and IsdB, a ‘YkyA‑like’ cell wall‑binding lipoprotein, 
the membrane proteins EbpS and LtaS, the non‑covalently cell wall‑bound and secreted 
proteins Atl, Sbi, IsaA, Emp, and the cytoplasmic proteins Afl1, Eno, and GAPDH. Future 
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studies will show whether any of these proteins can indeed serve as effective targets for 
antistaphylococcal immunotherapy.
Chapter 6 describes the profiling of global interactions between human serum proteins and 
the S. aureus cell surface. The quantification of MS data by spectral counting showed that 
nine serum proteins were specifically enriched on the cell surfaces of the S. aureus strains 
USA300 and Newman. These include components of the complement system, namely factor 
H (fH), the fH‑related proteins 1 and 5, and component 7. In addition, significant amounts 
of a fifth protein, the platelet factor 4 (PF4), were detectable in samples derived from 
the surface of strain Newman, but not USA300. In addition, four serum proteins were clearly 
enriched on the staphylococcal cell surface, namely properdin, complement component C3, 
fibrinogen‑α, and isoform 1 of the inter‑α‑trypsin inhibitor heavy chain H4 (ITIH4). It was 
previously shown that almost all of these proteins are involved in the human host defences 
against S. aureus. One exception is  ITIH4, which was enrichment only on the cell surface 
of strain Newman. This protein has not yet been reported to interact with bacteria, but it is 
a well‑known acute‑phase serum protein, as was previously shown in a mouse model for 
cutaneous burn injuries. In addition to human proteins, various surface‑exposed S. aureus 
proteins were also identified. These included Coa, FnbpA, the secretory antigen SsaA, and 
several typical cytosolic proteins, including four ribosomal proteins, the elongation factor 
TU and GAPDH. Taken together, the findings reported in Chapter 6 show that the surface 
shaving technique is a versatile generally applicable tool for monitoring bacteria‑host 
interactions. 
To colonize or invade the human host, S.  aureus expresses different virulence factors 
that can, in fact, also represent targets for the human immune defenses as was shown 
and discussed in Chapters 3 and 5. These virulence factors are first synthesized as 
precursors with an N‑terminal signal peptide to direct their transport from the cytoplasm 
to an extra‑cytoplasmic location, such as the cell wall or extracellular milieu via different 
transport systems. As outlined in the introductory Chapter 1 of this thesis, the most 
commonly used pathway for protein transport across the membrane is the general secretory 
(Sec) pathway. The translocation via this pathways can be divided into three stages: (i) 
chaperoning of newly synthesized proteins to the membrane‑embedded translocon, (ii) 
membrane translocation, and (iii) post‑translocation modification and processing. In the 
present PhD research, several components that are involved in the latter two stages have 
been analyzed. 
The Sec machinery for protein translocation is composed of several subunits. The SecA 
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translocation motor binds pre‑proteins and pushes them through the membrane‑embedded 
SecYEG translocation channel via repeated cycles of ATP binding and hydrolysis. The core 
of the Sec translocon consists of the SecA, SecY and SecE proteins, which are essential for 
growth and viability. In addition to the major SecYEG channel proteins, S. aureus produces 
a second set of SecA and SecY proteins, generally referred to as SecA2 and SecY2. In 
Chapter 7, the analyses of isogenic secG and secY2 mutants of S. aureus is described. While 
the deletion of secY2 had no detectable effects on protein secretion, the importance of SecG 
became clearly evident upon analysis of the exoproteome of a secG mutant by 2‑D PAGE. 
Specifically, the extracellular accumulation of nine abundant exoproteins and seven cell 
wall‑bound proteins was significantly affected in the secG mutant. Among these proteins 
are some known virulence factors involved in host colonization (e.g. the serine‑aspartic acid 
repeat proteins SdrC and SdrD), invasion of host tissues (e.g. hemolysins and leukocidins), 
cell wall turnover (LytM), and evasion of the immune system (Spa). Another interesting 
finding was that the second IgG‑binding protein Sbi was almost completely absent from 
the cell wall of the secG mutant strain. Interestingly, deletion of secY2 exacerbated 
the secretion defects of secG mutants, affecting the extracellular accumulation of one 
additional exoprotein and one cell wall protein. Furthermore, the secG secY2 double mutant 
displayed a synthetic growth defect. This might relate to a slightly elevated expression 
of sraP, encoding the only known substrate for the Sec2 pathway, in cells lacking SecG. 
Additionally, the results suggest that SecY2 can interact with the Sec1 channel, which would 
be consistent with the presence of a single set of secE and secG genes in S. aureus. Notably, 
infection experiments in a mouse model did not reveal any attenuation of the secG mutant 
strain, suggesting that this component of the secretion machinery is dispensable for host 
subversion by S. aureus. This implies that the presence or absence of SecG or SecY2 is 
not critical for the virulence of S. aureus SH1000, at least under the conditions tested in 
the applied mouse infection model.
In recent years, the functions of many secretion machinery components of S. aureus have 
been elucidated as exemplified by studies on the Sec pathway. Intriguingly however, for 
several other predicted secretion machinery components, no biological functions had been 
described at the start of the present PhD research. This applied for example to the pseudopilin 
export machinery of S. aureus. This machinery is very similar to the Com machinery for 
DNA binding and uptake in B. subtilis. Assembly of the pseudopilus in B. subtilis requires 
the specific signal peptidase ComC, which processes the N‑terminal signal peptides of ComG 
proteins upon membrane translocation. Furthermore, stability of the B.  subtilis ComGC 
pseudopilin requires post‑translocational disulfide bond formation, which is catalyzed by 
the thiol‑disulfide oxidoreductases (TDOR) BdbC and BdbD. Interestingly, the genes coding 
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for most Com proteins are present in the sequenced S. aureus strains, suggesting that this 
bacterium is able to assemble pseudopili of the Com type. Chapter 8 describes studies on 
the processing and stability of S. aureus ComGC. In S. aureus, the transcription of most com 
genes, including comGC, is directed by the staphylococcal alternative sigma factor σH. Upon 
constitutive expression of σH, exponentially growing cells of S. aureus produced only the 
precursor form of ComGC, while cells in the post‑exponential growth phase showed low‑level 
ComC‑dependent processing of ComGC. Interestingly, the inefficient ComGC processing 
was due to limited ComC signal peptidase activity as shown by ComC overexpression. 
Furthermore, ComGC was barely detectable in cells lacking the TDOR DsbA, and this was 
also the case when cells were grown in the presence of the reducing agent β‑mercaptoethanol. 
Together, these observations imply that the TDOR activity of DsbA is required for disulfide 
bond formation in ComGC and that this disulfide bond is essential for ComGC stability. 
Notably, both pre‑ComGC and mature ComGC were found to localize to the cytoplasmic 
membrane and cell wall of S.  aureus. However, as shown by immunofluorescence 
microscopy, the overproduction of ComC resulted in strongly enhanced surface exposure 
of ComGC. These findings thus show that ComC‑dependent processing of ComGC is of 
importance for the optimal cell surface exposure of ComGC. It is presently not clear, why 
S. aureus cells seem to produce ComC in limiting amounts for ComGC biogenesis, but this 
observation may explain why S. aureus shows only marginal levels of natural competence.
The ability of S. aureus to invade and colonize almost all human tissues depends on various 
cell surface‑associated and secreted virulence factors. As described above these virulence 
factors are first synthesized with an N‑terminal signal peptide to direct them into one of 
the secretion pathways of the staphylococcal cell. The translocated proteins will then pass 
the cell wall and are released into the extracellular environment, unless they are specifically 
retained in the cell. The signal for covalent attachment of translocated proteins to the cell wall 
is formed by a so‑called LPxTG motif, which is located in the C‑terminus of the exported 
proteins. This LPxTG motif is recognized by membrane‑associated transpeptidases 
known as sortases. S. aureus possesses two sortase enzymes, named sortase A (SrtA) and 
sortase B (SrtB). SrtA recognizes the canonical LPxTG motif. In contrast, SrtB recognizes 
a degenerate LPxTG motif, namely NPQTN. 
The research described in Chapter 9 was aimed at assessing the roles of SrtA and SrtB in 
the in vitro growth of S. aureus on human plasma, which mimics to some extent the in vivo 
growth condition encountered during bacteremia. As exemplified with the S. aureus strain 
SH1000, the results show that srtA can be an important determinant for efficient growth of 
certain staphylococcal strains in human plasma. Importantly, transcript profiling analyses 
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showed that a srtA mutation altered the expression of 39 genes. In contrast, no stress 
response was detectable in srtB mutant cells grown on human plasma. Among the genes 
affected by the srtA mutation, the genes putatively required for phosphate acquisition by 
S.  aureus appeared to be enriched. These include the genes for the phosphate‑specific 
transport (Pst) system, which is similar to the Pst system from B.  subtilis, and the gene 
for a secreted alkaline phosphatase (PhoB). In B.  subtilis the pst operon is a member of 
the Pho regulon, which is controlled by the PhoP‑PhoR two‑component regulatory system. 
The high similarity between the PhoP regulator components of S.  aureus and B.  subtilis 
suggested that the Pho box motif could be conserved in these two species. Indeed, a Pho 
box‑like motif was identified in the upstream region of the S. aureus pstSCAB and phoB 
genes. Together, these findings imply that the srtA mutant cells grown in human plasma 
displayed a phosphate starvation response. Interestingly, our tiling array data show that 
the gene encoding the LPxTG protein FnbpA, was 2.3 times up‑regulated in the srtA mutant. 
In addition, the fnbpB gene was also up‑regulated, albeit only 1.7‑fold, which was just below 
the somewhat arbitrarily chosen cut‑off of 1.8 fold. This would suggest that FnbpA and 
possibly also FnbpB have a role in phosphate acquisition. Both proteins are important in 
infections caused by S. aureus, because of their central role in the adhesion to and invasion 
of host cells. Especially, FnbpA was shown to be a multifunctional adhesin with the capacity 
to bind to fibrinogen, fibronectin, elastin and several other proteins. Intriguingly, it has been 
shown that soluble fibronectin contains covalently bound phosphate. Thus, it is conceivable 
that Fnbp’s are somehow involved in the scavenging of phosphate from fibronectin, thereby 
contributing to the phosphate homeostasis in S. aureus. This view is further supported by the 
fact that putative Pho boxes are present in the promoter regions of both fnbpA and fnbpB. 
On the other hand, most phosphate in human serum is present in an unbound state, at least 
according to the available literature data. This would imply that FnbpA and FnbpB could 
also be involved in the binding of free phosphate.
Chapter 10 addresses the influence of srtA or srtB mutations on the S. aureus growth in 
RPMI medium as well as on the surfacome. The growth experiments of S. aureus SH1000 and 
its sortase mutant derivatives showed that only the deletion of srtA, but not srtB drastically 
affected the growth rate of S. aureus. This shows that SrtA is important for the growth of 
S. aureus in RPMI medium, as was also shown to be the case for growth in human plasma in 
Chapter 9. Importantly, the surfacome analysis of exponentially growing cells of the parental 
strain SH1000, the ΔsrtA mutant and the ΔsrtB mutant resulted in the identification of 
27, 11 and 17 surface‑exposed proteins, respectively. In stationary growing cells these 
numbers were increased to 31, 23 and 19 proteins, respectively. These findings indicate that 
not only the numbers secreted S. aureus proteins increase in the stationary phase, but also 
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the numbers of cell surface‑exposed proteins. More importantly, our analyses revealed that 
the identified surface‑exposed proteins of the parental strain included 9 LPxTG proteins. 
Of these nine, only the SasG protein was identified exclusively in the parental strain. Five 
LPxTG proteins, namely ClfA, ClfB, IsdA, IsdB and SdrD were identified in the parental 
strain, but not in the srtA mutant. This suggests that these proteins require SrtA for proper 
cell surface exposure. Intriguingly, two LPxTG proteins, Spa and SasF, were identified at 
the surface of both srtA mutant cells and cells of the parental strain. Previous studies have 
shown that indeed some Spa remains bound to the wall of srtA mutant S. aureus cells, albeit 
in reduced amounts, while this protein is secreted into the growth medium at substantially 
increased levels. Our findings show that the wall‑bound Spa of SrtA‑deficient mutant cells 
is exposed at the cell surface, but potentially in a different manner than in SrtA‑proficient 
cells. Specifically, our MS analyses identified additional peptides from the second and third 
IgG‑binding domains and the C‑terminal LysM domain of Spa as being surface‑exposed 
in SrtA‑deficient cells. Possibly, this reflects a mis‑localization of Spa in the absence of its 
covalent binding to the peptidoglycan. The LysM domain, which is thus still present in the 
non‑covalently cell wall‑bound Spa, is most likely responsible for the observed cell wall 
retention of this protein.
In conclusion, the research described in this thesis has addressed genome‑ and proteome‑wide 
‘global’ interactions between S. aureus and its human host. To this end, different studies 
were performed in vivo and in vitro, addressing (i) the colonization of chronic wounds by 
S. aureus, (ii) the IgG responses of colonized patients to particular staphylococcal proteins, 
(iii) the subcellular localization of these staphylococcal proteins, and (iv) the mechanisms 
by which these proteins are localized to the staphylococcal cell wall, cell surface and 
exoproteome. As such, it can be concluded that the main goals of the present thesis research 
have been achieved. The main challenges for future research now lie in the translation of 
the present findings into novel strategies for antistaphylococcal therapy. An important question 
that should be addressed on the short term would be how to apply the knowledge gained on 
wound colonization by S. aureus for the development of new approaches to achieve better 
wound care and faster wound healing. This would be highly relevant for EB patients who 
suffer from chronic wounds. An important long‑term research goal is the implementation of 
the identified immunodominant cell surface‑exposed targets for the development of novel 






De meest diverse groep van levende organismen op aarde wordt gevormd door bacteriën. 
Bacteriën hebben hun levensstijl aan verschillende ecologische niches aangepast, waaronder 
de mens. In de humane darm leven bijvoorbeeld 500 tot 1000 verschillende bacteriesoorten 
en vergelijkbare aantallen kunnen op de menselijke huid geïdentificeerd worden. In de meeste 
gevallen lijken zowel de bacteriën als de mens te profiteren van deze coëxistentie, maar in 
sommige gevallen kunnen commensale bacteriën de menselijke gastheer binnendringen, 
hetgeen tot levensbedreigende ziektes kan leiden. Eén van deze opportunistische bacteriën 
is Staphylococcus aureus. S. aureus koloniseert ongeveer 30% van de gezonde humane 
populatie. Wanneer echter de primaire barrièrefunctie van de huid verstoord is of wanneer 
het immuunsysteem is aangetast, dan heeft S. aureus de mogelijkheid om invasief te groeien 
en bijna alle weefsels en organen van het lichaam binnen te dringen en een breed scala aan 
ziektes te veroorzaken. Zoals in hoofdstuk 1 van dit proefschrift is aangegeven hangt de 
pathogeniciteit van S. aureus af van de aanwezigheid van verschillende virulentiefactoren. 
Deze omvatten eiwitten aan het celoppervlak van de bacterie die betrokken zijn bij de 
binding en kolonisatie van gastheerweefsels, geëxporteerde invasines die de bacteriële 
verspreiding binnen het geïnfecteerde weefsel bevorderen, verschillende moleculen die 
de kans op overleving van staphylokokken na opname door fagocyterende immuuncellen 
vergroten, eiwitten die helpen het immuunsysteem van de gastheer te ontwijken en toxines 
die de membranen van gastheercellen beschadigen.
Niet alleen de ziektes die door S. aureus veroorzaakt worden zijn zorgwekkend, maar ook 
het sterke vermogen van deze bacterie om resistentie tegen antibiotica te ontwikkelen. Tot 
nu toe zijn de therapieën tegen S. aureus infecties voornamelijk gebaseerd op het gebruik 
van antibiotica. Vanwege de snelle toename van antibioticum-resistente S. aureus varianten 
is er echter een groeiende behoefte aan alternatieve therapieën, waaronder actieve en 
passieve immunisatie om ziektes veroorzaakt door S. aureus te voorkomen of te genezen. 
Momenteel zijn er echter nog geen vaccins of beschermende antilichamen beschikbaar om 
deze zo succesvolle ziekteverwekker te stoppen. Daarom moeten nieuwe strategieën om 
deze ziekteverwekker te bestrijden door middel van immuuntherapie gebaseerd zijn op 
een geïntegreerde aanpak, die leidt tot de identificatie van invariante immunodominante 
targets die in alle cellen van S. aureus aanwezig zijn. De identificatie van deze targets 
vereist (i) een gedetailleerde kennis van de lokalisatie van eiwitten en andere moleculen op 
het celoppervlak van S. aureus en (ii) een goed begrip van de menselijke immuunreacties 
tegen deze componenten. Het onderzoek beschreven in dit proefschrift was daarom gericht 
op de bestudering van de interacties tussen S. aureus en de menselijke gastheer, zoveel 
in vivo als in vitro. Het beschreven onderzoek naar de immuunresponsen van patiënten met 
de erfelijke blaarziekte epidermolysis bullosa (EB) ten gevolge van langdurig S. aureus 
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dragerschap heeft geleid tot de identificatie van meerdere zeer immunogene eiwitten van 
S. aureus en de immunodominante epitopen in deze eiwitten. Daarnaast hebben in vitro 
studies verschillende mechanismen opgehelderd die van belang zijn voor localisatie van 
S. aureus eiwitten op het celoppervlak. Tezamen dragen de bevindingen beschreven in dit 
proefschrift bij aan een beter begrip van de interacties tussen S. aureus en zijn menselijke 
gastheer tijdens kolonisatie en infectie.
EB is de verzamelnaam voor een groep van erfelijke huidaandoeningen, die veroorzaakt 
worden door mutaties in verschillende structurele eiwitten in de huid. Als gevolg van kleine 
mechanische beschadigingen van de huid ontwikkelen patiënten met EB blaren. De resulterende 
ulceratie van de huid leidt tot de ontwikkeling van wonden die gemakkelijk gekoloniseerd 
worden door verschillende bacteriën. In hoofdstuk 2 van dit proefschrift wordt beschreven, 
dat EB-patiënten een onverwacht hoog percentage van S. aureus-dragerschap vertonen. Alle 
EB-patiënten met chronische wonden en 75% van de patiënten zonder chronische wonden 
bleken gekoloniseerd te zijn met S. aureus op ten minste één plaats op het lichaam. Zelfs 
wanneer uitsluitend naar de kolonisatie van de bovenste luchtwegen gekeken werd, bleek 
het S. aureus kolonisatiepercentage bij EB-patiënten (56 tot 90%) aanzienlijk hoger te liggen 
dan bij gezonde personen (25 tot 37%) of zorgverleners die regelmatig contact hebben met 
EB-patiënten (39%). Dit betekent dat de wonden van EB-patiënten een aantrekkelijke 
niche voor S. aureus vormen. Moleculaire typering van de S. aureus-isolaten met behulp 
van de zogenaamde MLVA methode liet zien (i) dat de kolonisatie van EB-patiënten niet 
beperkt is tot specifieke S. aureus types, (ii) dat individuele patiënten met EB maar liefst vier 
verschillende S. aureus types kunnen dragen op een willekeurig tijdstip en (iii) dat overdracht 
van stafylokokken tussen de bovenste luchtwegen en wonden van EB-patiënten regelmatig 
voorkomt. De opvatting, dat kolonisatie van EB-patiënten door S. aureus een willekeurig 
proces is werd verder ondersteund door zogenaamde spa-typeringsanalyses, waaruit bleek 
dat het grootste deel van de bij EB-patiënten gevonden S. aureus spa-types behoren tot 
de meest dominante spa-types in het woongebied van de respectievelijke EB-patiënten. 
Dit betekent dat de S. aureus populatiestructuur in de bemonsterde EB-patiënten de 
algemene S. aureus populatiestructuur in Nederland weerspiegelt. Een andere belangrijke 
bevinding was, dat de mate van S. aureus transmissie tussen verschillende EB-patiënten 
in de bemonsterde populatie relatief laag is. In de weinige gevallen, waarbij verschillende 
EB-patiënten dezelfde S. aureus types bij zich droegen betrof dit gezinsleden of personen 
die in een gebied leven waar de respectievelijke S. aureus types ook frequent bij andere 
personen voorkomen.
Onderzoek beschreven in hoofdstuk 3 was gericht op analyse van (i) de S. aureus kolonisatie 
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van EB-patiënten over een lange periode en (ii) de invloed van S. aureus kolonisatie op de 
titers van immuunglobulines G (IgG) tegen S. aureus bij deze patiënten. De resultaten laten 
zien, dat eenzelfde S. aureus type alleen aangetoond werd bij ~42,5% van de onderzochte 
patiënten. Daarentegen bleken de overige onderzochte EB-patiënten over een langere 
periode gekoloniseerd te worden door afwisselende S. aureus types. Deze waarnemingen 
laten zien, dat EB-patiënten voortdurend geconfronteerd worden met verschillende S. aureus 
types en dat de koloniserende S. aureus populatie in de tijd snel kan veranderen. Verder 
liet het onderzoek zien, dat sera van EB-patiënten hogere niveaus van anti-S. aureus IgG’s 
bevatten dan sera van gezonde personen. Dit geldt in het bijzonder voor IgG’s tegen negen 
belangrijke virulentiefactoren: de oppervlakteeiwitten IsdA en SasG, de geëxporteerde 
eiwitten IsaA, SCIN, Nuc en LytM en de superantigenen SEM, SEN en SEO. EB-patiënten 
die met verschillende S. aureus types gekoloniseerd waren bevatten hogere niveaus van 
anti-Staphylococcus antilichamen dan EB-patiënten gekoloniseerd door slechts één S. aureus 
type. Dit was vooral evident voor IgG’s tegen de IsdA, LukD, HlgB, LytM, LukS, LukF en 
ETA eiwitten van S. aureus. Tezamen tonen deze waarnemingen aan, dat het immuunsysteem 
van EB-patiënten die verschillende S. aureus types dragen zeer sterk wordt uitgedaagd door 
deze bacterie en dat het dragerschap van meerdere S. aureus types de hoogste humorale 
responsen bij deze patiënten opwekt. 
In de meeste voorgaande studies werd mogelijk S. aureus-dragerschap onderzocht 
door middel van uitstrijkjes van verschillende plaatsen van het lichaam met behulp van 
wattenstaafjes. Vervolgens werden deze wattenstaafjes gebruikt om de daarin aanwezige 
bacteriën te isoleren, waarna slechts één S. aureus kolonie per wattenstafje verder werd 
geanalyseerd. Dit heeft waarschijnlijk geresulteerd in een onderschatting van het aantal 
koloniserende S. aureus soorten, vooral bij personen die verhoogd vatbaar zijn voor S. aureus-
kolonisatie. Daarom waren de studies beschreven in hoofdstuk 4 gericht op het onderzoeken 
van de mogelijke coëxistentie van verschillende S. aureus types in individuele wonden van 
EB-patiënten. Hiertoe werd de ‘replica plating’ methode gebruikt voor het verzamelen van 
koloniserende bacteriën in plaats van de eerder gebruikte wattenstaafjes. Na replica plating 
van gebruikte verbanden van vijf verschillende EB-patiënten werd in sommige gevallen 
confluënte bacteriegroei en in andere gevallen de vorming van losse kolonies waargenomen. 
Uit de analyse van 12 tot 48 bacterie-isolaten per wond bleek, dat dit in de meeste gevallen 
S. aureus betrof. Met behulp van fluorescentie in situ hybridisatie werd vervolgens zichtbaar 
gemaakt, dat S. aureus meestal aanwezig was in de vorm van microkolonies, hoewel 
afzonderlijke S. aureus cellen ook gedetecteerd werden. Op grond van deze waarnemingen 
kon geconcludeerd worden, dat de bacteriële wondtopografie, zoals waargenomen door de 
replica plating van de gebruikte verbanden, de werkelijke bacteriële S. aureus topografie in 
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de wonden van de onderzochte EB-patiënten weerspiegelt. Het typeren van alle verkregen 
S. aureus isolaten liet zien, dat individuele chronische wonden wel zes verschillende S. aureus 
types konden bevatten op één bepaald moment, en maar liefst 10 verschillende S. aureus 
types over langere tijdsintervallen. Sommige van de gevonden S. aureus types blijken nauw 
verwant te zijn wat suggereert, dat ze een recente gemeenschappelijke afstamming hebben. 
Andere isolaten afkomstig van aangrenzende wondlocaties behoren tot zeer verschillende 
S. aureus types. Er kan daarom geconcludeerd worden, dat de algemene veronderstelling dat 
één persoon door één type S. aureus gekoloniseerd wordt met zekerheid niet geldt voor de 
chronische wonden van patiënten met EB.
Zoals in de hoofdstukken 2, 3 en 4 beschreven, is de S. aureus-kolonisatie bij patiënten met 
EB zeer hoog. Hoogst waarschijnlijk leidt dit tot de waargenomen verhoging in de IgG-niveaus 
tegen verschillende componenten van S. aureus. Tot op heden was echter niet bekend of deze 
anti-Staphylococcus IgG’s bescherming bieden tegen invasieve ziektes veroorzaakt door 
S. aureus. Dit is echter een interessante mogelijkheid voor verder onderzoek, met name met 
het oog op de ontwikkeling van een immunotherapie tegen S. aureus infecties. De studies 
beschreven in hoofdstuk 5 combineren daarom een proteomics-gebaseerde identificatie van 
de celwand- en celoppervlak-geassocieerde eiwitten van S. aureus met een array-gebaseerde 
screening voor immuno-dominante epitopen in de geïdentificeerde eiwitten. Voor de epitoop-
screening werd door EB-patiënten gedoneerd bloedplasma gebruikt. Via proteomics analyses 
werd een groot aantal eiwitten op het celoppervlak van twee verschillende S. aureus stammen, 
de meticilline-gevoelige (MSSA) stam Newman en de ‘community-acquired’ meticilline-
resistente (MRSA) stam USA300, geïdentificeerd. Op het celoppervlak van de USA300 
stam werden naast bekende en voorspelde celwandeiwitten veel typisch cytoplasmatische 
eiwitten gevonden. Dit opmerkelijke fenomeen werd ook in eerdere studies waargenomen 
en voor enkele van de geïdentificeerde cytoplasmatische eiwitten wordt een zogenaamde 
‘moonlighting functie’ in pathogenese verondersteld. In overeenstemming met het idee, dat 
deze cytoplasmatische eiwitten ook in vivo op het celoppervlak van S. aureus aanwezig 
zijn, werd gevonden dat het plasma van EB-patiënten inderdaad IgG’s tegen cytosolische 
eiwitten bevatte, waaronder de fructose-bisfosfaataldolase Alf1, de enolase Eno, de 
triosefosfaatisomerase Tim, de elongatiefactoren G and Ts, de ribosomale eiwitten S5, S13 
en L25, de fosfoglyceraatkinase Pgk en de glyceraldehyde-3-fosfaatdehydrogenase GAPDH. 
Het is eerder aangetoond, dat antilichamen gericht tegen Eno de opsonophagocytische 
eliminatie van S. aureus faciliteren en dat Eno op het celoppervlak van Streptococcus suis 
een beschermende antigeenfunctie heeft. 
Een interessante waarneming beschreven in hoofdstuk 5 is, dat een aantal eiwitten op het 
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S. aureus celoppervlak clusters van epitopen lijken te bevatten die geëxponeerd zijn in het 
extracellulaire milieu van de gastheer. De beste voorbeelden van dergelijke eiwitten zijn 
het celwand-verankerde IsdB eiwit, het bifunctionele autolysine Atl, het adhesine Emp en 
de transglycosylase IsaA. Opmerkelijk was dat de IgG’s van verschillende EB-patiënten 
niet altijd bleken te binden aan hetzelfde epitoop van de onderzochte eiwitten. Dit kan 
verschillende oorzaken hebben. Ten eerste werden de meeste epitoopmapping-analyses 
uitgevoerd met arrays die voornamelijk lineaire peptiden bevatten. Hierdoor kunnen 
IgG’s die uitsluitend conformationele epitopen herkennen over het hoofd gezien worden. 
Een tweede mogelijke reden voor de hoge variabiliteit in de binding van IgG’s van 
verschillende EB-patiënten aan de peptide arrays is gelegen in het feit, dat verschillende 
EB-patiënten gekoloniseerd zijn door verschillende S. aureus types. De expressie van de 
verschillende celoppervlakte-eiwitten kan verschillen in verschillende S. aureus types en 
hierdoor kunnen verschillende immuunreacties in verschillende patiënten opwekt worden. 
Niettemin hebben de analyses beschreven in hoofdstuk 5 geleid tot de identificatie van 
verschillende immunodominante celoppervlakte-eiwitten van S. aureus en specifieke 
sub-domeinen van deze eiwitten die als mogelijke targets voor nieuwe actieve of passieve 
immunisatie kunnen dienen. Hiertoe behoren de covalent gebonden celwandeiwitten ClfB 
and IsdB, een ‘YkyA-achtig’ celwand-bindend lipoproteine, de membraaneiwitten EbpS en 
LtaS, de geëxporteerde en niet-covalent gebonden celwandeiwitten Atl, Sbi, IsaA en Emp 
en de cytoplasmatische eiwitten Afl1, Eno en GAPDH. Toekomstige studies zullen moeten 
aantonen of deze eiwitten inderdaad als effectieve targets voor immunotherapieën tegen 
S. aureus ingezet kunnen worden.
Hoofdstuk 6 beschrijft de karakterisering van de globale interacties tussen humane 
serumeiwitten en het S. aureus celoppervlak. Hiertoe werden S. aureus cellen geïncubeerd 
in humaan plasma. De kwantificering van massaspectrometriegegevens toonde aan 
dat, na incubatie in plasma, negen serumeiwitten specifiek verrijkt aanwezig zijn op het 
celoppervlak van de S. aureus stammen USA300 en Newman. Hiertoe behoren componenten 
van het complementsysteem, namelijk factor H (fH), de fH-gerelateerde eiwitten 1 en 5 
en component 7. Bovendien waren aanzienlijke hoeveelheden van een vijfde eiwit, de 
platelet factor 4 (PF4), detecteerbaar in monsters afkomstig van het celoppervlak van stam 
Newman. Daarnaast waren vier serumeiwitten duidelijk verrijkt aanwezig op het S. aureus 
celoppervlak, namelijk properdin, complement component C3, fibrinogeen-α en isovorm 
1 van de inter-α-trypsine inhibitor heavy chain H4 (ITIH4). Het was al eerder aangetoond, 
dat bijna al deze eiwitten betrokken zijn bij humane afweerreacties tegen S. aureus. Een 
uitzondering is ITIH4, waarvan nog niet bekend was dat het interacties aangaat met bacteriën. 
ITIH4 is echter wel een bekend acute fase serumeiwit, zoals eerder werd aangetoond in 
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een muismodel voor brandwonden. Naast de humane eiwitten werden ook verschillende 
S. aureus oppervlakte-eiwitten geïdentificeerd, waaronder Coa, FnbpA, het gesectereerde 
antigeen SsaA en enkele cytosolische eiwitten, waaronder vier ribosomale eiwitten, de 
elongatiefactor TU en GAPDH. Tezamen laten de bevindingen gerapporteerd in hoofdstuk 6 
zien, dat de oppervlakte shaving-techniek een veelzijdig en algemeen toepasbaar instrument 
is voor de analyse van bacterie-gastheer interacties. 
Om de menselijke gastheer te koloniseren of binnen te dringen, brengt S. aureus verschillende 
virulentiefactoren tot expressie, die ook targets voor de menselijke afweer vertegenwoordigen, 
zoals werd aangetoond en besproken in de hoofdstukken 3 en 5. Deze virulentiefactoren 
worden eerst gesynthetiseerd als precursors met een N-terminaal signaalpeptide om hun 
transpoort van het cytoplasma naar een extracytoplasmatische locatie, zoals de celwand 
of het extracellulaire milieu via verschillende transportsystemen te initiëren. Zoals 
beschreven in het inleidende hoofdstuk 1 van dit proefschrift is het algemene secretie (Sec) 
systeem de meest gebruikte route voor eiwittransport over de cytoplasmamembraan. Het 
eiwittransport via deze route kan in drie fases verdeeld worden: (i) targeting van nieuw-
gesynthetiseerde eiwitten naar de translocatie-machinerie in de cytoplasmamembraan, (ii) 
membraantranslocatie, en (iii) post-translocationele modificatie en processing. In de context 
van het onderhavige promotieonderzoek zijn verschillende componenten van de laatste twee 
stappen geanalyseerd.
Het Sec-systeem bestaat uit verschillende subeenheden. De SecA translocatiemotor bindt 
precursor-eiwitten en duwt deze door het SecYEG translocatiekanaal in de membraan via 
herhaalde cycli van ATP-binding en hydrolyse. De kern van het Sec-translocon bestaat uit 
de SecA, SecY en SecE eiwitten die essentieel zijn voor groei en levensvatbaarheid van 
bacteriecellen. Naast de belangrijke SecYEG eiwitten produceert S. aureus een additionele 
set SecA en SecY eiwitten, SecA2 en SecY2 genaamd. In hoofdstuk 7 wordt de analyse 
van isogene secG en secY2 mutanten van S. aureus beschreven. Terwijl de deletie van het 
secY2 gen geen detecteerbaar effect had op de eiwitsecretie, bleek de deletie van het secG 
gen de eiwitsecretie in aanzienlijke mate te beïnvloeden. Exoproteoomanalyses lieten zien, 
dat de extracellulaire accumulatie van negen gesecreteerde eiwitten en zeven celwand-
gebonden eiwitten significant beïnvloed was in de secG mutant. Tot deze eiwitten behoren 
een aantal bekende virulentiefactoren betrokken bij de gastheerkolonisatie (de ‘serine-
aspartic acid repeat proteins’ SdrC en SdrD), de invasie van gastheerweefsels (hemolysines 
en leukocidines), de celwand-turnover (LytM), en het ontwijken van het immuunsysteem 
(Spa). Een andere opmerkelijke bevinding was, dat het tweede IgG-bindende eiwit van 
S. aureus, Sbi, bijna volledig afwezig was van de celwand van de secG mutant. Deletie 
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van het secY2 gen versterkte de secretiedefecten van de secG mutant, wat resulteerde in de 
extracellulaire accumulatie van een extra gesecreteerd eiwit en een celwandeiwit. Bovendien 
vertoonde de secG secY2 dubbelmutant een synthetisch groeidefect. Dit kan betrekking 
hebben op de enigszins verhoogde expressie van het sraP gen, dat codeert voor het enige 
tot dusver bekende substraat van het Sec2-systeem. De resultaten suggereren, dat SecY2 
een interactie kan aangaan met het reguliere Sec-kanaal. Dit is in overeenstemming met het 
gegeven, dat er slechts één paar secE en secG genen in S. aureus aanwezig is. Bovendien 
lieten infectie-experimenten zien, dat een secG mutant geen verminderde virulentie heeft 
in een muismodel. Dit suggereert, dat deze component van het Sec-systeem overbodig is 
voor gastheer-subversie door S. aureus. Dit betekent tevens, dat de aanwezigheid van SecG 
en/of SecY2 onder de geteste omstandigheden en in het toegepaste muisinfectiemodel niet 
essentieel is voor de virulentie van S. aureus.
In de afgelopen jaren zijn de functies van vele secretiesysteemcomponenten van S. aureus 
opgehelderd, zoals geïllustreerd met de voornoemde studies aan het Sec-systeem. De 
biologische functies van enkele andere secretiesysteemcomponenten waren echter nog niet 
bekend bij aanvang van het onderhavige promotieonderzoek. Dit gold bijvoorbeeld voor het 
pseudopilinesysteem van S. aureus. Dit systeem is zeer vergelijkbaar met het Com-systeem 
voor DNA-binding en opname door Bacillus subtilis. Assemblage van Com-pseudipili in 
B. subtilis vereist de activiteit van het specifieke signaalpeptidase ComC, dat de N-terminale 
signaalpeptides van verschillende ComG-eiwitten tijdens membraantranslocatie afsplitst. 
Daarnaast is de vorming van disulfidebruggen vereist voor de stabiele productie van het 
ComGC pseudopiline van B. subtilis. De vorming van deze disulfidebruggen die wordt 
gekatalyseerd door de thiol-disulfide oxidoreductases (TDORs) BdbC en BdbD. Interessant 
is, dat de genen die coderen voor de meeste Com-eiwitten van B. subtilis ook in alle 
S. aureus stammen aanwezig zijn. Dit suggereert dat de bacterie Com-type pseudopili kan 
vormen. Hoofdstuk 8 beschrijft daarom onderzoek naar de processing en stabiliteit van 
S. aureus ComGC. In S. aureus wordt de transcriptie van de meeste com genen, inclusief 
comGC, aangestuurd door de alternatieve sigma factor σH. Bij constitutieve expressie van 
σH produceerden exponentieel groeiende cellen van S. aureus alleen de precursorvorm 
van ComGC. In de post-exponentiële groeifase was daarentegen een laag gehalte matuur 
ComGC in de S. aureus cellen detecteerbaar. Dit was het resultaat van ComC-afhankelijke 
pre-ComGC processing. Door middel van ComC-overexpressie kon aangetoond worden, 
dat de inefficiënte processing van ComGC in wild-type cellen het gevolg was van beperkte 
ComC-expressie. Een opmerkelijke bevinding was, dat ComGC nauwelijks detecteerbaar 
was in cellen zonder de TDOR DsbA en dit was ook het geval wanneer de cellen gekweekt 
werden in de aanwezigheid van het reductiemiddel β-mercaptoethanol. Samen laten deze 
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waarnemingen zien, dat de TDOR-activiteit van DsbA essentieel is voor de vorming van 
disulfide-bruggen in ComGC en dat de gevormde disulfide-bindingen essentieel zijn voor 
ComGC-stabiliteit. Opmerkelijk was ook, dat zowel pre-ComGC als matuur ComGC in 
de cytoplasmamembraan en de celwand van S. aureus aantoonbaar waren. Overproductie 
van ComC resulteerde in een sterk verhoogde oppervlakte-presentatie van ComGC. Deze 
bevindingen tonen samen aan, dat ComC-afhankelijke maturatie van ComGC van belang 
is voor een optimale presentatie van ComGC aan het celoppervlak. Het is momenteel niet 
duidelijk, waarom S. aureus cellen de signaalpeptidase ComC in beperkte mate produceren, 
maar deze waarneming verklaart mogelijk ten dele waarom S. aureus slechts marginale 
niveaus van natuurlijke competentie vertoont.
Het vermogen van S. aureus tot invasie en kolonisatie van bijna alle humane weefsels hangt 
af van verschillende cel-geassocieerde en gesecreteerde virulentiefactoren. Zoals hiervoor 
beschreven worden deze virulentiefactoren eerst gesynthetiseerd met een N-terminaal 
signaalpeptide om ze naar één van de secretieroutes van de Staphylococcus cel te dirigeren. 
De getransloceerde eiwitten zullen vervolgens de celwand passeren om uiteindelijk losgelaten 
te worden in het extracellulaire milieu, tenzij ze specifiek vastgehouden worden in de cel. 
Het signaal voor covalente binding van getransloceerde eiwitten aan de celwand is het 
zogenaamde LPxTG motief, dat zich in de C-terminus van sommige geëxporteerde eiwitten 
bevindt. Dit LPxTG motief wordt herkend door membraan-geassocieerde transpeptidases 
die bekend staan onder de naam sortases. S. aureus bezit twee sortase enzymen die sortase 
A (SrtA) en sortase B (SrtB) genoemd worden. SrtA herkent het standaard LPxTG motief 
terwijl SrtB het afwijkende LPxTG motief NPQTN herkent. 
Het onderzoek beschreven in Hoofdstuk 9 was gericht op het bepalen van de rollen van 
SrtA en SrtB in de in vitro groei van S. aureus in humaan plasma. Dit weerspiegelt tot op 
zekere hoogte de in vivo groeicondities die de bacteriën tegenkomen bij een bacteriëmie. 
Zoals aangetoond voor de S. aureus stam SH1000 kan SrtA een belangrijke factor zijn voor 
efficiënte groei van S. aureus in humaan plasma. Transcriptie-profiling analyses lieten zien, 
dat een srtA mutatie leidt tot veranderde expressie van 39 genen. Daarentegen werd geen 
stress-reactie waargenomen in srtB mutante cellen die gekweekt waren in humaan plasma. 
Onder de genen die beïnvloed waren door de srtA mutatie waren genen, die nodig zijn voor 
de fosfaatopname door S. aureus. Hiertoe behoren de genen voor het fosfaat-specifieke 
transportsysteem Pst, dat sterk lijkt op het Pst-systeem van B. subtilis, en het gen voor de 
gesecreteerde alkalische fosfatase PhoB. In B. subtilis is het pst operon onderdeel van het 
Pho-regulon, dat gecontroleerd wordt door het twee-componenten regulatorische systeem 
PhoP-PhoR. De hoge mate van overeenkomst tussen de PhoP regulatoren van S. aureus en 
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B. subtilis suggereren, dat het Pho-box motief waaraan PhoP bindt geconserveerd is in deze 
twee bacteriesoorten. Een Pho box-achtig motief kon inderdaad geïdentificeerd worden in 
het promotergebied van de S. aureus pstSCAB en phoB genen. Tezamen impliceren deze 
waarnemingen, dat de srtA mutante cellen een fosfaathonger-reactie vertonen wanneer ze 
gekweekt worden in humaan plasma. In dit opzicht is het interessant, dat onze transcriptie 
analyses lieten zien dat het gen voor het LPxTG-eiwit FnbpA 2,3 keer verhoogd tot expressie 
kwam in de srtA mutante cellen die in humaan plasma gekweekt waren. Bovendien kwam 
het fnbpB gen onder deze condities ook 1,7 keer verhoogd tot expressie. Dit suggereert dat 
FnbpA en wellicht ook FnbpB een rol hebben in de fosfaatopname. Beide eiwitten zijn van 
belang bij S. aureus infecties, omdat ze een centrale rol spelen bij de adhesie aan en invasie 
van gastheercellen. Met name FnbpA blijkt een multifunctioneel adhesine te zijn, dat het 
vermogen bezit om te binden aan fibrinogeen, fibronectine, elastine en verschillende andere 
gastheereiwitten. Eerder onderzoek heeft laten zien, dat oplosbaar fibronectine covalent 
gebonden fosfaat bevat. Het is derhalve denkbaar dat Fnbp’s op de een of andere manier 
betrokken zijn bij het verkrijgen van fibronectine-gebonden fosfaat en alzo een bijdrage 
leveren aan de fosfaat-balans van de S. aureus cellen. Dit idee wordt verder ondersteund door 
het gegeven, dat potentiele Pho-boxen aanwezig zijn in de promotergebieden van de fnbpA 
en fnbpB genen. Hierbij dient opgemerkt te worden, dat het meeste fosfaat in humaan serum 
in een ongebonden staat aanwezig is. Dit zou kunnen suggereren, dat FnbpA en FnbpB ook 
betrokken zouden kunnen zijn bij de binding en opname van ongebonden fosfaat.
Hoofdstuk 10 behandelt de invloed van srtA en srtB mutaties op de groei van S. aureus 
in RPMI medium en de samenstelling van het oppervlakte proteoom van S. aureus. 
Groei-experimenten met S. aureus SH1000 en sortase mutanten van deze stam lieten zien, 
dat een deletie van het srtA gen een aanzienlijk groeiremmend effect had, terwijl deletie 
van het srtB gen geen effect had. Hieruit kan geconcludeerd worden, dat SrtA belangrijk 
is voor de groei van S. aureus in RPMI medium, zoals ook het geval was voor groei in 
humaan plasma (hoofdstuk 9). De analyses van het oppervlakteproteoom  van exponentieel 
groeiende cellen van stam SH1000 en de ΔsrtA of ΔsrtB mutanten resulteerde in de 
identificatie van respectievelijk 27, 11 en 17 oppervlakte-geëxponeerde eiwitten. De aantallen 
geïdentificeerde oppervlakte-eiwitten in de stationaire groeifase waren respectievelijk 31, 23 
en 19. Deze waarnemingen geven aan, dat niet alleen het aantal gesecreteerde S. aureus 
eiwitten toeneemt in de stationaire fase, maar ook het aantal celoppervlak-geëxponeerde 
eiwitten. Onze analyses lieten tevens zien, dat 9 LPxTG eiwitten detecteerbaar waren op 
het celoppervlak van de wild-type stam. Van deze negen eiwitten werd alleen het SasG 
eiwit exclusief in de wild-type stam geïdentificeerd. Vijf andere LPxTG eiwitten, te weten 
ClfA, ClfB, IsdA, IsdB en SdrD werden in de wild-type stam geïdentificeerd, maar niet in 
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de srtA mutant. Dit suggereert dat deze eiwitten afhankelijk zijn van SrtA voor hun correcte 
presentatie op het celoppervlak. Weer twee andere LPxTG eiwitten, Spa and SasF, werden 
geïdentificeerd op het oppervlak van zowel srtA mutante cellen als ook op het oppervlak 
van de wild-type stram. Eerdere studies hadden al laten zien, dat Spa nog steeds gebonden 
bleef aan de celwand van een S. aureus srtA mutant, maar wel in verminderde hoeveelheden, 
terwijl deze mutant aanzienlijk verhoogde hoeveelheden Spa in het groeimedium secreteerde. 
De waarnemingen beschreven in hoofdstuk 10 laten zien, dat het celwand-gebonden Spa 
van SrtA-deficiënte mutante cellen geëxponeerd wordt op het celoppervlak, maar mogelijk 
wel op een andere manier dan in SrtA-proficiënte cellen. Massa-spectrometrische analyses 
toonden namelijk aan, dat additionele peptides van het tweede en derde IgG-bindingsdomein 
en het C-terminale LysM domein van Spa geëxponeerd waren aan het celoppervlak van 
SrtA-deficiënte cellen. Dit weerspiegelt wellicht een verkeerde localisatie van Spa 
als dit eiwit niet covalent gebonden wordt aan het peptidoglycaan van de celwand. Het 
LysM domein, dat nog steeds aanwezig is in het non-covalent celwand-gebonden Spa, is 
waarschijnlijk verantwoordelijk voor de waargenomen celwand-retentie van dit eiwit in srtA 
mutante cellen.
Samenvattend kan geconcludeerd worden, dat het onderzoek beschreven in dit proefschrift 
de genoom- en proteoom-wijde ‘globale’ interacties tussen S. aureus en de humane 
gastheer beschrijft. Hiertoe zijn verschillende in vivo en in vitro experimenten uitgevoerd, 
die een dieper inzicht hebben verschaft in: (i) de kolonisatie van chronische wonden van 
EB-patiënten door S. aureus, (ii) de niveaus van IgG’s tegen bepaalde S. aureus eiwitten in 
verschillende EB-patiënten, (iii) de subcellulaire localisatie van deze Staphylococcus eiwitten 
en (iv) de mechanismes, waarmee deze eiwitten gelocaliseerd worden in de celwand, op het 
celoppervlak en in het exoproteoom van S. aureus. Alzo zijn de belangrijkste doelstellingen 
van het onderhavige promotieonderzoek gehaald. Belangrijke uitdagingen voor toekomstig 
onderzoek liggen in de translatie van de huidige resultaten naar nieuwe strategieën voor de 
voorkoming en bestrijding van S. aureus infecties. Een belangrijke vraag die op de korte 
termijn beantwoord zou moeten worden is, hoe de verkregen kennis over wondkolonisatie 
door S. aureus vertaald kan worden naar nieuwe benaderingen voor verbeterde wondzorg 
en snellere wondgenezing. Dit zou zeer relevant zijn voor EB-patiënten die leiden aan 
chronische wonden. Een belangrijk doel voor de langere termijn is de toepassing van de 
geïdentificeerde immunodominante celoppervlakeiwitten van S. aureus als doelwitten voor 
de ontwikkeling van nieuwe vaccins of beschermende antilichamen om infecties veroorzaakt 
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